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Impaction  allografting  is  used  to  fill  osteolytic  defects  during  revision  total  hip 
replacements  (rTHR).  However clinical  results  are  inconsistent  as  bone  fracture 
and  excessive  implant  migration  are  a  major  complication.  Most  importantly 
allograft does not adequately enhance new bone formation.  As a consequence the 
results o f rTHR are often inferior to primary THR due to lack o f bone stock.  Other 
studies  indicate  that  tissue  engineering  (TE)  using  Mesenchymal  Stromal  Cells 
(MSCs) seeded onto a resorbable scaffold can regenerate new bone.
The  overall  aim  o f my  thesis  was  to  test  the  hypothesis  that  TE  o f autologous 
MSCs  and MSC  derived osteoblast cells  incorporated with impaction allografting 
w ill  significantly  enhance  new  bone  formation  in  revision  THRs.  The  study  is 
divided  into  in  vitro  and  in  vivo  phases.  In  the  in  vitro  phase  the  technique  o f 
osteogenic differentiation and seeding o f the autologous ovine MSCs onto allograft 
was optimised.  Previously determined normal impaction forces  o f 3,  6  and 9kN 
were used to study the viability o f these impacted MSCs and osteogenically seeded 
cells on the allograft.  The results showed that both MSCs and osteoblast cells are 
affected  by  the  impaction  forces.  However  the  MSCs  can  survive  normal 
impaction forces o f 3-6kN while osteoblast cells can only survive impaction forces 
under 3kN.
The  in  vivo  phase  was  an  ovine  model  used  to  compare  new  bone  formation 
between  MSCs,  osteoblasts  and  a  control  group  in  an  orthotopic,  ectopic  and 
revision hip.  The results show that overall MSCs enhance new bone formation in 
all  the  scaffolds  compared  with  the  osteoblast  and  control  group.  However 
osteoblast cells do not contribute to new bone formation.  The conclusion from the 
study  was  that  MSCs  in  conjunction  with  the  impaction  allografting  technique 
enhance new bone formation.  The tissue engineering technique can be developed 
into a clinical application in revision THRs where large bone defects have become 
problematic.
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23CHAPTER 1:  INTRODUCTION
241.1  Background
Bone  and joint diseases  are  among the  most  common conditions  affecting health 
and quality o f life in the UK.  For severe osteoarthritis o f the hip joint, total hip 
replacement (THR) is one o f the most successful procedures for improving quality 
o f life. The survival o f the implant is effected, amongst other things, by the age and 
the  activity  level  o f the  patient  (Birrell  et al.  1999).  In  the  UK  approximately 
43,000 hip replacements  are  inserted every year (Bourn 2003).  According to the 
National  Joint  Registry  for England  and  Wales  the  overall  revision  rate  in  2003 
was 9.3% (van der Meulin et al. 2004).  Reasons for revision include loosening due 
to poor initial fixation (Amstutz et al.  1992),  stem fracture,  recurrent dislocations 
(Franklin et al.  2003) and infection (Masterson et al.  1997).  Aseptic loosening as a 
result o f osteolysis is the predominant cause o f failure o f THRs in both cemented 
and uncemented cups and stems (Harris  1995; Cooper et al.  1992).  Articulation o f 
implant surfaces leads to the release o f wear debris resulting in local inflammation, 
osteolysis and dislocation (Harris 1995; Cooper et al.  1992; Amstutz et al.  1992).
Bone  is  a  regenerative  material  that,  under  homeostatic  conditions,  undergoes  a 
continual cycle o f resorption and mineralisation.  The normal balance o f this cycle 
is  disrupted  by  osteolysis.  The  lack  o f bone  stock  caused by  osteolysis  o f bone 
surrounding  the  primary  implant  effects  the  fixation  o f  the  revision  implant 
(Masterson  et  al.  1997).  As  a  consequence,  the  results  for  revision  hip 
replacements  are  inferior  compared  to  primary  hip  replacements.  This  was 
reflected by a more  rapid  increase  in revision operations  compared with primary 
operations  (154%  and  18%  increase  in  procedure  rates  repectively)  which  rose 
from  1   in 12 in 1991 to 1  in 5 in 2000 (Dixon et al.  2003).  Subsequent re-revisions 
can  lead  to  a  cumulative  depletion  in  bone  stock  that  would  normally  provide 
stability for the  implant (Krishnanmurthy et al.  1997;  Sporer and Paprosky 2004; 
Eldridge  et al.  1997).  In  cemented  applications,  fixation has  been  improved  by 
developing  better  methods  o f cementing  the  hip  in  place.  The  first  generation 
technique included mixing the cement by hand and manual insertion with little or 
no  canal  preparation.  Techniques  developed  for the  second  generation  involved
25preparing  the  canal  by  brushing  and  pulsatile  irrigation,  but  still  with  a  manual 
technique.  A  third  generation  technique  involved  cement  void  reduction  by 
vacuum  or  centrifuge  mixing  which  leads  to  improvements  in  tensile  strength, 
cement  gun injection by pressurisation,  which allows the  cement to  intrude more 
easily  into  the  bone,  and  pulsatile  lavage  o f the  femoral  cavity  (W right  and  Li 
2000; DiMaio 2002).
The problem  o f osseous integration o f host bone with the  implant in uncemented 
applications has been addressed by the introduction o f porous implant coatings o f 
titanium (Stephenson et al.  2003; Soballe et al.  1992), or cobalt chromium (Jacobs 
et  al.  2000).  The  suggestion  is  that  bone  interdigitates  with  the  pores  o f the 
implant surface resulting in more permanent fixation.  Adversely,  a porous coated 
stem  has  a  higher  surface  area  for  metal  particle  release  (Jacobs  et  al.  2000). 
Although metal particles are less implicated in osteolysis than ultra high molecular 
weight  polyethylene  (UHMWPE)  (Shanbhag  et  al.  1993),  they  do  contribute  to 
increased wear o f polyethylene  liners  (Amstutz  et al.  1992).  It  could be  argued 
that hydroxyapatite (HA) coatings are more successful at improving bone ingrowth 
into  implants  (Stephenson  et al.  2003)  whilst  sealing the  bone-implant  interface, 
preventing migration o f wear debris  (Coathup  et al.  2005).  However,  reports  on 
HA  coatings  have  been  inconsistent.  In  some  studies  HA  has  been  optimal  in 
providing anchorage  and  integration,  but on closer examination the  apposition o f 
the  implant  was  with  fibrous  and  soft  tissue  (Buma  and  Gardeniers  1995)  or 
fibrocartilagenous  tissue  (Soballe  et  al.  1992).  The  problems  associated  with 
fixation are exacerbated in revision situations where bone stock is reduced.
Aim
To  enhance  new  bone  formation  around  revision  THRs  by  incorporating 
mesenchymal stromal cells (MSCs) with allograft used for impaction grafting.
Hypothesis
Incorporating MSCs into allograft or HA granules which are then impacted, 
will increase the rate and extent of bone formation.
261.2 The hip joint
1.2.1 Anatomy and pathology of the hip joint
Improvement  in  hip  function  and  pain  relief are  the  two  main  reasons  for  hip 
surgery.  Most commonly THR  is performed to relieve  pain and restore  function 
which  is  affected by  diseases  such as  osteoarthritis,  rheumatoid  arthritis,  trauma, 
osteonecrosis  and  ankylosing  spondylitis.  The  hip  joint  constitutes  a  ball  and 
socket anatomy.  The ball, known as the femoral head, is the proximal extension o f 
the  thighbone  which fits  closely  into  the  socket,  a  depression  in the  pelvic  bone 
called the acetabulum.  The aim o f a total hip replacement (THR) is to remove the 
diseased or deformed and damaged hip joint  and replace  it  with an artificial  hip, 
resulting in resilience and range o f movement as close as possible to that o f a fully 
functioning natural hip joint.  The nature o f the condition requiring treatment and 
the age and activity level o f the patient w ill determine the suitability o f the surgical 
approach used to achieve the optimal outcome  for the patient.  In some  instances 
only hemiarthroplasty may be required.  In this case the surgeon replaces only the 
femoral  head  and  leaves  the  acetabulum  intact.  This  is  used  for  patients  where 
circulation to  the  femoral  head has  failed,  due  to  dislocation  or fracture,  and the 
femoral head has died.
1.2.1.1 Bone architecture, physiology and function
Bone  is a hard,  vascularised and innervated tissue that comprises the  mammalian 
skeleton.  The skeleton provides mechanical support, where bones act as a lever to 
which muscles  are  attached  for locomotion;  it protects  the  internal  organs  o f the 
body,  such  as  the  brain  and  spinal  cord,  and  maintains  calcium  homeostasis  via 
hormonal  control.  Calcium  release  from  the  bone  into  the  blood  is  under  the 
control  o f the  parathyroid  hormone  (PTH).  Conversley,  hormones  interact  with 
cellular receptors in feedback loops, allowing calcium to be taken from the blood 
and  incorporated  into  bone  (Hancox  1972).  Another  protective  role  o f  the 
endoskeleton  is  that  it  contains  the  marrow,  which  is  the  origin  o f  the 
haematopoeitic system.
27The  external  surface  o f  a  typical  long  bone  is  surrounded  by  the  periosteum, 
consisting  o f a  fibrous  layer  and  inner  cambial  layer  which  supplies  blood  and 
lymphatic vessels, as well as nerves, to the bone.  This encases cortical or compact 
bone,  which  is  comprised o f concentric  cylinders  o f lamellae  called  osteons.  At 
the centre is a Harvasian canal through which the blood vessels, lymphatic vessels 
and  nerves  pass.  Capillaries  also  communicate  between  Harvasian  systems 
through Volkmann’s  canals.  Between the  osteons  are  interstitial  lamellae, which 
are the remains o f older, remodelled Harvasian systems.  Cortical bone makes up 
80% o f the  skeleton and has a slow turnover rate.  Situated between the  lamellae 
are  osteoblast  derived  cells  that,  once  having  become  trapped  in  small  cavities 
called lacunae, change in phenotype and are termed osteocytes.  The cortical bone 
is  the  outer  casing  which  contains  cancellous  or  trabecular  bone,  made  o f 
interconnected struts called trabeculae (figure  1.1).  The  struts interspersed with a 
series  o f voids  allow the  bone to be  strong as  well  as  light without adding mass. 
Therefore the structure o f bone is efficient as it provides the maximum strength for 
the minimum weight.  The hollow geometry o f the long bone resists bending loads 
because most cortical bone lies far from the neutral axis o f the cross section o f the 
bone.  This  gives  it  a  high  moment  o f inertia  o f an  area,  which  is  resistant  to 
bending.  As  well  as  playing  a  biomechanical  role,  the  central  canal  has  a 
physiological function as an  unstressed cavity, that houses a marrow reservoir and 
a medullary blood supply (Bostrom et al. 2000).
Four  cell  types  contribute  to  bone  formation  and  remodelling:  osteoblasts, 
osteoclasts,  osteocytes  and  bone  lining  cells.  The  osteoblast  cell  is  mainly 
responsible for laying down the organic matrix o f the bone in the form o f osteoid, 
which  is  calcified  soon  after  deposition.  This  is  coupled  to  bone  resorbtion  by 
osteoclasts.  The  osteoclast  is  a  multinucleated,  phagocytic  cell  involved  in  the 
resorption  o f  bone  during  remodelling.  The  osteocyte  originates  from  the 
osteoblast as described above, but is less active  in matrix production and is more 
likely  to  behave  in  a  communicating  role  with  other  osteocytes  through  its  long 
processes.  Osteocytes may be involved in the transduction o f mechanical  signals 
to other more active cells and certainly have a role in calcium homeostasis. Bone 
lining  cells  are  osteoblasts  that  cover  the  surface  o f all  bones.  The  functional 
activity o f the  cell  depends  on the  structure.  Tall,  plump  cells  are  metabolically
28active regulating bone osteoid production.  Elongated, flat cells are quiescent bone 
lining cells that are involved in the process of bone matrix degradation  (Bostrom 
etal. 2000).
Smaller voids  on the  bone  are  also  filled  with  marrow.  The  structure  of bone 
reflects  its  function  as  a  dynamic  organ.  The  surface  area  to  volume  ratio  of 
trabecular bone allows interplay of resorption and mineralisation required for the 
constant remodelling of bone that occurs throughout life.
Figure 1.1  Long bone physiology (from Wikipedia: The Free Encyclopaedia 
http://en.wikipedia.org/wiki/Osseous_tissue)
Organic and inorganic components of  bone
Bone  development  is  either  by  endochondral  or  intramembranous  ossification. 
Endochondral  ossification  is  the  process  whereby  cartilage  is  calcified  forming 
trabecular bone.  Intramembranous ossification is where mineral is deposited on a 
membrane such as the periosteum.  Remodelling involves mineral being laid down 
onto bone by osteoblasts and removed by cells called osteoclasts.  This process is 
controlled by hormones, local cytokines and by mechanical loads.
The  organic  matrix  of the  bone  is mainly made  of type  I  collagen  (collagen I). 
Collagen comprises 90% of the organic matrix with osteocalcin (OC), osteonectin 
(ON),  osteopontin  (OP),  and proteoglycans  contributing  10%.  Essentially these 
proteins  have  a  role  in  the  bone  orientation  and  structure.  The  inorganic 
component  of bone  reinforces  the  organic  matrix,  making  it  strong  and  rigid. 
Mineralisation  of bone  occurs  after the  osteoblasts  have  secreted  osteoid  in  the
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29form  of  collagen.  Matrix  vesicles  are  contiguously  secreted  and  contain  the 
enzyme  Alkaline  phosphatase  (ALP).  ALP  encourages  phosphate  and  calcium 
ions to  accumulate between collagen fibrils  in  ‘hole  zones’.  Eventually calcium 
hydroxyapatite (HA) crystals precipitate (Young and Heath 2000).  Hydroxypatite, 
the  inorganic  component  of  bone,  has  the  general  formula  Caio(PO)4(OH)2. 
Knowledge of the chemistry of HA is important in creating new synthetic materials 
that are bioactive as well as biocompatible.
1.2.2  The evolution of hip joint surgery
In the latter part of the 1700’s amputation of the limb was considered an expedient 
solution  and  a  panacea  for  all  injuries.  The  history  of bone  repair  began  with 
techniques where treatment was restricted to  limb  salvage.  As  a variety  of bone 
pathologies were identified and technology and materials concurrently improved, 
treatment became more specific to musculoskeletal disorders.  Eventually metals, 
ceramics  and  polymers  were  employed  in  various  combinations  to  treat 
musculoskeletal disorders, including fracture, non-union,  ligament reconstruction, 
spinal disk replacement and total hip arthroplasty.
Henry Park (1744-1831)  developed the technique  of joint  excision,  which is the 
removal  of ‘all  the  bones  which  form  the joints’,  thereby  creating  a  callus  that 
replaced  the  diseased  parts  (Gomez  and  Morcuende  2005).  Joint  excision  was 
widely practiced, regardless of the etiology of the joint disease being treated.  The 
first  example  of reparative  hip  surgery  in  the  form  of exision  arthroplasty  is 
attributed to Anthony White of Westminster Hopital in 1822.  He excised the upper 
end of the femur in a nine year old boy for sepsis and deformity, restoring mobility 
and  relieving  pain  but  compromising  stability  (Newman  1971).  Girdlestone 
(Gomez  and  Morcuende  2005)  was  the  first  to  use  the  excision  technique  for 
degenerative  disease.  Further  surgical  developments  included  interpositional 
arthroplasty to prevent recurrence of ankylosis.  This was pioneered by Oilier and 
others  where  soft  tissue  was  inserted  between  the  joint  surfaces  (Gomez  and 
Morcuende 2005).  Other materials placed between bone surfaces ranged from pig 
bladder (William Steven Baer at the Johns Hopkins Hospital), to gold foil (Robert 
Jones) (Newman 1971).
301.2.2.1  Artificial Joints
The earliest pioneer in total hip replacement is widely recognised as Themistocles 
Gluck who, in 1891, constructed an ivory ball and socket joint which was fixed to 
the bone with nickel plated screws (Newman  1971).  The materials were refined 
using Wiles’  design in  1938 of a stainless steel head and acetabulum and also by 
the  Judet  brothers  who  used  acrylic  prostheses  in  1948,  improving  fit  and 
simplifying  the  operation  (Newman  1971).  Other  refinements  of  prostheses 
followed,  including the  use  of dental  acrylic  cement  for implant  fixation,  cobalt 
chrome components by McKee and Peter Ring’s cementless implants, which had 
metal  on  metal  components.  However,  the  biggest  landmark  in  total  hip 
replacement  came  with  the  development  in  the  1960s  of  the  low  friction 
arthroplasty concept by Sir John Chamley (Newman 1971).
After first using polytetrafluoroethylene (PTFE), Chamley used the relatively low 
friction  couple  between  the  high  density  polyethylene  for  the  acetabulum  and 
stainless steel for the femoral head components.  The use of these materials was a 
major  factor  in  reducing  wear.  His  implants  were  also  designed  to  have  small 
metal  heads,  22mm  in diameter,  conferring  less  torque  whilst  providing  a thick 
plastic  cup.  Ever  since  Chamley  pioneered  the  use  of metal  on  polyethelene 
components  in  hip  replacements  in  the  1960s,  THRs  have  provided  the  most 
expedient solution to joint pain as a result of severe osteoarthritis.
1.2.3  Primary Total Hip Replacement
A thin layer of cartilage covering the articulating surfaces of the femoral head and 
the  acetabulum  allows  them  to  glide  against  one  another.  In  the  operation the 
diseased  parts  of  the  hip  joint  are  removed,  including  cartilage  covering  the 
acetabulum  and parts of the femur that may occlude  access to the femoral  shaft. 
The  acetabulum  is  reamed  to  receive  a  prosthetic  component  composed  of  a 
polyethylene  liner  that  is  either  cemented  directly  into  the  socket  or  is  metal 
backed,  which  allows  the  implant  to  be  fixed  using  cement  or  by  direct  bone 
apposition.  For the femoral component, the intramedullary canal is prepared using 
rasps which re-shape the canal to receive a metal stem that is either cemented or 
press fit into place. A metal or ceramic head, that replaces the ball of the joint, is 
then  fitted  onto  the  stem  (Figure  1.2).  The  possible  combinations  of  bearing
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as  a  cobalt-chrome  head  with  ultra  high  molecular  weight  polyethylene 
(UHMWPE) or more recently cross linked polyethelene liners; metal-on-metal, for 
instance  a  cobalt-chrome  femoral  head  coupled  with  a  cobalt-chrome  liner,  or 
ceramic-on-ceramic combinations of head and liner (Heisel et al. 2003; Park et al 
1995).  In the UK the most common bearing combination is a cemented UHMWPE 
acetabular  cup  articulating  with  cobalt-chrome,  whereas  in  the  USA  the  metal 
femoral head articulates against a cementless UHMWPE cup.
acetabular cup femur
Figure 1.2 Total Hip Replacement (from 
http://www. materials, qmul.ac.casstud/implants)
1.2.4  Osteolysis in the failure of THRs
Wear particle induced osteolysis often results in a decrease in the bone stock which 
is required for implant fixation in revision hip replacements (Harris  1995; Cooper 
et  al.  1992).  The  mechanism  of osteolysis  is  triggered  by  particles  of metal, 
cement or polyethylene that are released when surfaces of the  implant articulate 
with one another.  These particles are able to travel along small spaces between the 
implant  interfaces,  such  as  the  stem-cement  interface.  When  they  come  into 
contact with biological tissues these particles  become  engulfed by  inflammatory 
cells,  such  as  macrophages  and  giant  cells.  This  activates  macrophages  which 
release bone resorbing mediators such as interleukin-1   (IL-1) and tumour necrosis 
factor  (TNF-a),  an  osteoclast  activating  cytokine  stimulating  osteoclasts  to 
differentiate from monocytes and resorb bone (Athanasou 1996). There is evidence 
that  macrophages  contribute  directly  to  osteolysis  by  differentiation  into
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differentiated  into  osteoclasts  in  vitro  (Sabokbar  et  al.  1997).  The  RANK- 
RANKL-OPG  pathway  constitutes  a  basic  control  network  that  regulates  bone 
remodelling.  This  is  also  the  case  in  osteolysis  where  bone  cells  such  as 
osteoblasts  and  osteoclasts  regulate  bone  turnover.  The  transmembrane  receptor, 
Receptor Activator of Nuclear factor kappa B  ligand  (RANKL),  is  expressed on 
the surface of preosteoblastic cells which binds to (Receptor Activator of Nuclear 
factor kappa B (RANK) on osteoclast precursors.  This allows differentiation and 
activation of cells of the  macrophage/monocyte  lineage  into  osteoclasts  and thus 
leads  to  resorption.  The  ability  of  pre-osteoblasts  to  support  osteoclastic 
development  is  lost  during  differentiation  down  the  osteoblastic  pathway  as 
RANKL  is  downregulated  and  osteoprotegerin  (OPG),  an  osteoclast  inhibitor 
produced by the osteoblasts,  is increased.  It would be  counterproductive for the 
mature  osteoblasts to  stimulate  osteoclasts to  destroy  osteoid they  have just  laid 
down  (Khosla  2001).  There  is  also  evidence  that  osteolysis  is  triggered  by 
hydrostatic  pressure  around  hip  components  after  hip  replacements.  In  a  study 
comparing  the  resorptive  effect  of cement  particles  and  pressure  in  a  rat  tibial 
diaphysis,  the  osteolytic  process  was  more  greatly  influenced  by  biomechanical 
stimuli than the cement particles (Bjom and Aspenberg 2003).
The most aggressive form of osteolysis is described clinically as erosive inflamed 
bone  resorption,  where  a  fibrous  membrane  eventually  surrounds  the  loosened 
implant.  This can be observed in cemented acetabular components.  Figure  1.3 
shows  periprosthetic  osteolysis  of  a  cemented  femoral  component  in  a  male 
patient.  The  front  view  (figure  1.3a)  displays  gross  osteolysis  on  the  medial 
aspect, showing aseptic  loosening between the cement and the bone.  The  lateral 
view  (figure  1.3b)  shows  localised  osteolysis  on  the  distal  stem  on  the  anterior 
side.  However,  periprosthetic  osteolysis  is  also  prevalent  in  cementless  femoral 
components despite excellent femoral  fixation at five years  (Cooper et al  1992). 
This indicates that despite improvements in fixation techniques and optimisation of 
surface characteristics, such as implant coatings of HA (Coathup et al. 2005), there 
is  still  debris  release  due  to  wear  (Amstutz  et  al.  1992).  Although  it  may  be 
possible  to  minimise  wear  debris  release,  it  is  likely  that  bone  stock  will  be 
depleted by osteolysis for the foreseeable future.
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1.3  Revision THR
The purpose of revision total hip replacement is to replace the previously loosened 
stem  and  restore  function.  However,  often  there  is  not  sufficient  bone  stock 
available for fixation of the revision stem.  Provided the implant is mechanically 
stable,  the  load  transferred  onto  the  remaining  bone  should  stimulate  bone 
regeneration.  In  the  past,  revision  THRs  have  used  the  cemented  stem  or  an 
extensively porous coated uncemented stem i.e titanium plasma sprayed with HA 
(Nelissen  et  al.  1995).  In these  situations  the  femoral  stem  often  by-passes  the 
proximal  osteolytic  lesions  and  is  fixed  more  distally  than  in  primary  hip 
replacement.  Unfortunately,  bone  stock  is  not  only  depleted  by  osteolysis  but 
further  loss  of bone  is  incurred  when  the  primary  implant  is  removed  during 
revision  surgery,  resulting  in  an  additional  challenge  for  the  surgeon  in 
reconstituting bone stock.
1.3.1  Impaction grafting
One of the techniques in use today is implantation of bone graft, which is impacted 
into  the  endosteal  cavity  to  create  a  neo-medullary  canal  in  the  femoral  shaft. 
Debridement  of the  femoral  canal  involves  the  removal  of the  loose  prosthesis,
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cortical defects, the graft is constrained within the femoral canal using a mesh with 
wire cerclage.  The neo-medullary canal is shaped by a series of tapers that allow 
the graft to be packed under force against the walls of the femoral canal and then 
the  cemented  component  is  introduced  (Gie  et  al.  1992;  Gie  et  al.  1993). 
Impaction of morsellised cancellous graft is widely accepted in clinical practice as 
the  best  way  to  reconstitute  bone  stock  from  a  mechanical,  as  well  as  a 
physiological approach.
Impaction  grafting,  predominantly  combined  with  the  Exeter  X  Change  system 
developed  by  Slooff,  Gie  and  Ling  (Ling  1997),  goes  some  way  towards 
addressing the requirements of immediate fixation and reconstitution of the bone 
stock  at  revision  operations.  In  the  ‘Slooff  and  Ling  technique’  impacted 
morsellised  graft  provides  a  firm  mantle  for  the  femoral  implant  (Tagil  2000; 
Leopold  et al.  1999)  which  is  cemented  in place.  Originally  autograft  had  been 
used to correct acetabular protrusion in rheumatoid arthritis, as it was found to be 
an improvement compared to wire mesh or oversized acetabular cups (Leopold et 
al.  2000).  Slooff  modified  the  technique  by  impacting  allograft  instead  of 
autograft  into  osteolytic  defects  of the  acetabulum  (Sloof et  al.  1984).  Ling 
developed the technique further by using allograft in femoral reconstruction (Gie et 
al.  1993).  Impaction  grafting  is  now  widely  used  worldwide  for  reconstructive 
surgery for fractures, limb salvage, spinal reconstruction and THR.
1.3.2  Autograft
Bone  is  the  most  frequently  transplanted  tissue  in  humans  after  blood,  with 
200,000 bone transplants performed yearly in the United States.  The first recorded 
successful bone graft was by Job Van Meek’ren in 1668 (Lane and Sandhu  1987). 
Autograft is boney tissue that has been removed from a non-essential part of the 
skeleton  e.g.  the  iliac  crest,  and  transferred  to  another  location  in  the  same 
individual to repair bones essential for weight bearing (Niklason 2000).  There is 
undoubted histocompatibility of autograft (Burchardt 1987).  Autograft is the safest 
method of bone transplant as  it involves a closed  surgical  system.  Bone  merely 
requires transport from one site on the patient to another, so there is less chance of
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with allograft.
Autograft is widely accepted as the  ‘gold standard’  for bone transplant due to its 
osteogenic,  osteoinductive  and  osteoconductive  properties.  Osteogenesis  is  bone 
regeneration by pre-existing differentiated or determined bone forming cells from 
either the graft or the host (Lane and Sandhu 1987). The morsellised autograft may 
contain active osteoblasts or osteoprogenitors from the periosteum or marrow.  As 
the autograft is freshly harvested, this means that the host’s own viable cells will 
contribute to osteogenesis.  However, it is debatable whether osteocytes trapped in 
bone  lacunae  are  active  or would be  able to  free themselves to  contribute to the 
surrounding  environment  for  osteogenesis  (Andrew  and  Bassett  1972).  The 
autograft would also act as a mechanical support for bone formation and encourage 
osteoconduction.  Osteoconduction is the formation of bone conducted along the 
graft surface.  Cancellous graft is ideal for this purpose as it is composed of a large 
surface area (Khan et al. 2005).  The possibility that autograft, if handled correctly, 
will contain a reservoir of bioactive substances as well as cells means that it will 
also  be osteoinductive.  Osteoinduction can be defined as  a process whereby the 
donor  tissue  causes  the  host’s  mesenchymal  stem  cells  to  differentiate  into 
osteoblasts, producing bone (Logeart-Avramoglou et al. 2004).
There are many drawbacks to autologous grafting.  An additional cost is associated 
with  harvesting  autologous  bone  (Khan  et  al.  2005).  The  invasive  procedure 
involved in autologous harvesting can cause unnecessary pain, haemorrhage, nerve 
damage, risk of bacterial infection, muscle weakness, nerve injury and blood loss. 
The  associated  pain  from  a  combination  of damage  is  referred  to  as  donor  site 
morbidity (Niklason 2000).  There is  also  a limited bone  supply, particularly for 
large defects and defects in children.  The ability to form a functional shape from 
this tissue is also compromised (Lane and Sandhu 1987).  Therefore allografts have 
become  the  most  common  alternative  to  autografts  and  are  used  in  revision 
techniques such as the Exeter X Change System described above.
361.3.3  Allograft
Allograft is bony tissue  transplanted from  one  individual to  another of the  same 
species  that  is  genetically  disimilar  (Burchardt  1987).  It  supplies  a mechanical 
function by supporting the implant when subjected to load.  Although allograft is 
less  osteoinductive  than  autograft,  as  deactivation  of  cells  may  have  I  from 
irradiation,  it  is  still  osteoconductive.  Allograft  provides  a  scaffold  for  the 
ingrowth of blood vessels and new bone and a surface for cell migration from the 
host matrix.
Tissue banks prepare, screen and store allograft, in a function akin to modem blood 
banks.  Bone  tissue  is  harvested  from  cadavers,  or  living  donors  e.g.  amputees, 
femoral neck fractures (Tomford et al.  1987). Allograft is commonly sourced from 
the cancellous bone of femoral heads removed during primary THR.  This can be 
stored  locally  in  regional  bone  banks.  The  bone  is  subsequently  morsellised  by 
passing  through  a bone  mill.  The  resulting  bone  chips  can  be  used  directly  or 
preserved  by  either  freezing  (Gie  et  al.  1993),  or  freeze  drying  under  aseptic 
conditions.  It  may  also  be  sterilised  using  gamma  irradiation.  The  relative 
advantages  of  long  term  storage  of  freeze  dried  graft  is  outweighed  by  the 
suggestion  that  it’s  mechanical  properties  are  adversely  affected  (Khan  et  al. 
2005).  The incorporation of both allograft and autograft is similar to the process of 
fracture  healing,  with  autograft  incorporation  proceeding  more  quickly  than 
allograft  incorporation  (Ullmark  and  Obrant  2002;  Burchardt  1987).  There  is 
evidence  of remodelling  of bone  graft  after  revision  surgery  in  the  femur  with 
osteocalstic resorption of the surface of graft granules and simultaneous deposition 
of osteoid and bone (Linder 2000).
Essentially  bone  remodels  as  a  response  to  mechanical  loading  according  to 
W olffs law:  ‘Remodelling of bone ... occurs in response to physical stresses -  or 
to the lack of them -  in that bone is  deposited in sites  subjected to  stress  and is 
resorbed from sites where there is little stress’ (Andrew and Bassett 1972).  Load is 
not the only impetus for new bone formation, but it is the predominant signal for 
directing and maintaining bone formation in sites of depleted bone stock.  Bone 
responds to injury in three phases:  inflammation, repair in the form of soft callus
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invaded by cells as a response to haemorrhage.  Motion between graft particles and 
host  is  minimised  by  a  bridging  of  soft  callus,  consisting  of  osteoblasts  and 
eventually a callus of woven bone.  This is accompanied by vascular invasion of 
the  graft  from  host  tissue.  The  graft  facilitates  the  migration  of bone  forming 
components,  termed  ‘creeping  substitution’,  because  of  its  biomechanical 
properties (Khan et al 2005; Lane and Sandhu 1987; Andrew and Bassett 1972).
The  most  emphatic  reason  against  the  use  of  allograft  is  the  potential  for 
transmission  of viral  pathogens  such  as  HIV.  Musculoskeletal  allografting  has 
resulted  in two  reported  cases  of HIV  infection  since  1980  (Khan  et  al  2005). 
However tissue banks now adhere to stringent pre-screening including serological 
tests for transmittable diseases such as HIV, Hepatitis B and Hepatits C (Buck and 
Malinin  1994).  Bacterial  and  some  viral  contamination  can  be  overcome  by 
sterilisation  methods  such  as  gamma  irradiation  or  ethylene  oxide  treatments. 
Although sterilisation can reduce the risk of infection, there is still risk of resilient 
HIV  (Buck  and Malinin  1994) or infection through  careless  handling.  This  may 
have been the scenario in the fatal case of Clostridium species infection  as a result 
of allografting  (Khan  et  al  2005).  Sterilisation  by  gamma  irradiation  can  also 
prevent an immunogenic response.  The possibility of rejection of the allograft is 
high  unless  the  antigenic  components  of the  graft  are  removed  by  a  series  of 
washing steps then irradiation.  The processing techniques ultimately compromise 
the mechanical strength of the graft to some degree (Khan et al  2005; Pelker and 
Friedlaender  1987).  Additionally, processing in tissue banks means that allograft 
production is more expensive and time consuming than obtaining autograft.  As the 
tissue bank relies on continual donation of graft, there is a finite supply. Due to the 
varying ages of the donors, combined with their disease status (e.g. osteoporosis), 
the allograft will also be of inconsistent quality.
Impacted cancellous allograft has been widely used as  a bone  stock replacement 
with and without cement (Ling et al  1993;  Gie et al  1993;  Isacson et al  2000). 
However,  allograft  surgery  is  subject  to  the  same  complications  as  autograft. 
Subsidence  has  been  show  to  occur  in  cemented  stems  in  11%  of 79  femoral 
prostheses in a study by Eldridge et al. (Eldridge et al  1997). Masterson et al also
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Other  complications  leading  to  failure  are  avascular  necrosis,  post-operative 
fractures (Heliotis and Tsiridis 2001),  a high incidence of trochanteric non-union 
and prosthetic dislocation (Leopold et al. 2000).  Subsidence suggests that graft is 
not sufficiently impacted or in the longer term that the graft has not incorporated 
into host bone  (Heliotis  and Tsiridis 2001).  There  is a possibility that problems 
associated with graft incorporation could be  addressed by tissue  engineering the 
graft, making it more osteoinductive.
1.3.4  Bone substitutes
It may be possible to engineer a graft that is more  suitable for bone regeneration 
than allograft.  This material must be porous and biocompatible i.e. non-toxic and 
non-immunogenic, enabling integration and bone ingrowth whilst at the same time 
being resorbable, thus allowing the graft material to withstand the forces imposed 
by everyday activity.
1.3.4.1  Synthetic HA
Synthetic  HA  is  the  most  similar  material  to  bone  mineral  compared  to  other 
synthetic  ceramic  substitutes.  It  is  one  of the  most  obvious  choices  as  a  bone 
substitute because it allows consistent reproduction, it is possible to manipulate its 
properties  for  use  in  various  applications,  for  instance  as  an  implant  coating 
(Stephenson  et  al.  2003)  or  as  blocks  and  granules  of pre-specified  sizes  and 
shapes for grafting (Boyde et al.  1999;  Oonishi et al.  2000) in combination with 
allograft or autograft (Oonishi  1991).  It can mimick the porosity and pore sizes of 
the  trabecular  network,  having  interconnectivity  for  vascularisation  and  200- 
900pm pores for cellular invasion.  (Logeart-Avramoglou et al.  2004; Lanza et al. 
2000; Salgado et al.  2004).  HA coatings on implants led to osseointegration and 
the resultant increased rate of osseointegration increases mechanical stability faster 
than with a non-coated implant (Soballe et al.  1992).  In another canine model, 
Stephenson et al. state that HA helped to close gaps at the bone-prosthesis junction 
(Stephenson et al.  2003).  However,  Buma et al.  found that  in  a  study  of four 
retrieved HA coated implants, after a period of between 5-24 months, the HA had 
degraded  leaving no  bond between the  implant and bone  (Buma and  Gardeniers 
1995).  HA is classed as a ceramic and is a relatively stiff material  compared to
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by the presence of collagen.  Disadvantages of HA as a graft substitute also include 
unpredictable dissolution rates in vivo (Salgado et al. 2004).  This means that HA 
is not the perfect substitute for weight bearing bone grafts (Tachibana et al  2003). 
These  problems  may  be  addressed  in  the  future  by  utilising  the  knowledge  of 
calcium  phosphate  chemistry  to  produce  bioresponsive  constructs  that  have 
bioactive  molecules  integrated  with  the  substrate.  As  HA  is  resorbed  these 
substances  would  be  released  and  would  act  locally  as  osteoinductive  factors. 
Currently HA cement is being developed to allow molding of the substrate into a 
specific defect (Gosain et al. 2003a).
1.3.4.2 Natural bone substitutes: Demineralised bone matrix (DBM)
Marshall  R.  Urist  identified bone  formation by  autoinduction  in  1965.  He  took 
samples  of human  and  rabbit  bone,  decalcified  in  0.6N  Hydrochloric  acid,  and 
implanted  them  into  the  muscles  of  a  variety  of  animals.  The  DBM  was 
osteoinductive  with new bone  forming rapidly  in weeks to months  (Urist 2002). 
The mineral part of the matrix is thought to obscure the inductive properties of the 
matrix which are exposed by demineralisation (Lane and Sandhu 1987).  Although 
this is good for craniofacial defects, the material properties of DBM mean that it is 
not suitable as allograft in weight bearing situations.
1.3.4.3 Growth factors
Growth factors,  also known as cytokines,  occur naturally  in the bone matrix and 
act  as  signalling  molecules  between  cells.  They  include  the  following: 
transforming  growth factor p  (TGF-P)  superfamily containing bone  morphogenic 
proteins (BMPs); insulin-like growth factors (IGF-1, IGF-2), involved in collagen 
synthesis and found in fracture healing sites;  interleukins (IL-1, IL-6), involved in 
bone resorption;  fibroblast growth factors (FGFs),  involved in bone remodelling; 
platelet  derived  growth  factors  (PDGFs)  involved  in  bone  regeneration;  and 
vascular endothelial growth factor (VEGF) which is angiogenic.  Urist’s discovery 
of  autoinduction  has  been  attributed  to  growth  factors  being  exposed  after 
demineralisation of the bone (Lane and Sandhu 1987) as it is known that BMPs are 
trapped within the bone matrix (Deans and Moseley 2000).  It has been proposed 
that  BMPs  could  be  used  to  replace  or  augment  autograft  or  allograft
40administration  in  treating  fracture  non-union,  accelerating  the  healing  of bone 
defects and increasing union in distraction osteogenesis, the strength of bone union 
in spine arthrodesis and other arthrodeses and increasing bone mass in osteoporosis 
(Lane 2001).  BMP-2  is thought to recruit and differentiate  cells  such as MSCs 
into the osteoblastic lineage (Deans and Moseley 2000) and recombinant BMP-2, 4 
and 7 can heal critical sized defects in animal models when combined with a DBM, 
HA or biodegradable polymer carrier (Lane 2001). Clinical trials using BMPs have 
also been promising with clinical and radiological union in 82% of patients after 
BMP-7  application  in  persistent  fracture  non-unions  and  other  orthopaedic 
complications (Giannoudis and Tzioupis 2005).  The precedent was set in a clinical 
trial in tibial non-unions where patients either received intramedullary nail fixation 
and  autologous  bone  grafting  or  the  same  procedure  with  the  addition  of 
recombinant  BMP-7  (Friedlaender  et  al.  2001).  Recovery  was  equivalent  with 
both treatments and formed the basis of FDA approval for BMP-7 as an alternative 
to autograft in recalcitrant long bone non-unions under extenuating circumstances 
(Einhom 2003).  There was also a clinical trial using BMP-2 in lumbar spine disc 
degeneration where the fusion rate in the BMP treated group was higher than in the 
non BMP group (Einhorn 2003).
Despite  the  potential  inherent  in  BMPs,  the  drawbacks  are  that  animal  models 
often  show  better  bone  healing  than  human  clinical  trials  (Einhom  2003).  In 
mammals higher up the phylogenic scale, BMPs may need to persist in the vicinity 
of the  carrier  for  longer  (Lane  2001).  This  raises  issues  concerning  systemic 
circulation  of BMPs  whereby  a  large  dose  may  be  toxic  if not  localised  to  the 
defect site.  Very large pharmacological  doses are used  in relation to  naturally 
occurring physiological quantities of BMP.  In one study, concentrations of BMP 
extracted from the DBM of 20 patients were 21.4ng/g,  5.45ng/g and 84.1ng/g of 
BMP-2,  BMP-4  and  BMP-7  respectively  (Pietrzak  et  al  2006).  However  the 
effective  quantity  of BMP  used  in  spinal  fusions  is  about  1.5mg/ml  of collagen 
carrier (Carlisle and Fischgmnd 2005).  In a randomised clinical trial, one unit of 
the rhOP-1  (recombinant human osteogenic protein-1) implant supplied by Stryker 
Biotech and used in the treatment of tibial non-unions contains 3.5mg of OP-1  per 
gram of collagen (Friedlaender et al.  2001).  A maximum of two units was used 
and this by far exceeds the quantities found in human bone.  Another concern is
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compromised  in  a  cohort  of unhealthy  patients  compared  to  a  healthy  animal 
model.  In addition,  the  application of large  doses  of BMP has been associated 
with osteoclast recruitment which may lead to a resorptive response (Lane 2001). 
There has been a recent study in sheep of impaction grafting with the addition of 
BMPs  (McGee  et  al.  2004).  New  bone  formation  and  graft  remodelling  was 
accelerated in the OP-1  group compared to the control.  However, there was also 
an  accelerated  resorption  at  the  early  time-point  in the  OP-1  group  which  may 
compromise  fixation of implants  (McGee  et al.  2004).  The  issues  of toxity and 
controlled release of BMP may be addressed in the future with bioactive scaffolds 
that  release  bound  growth factors  in relation to  the  demands  of the  surrounding 
tissue.  Apart from the pharmacological issues, there is the problem of expense and 
availability of commercially produced BMP (Einhom 2003).  For the purposes of 
this thesis I suggest that using cells alone with a scaffold will be  self regulating, 
allowing the cells to produce the required amount of growth factors depending on 
the demands of the defect site.
1.4  Tissue engineering
1.4.1  Definition and history of tissue engineering
Tissue engineering usually involves the use of cells on a resorbable  scaffold and 
sometimes  biochemical  cues  to  encourage  appropriate  cell  function  in  a clinical 
application.  A variety of scaffolds for bone tissue engineering have already been 
discussed.  One of the main criteria for determining the  scaffold is how the cells 
interact with the scaffold material in vitro, which will influence tissue regeneration 
in vivo.  Tissue will only form through the activity of living cells (Muschler and 
Midura  2002).  Tissue  engineering  as  a  commercial  enterprise  was  initially 
pioneered by Organogenesis  Inc.  in the creation of skin grafts (Bell 2000).  This 
cell  based  therapy  was  originally  devised  by  Rheinwald  and  Green  in  the  late 
1970’s using autologous keratinocytes to create epidermal grafts for bums victims 
(McPherson and Tubo 2000).  Organogenesis’  currently marketed product to treat 
venous leg ulcers and diabetic foot ulcers is Apligraf®, which is a cultured bilayer 
of allogenic  dermis  and  epidermis,  excluding  cells  of the  immune  system  that 
initiate  graft  rejection  (Organogenesis  2006).  Another  example  of  tissue
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defects  of the  knee.  A  biopsy  of articular  cartilage  is  extracted,  enzymatically 
digested,  the  resulting  chondrocytes  cultured  and  reintroduced  into  an  articular 
defect (McPherson and Tubo 2000).
A recent breakthrough towards applying stem cells to tissue engineering has been 
in skin grafting.  Previously and unexpectedly, when human ES (embryonic stem) 
cells  were  purified  they  grew  poorly.  However.  In  a  recent  study,  human  ES 
derived keratinocytes were immortalised by transduction with viral genes and were 
maintained  as  keratinocytes  in  culture  (Iuchi  et  al.  2006).  There  are  several 
instances  where  stem  cells  have  had  a  positive  effect  in  treating  a  range  of 
disorders.  Peripheral blood stem cells have been used to treat leukaemia since the 
mid 1980’s (Jansen et al.  2005).  Also known as haematopoeitic stem cells (HSC), 
they  are  transplanted  following  irradiation  of  the  patient.  As  irradiation  is 
indiscriminate,  killing  healthy  HSCs,  leukophoresis  is  employed  whereby  donor 
HSCs  are  removed,  expanded  and  transplanted  back  into  the  marrow  after 
irradiation  treatment  (Jansen  et  al.  2005).  In  a  recent  study  ES  cells  from  the 
neural tissue  of embryos  have  slowed the  progress  of Huntington’s  disease  after 
implantation into the brain of 5 patients (Bachoud-Levi et al. 2006).
Examples  of adult  stem  cells  contributing  to  alleviation  of disease  in  humans 
include: umbilical cord stem cells injected into the spinal cord of a 37 year old with 
spinal  cord  injury,  regenerating the  spinal  cord,  returning  feeling  and movement 
(Kang et al. 2005); allogenic corneal stem cells which were cultured on plastic and 
transplanted  as  a  cell  sheet  onto  the  patient’s  corneal  surface,  resulting  in 
improvements in the ocular surface and improved vision in 2 out of 4 people (Daya 
et  al.  2005);  and  bone  marrow  derived  autologous  hemaotopoeitic  stem  cells 
injected  directly  into  the  myocardium  resulted  in  a  significant  improvement  in 
cardiac  function  when  incorporated  with  coronary  artery  bypass  grafting  for 
congestive heart failure (Patel et al. 2005).
Mesenchymal  Stromal  Cells  (MSCs)  derived  from  bone  marrow  are  considered 
most  promising  for  bone  tissue  engineering.  Bone  marrow  has  been  injected 
directly into tibial non-unions and showed a positive correlation between stem cell
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have also been used in a trial to treat osteogenesis imperfecta (Horwitz et al.  1999). 
These  studies  using  bone  derived  stem  cells  did  not  employ  scaffolds.  In  my 
thesis,  using  MSCs  in  combination  with  a  scaffold  may  solve  some  of the 
problems associated with allogenic bone grafts.  These advantages may be that:
1.  It  may  redress  the  balance  in  favour  of  osteogenesis  and  away  from 
osteoclastic resorbtion.
2.  Graft may become more osteoinductive, increasing new bone formation.
3.  Compared with autograft there is a greater supply of allograft.
1.4.2  Origin of MSCs and ES ceils
The embryo consists of a mass of cells called the blastocyst, resulting in three germ 
layers  that  form  all  embryonic  tissues:  the  ectoderm,  endoderm  and  mesoderm. 
MSCs  originate  from  the  mesoderm  and  contribute  to  bone  formation  in  the 
embryo, fracture repair and remodelling in the adult (Bruder et al.  1994; Shamblott 
et al.  2000; Shamblott et al.  1998).  Blastocyst cells have the ability to regenerate 
an entire individual (Muschler and Midura 2002).  The ability of these embryonic 
cells to give rise to the full complement of cell types can be defined as totipotent. 
Totipotent cells are the fertilised egg and the first 4 cells produced by its cleavage. 
Pluripotent cells have the ability to differentiate into any cell in the human body, as 
well  as  replicate  themselves.  There  are  three  types  of  pluripotent  stem  cell: 
embryonal carcinoma (EC), isolated from teratocarcinomas; embryonic germ (EG) 
cells,  isolated from the precursor to the  gonads  in aborted foetuses and ES  cells, 
from the inner cell mass of the blastocyst (Shamblott et al.  2000).  As the embryo 
develops  into  an  adult,  MSCs  acquire  a  restricted  potential  to  differentiate  into 
skeletal tissue lineages such as: bone, cartilage, tendon, ligament, marrow stroma, 
fat, dermis, muscle and connective tissue, termed multipotent (Caplan 1991).
Whilst ethical considerations may prevent the use of ES cells in tissue engineering 
applications, adult MSCs may be obtained and cultured with less ethical  concern 
(Orkin  and  Morrison  2002).  ES  cells  have  a  tendency  to  form  teratomas  and 
teratocarcinomas  in  vivo  (Salgado  et  al.  2004),  so  extra  care  has  to  be  taken to 
differentiate the cells pre-implantation.  Even with this precaution, there is still a
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compared with adult MSCs (Orkin and Morrison 2002).  In order to maintain their 
undifferentiated status, human ES cells are cultured on murine matrigel or laminin 
in  embryonic  fibroblast  conditioned  media  (Salgado  et  al.  2004).  It  is  also 
academic  that  MSCs  would  be  non-immunogenic  as  most  uses  would  be 
autologous.
1.4.3  Definition of MSCs
MSCs  can  be  defined  as  self-replicating  cells  that  can  give  rise  to  multiple 
mesodermal  tissues  (Bruder  et  al.  1997).  The  definition  of  MSCs  is  under 
continual  discussion and revision as researchers  uncover new characteristics that 
suggest  the  boundaries  of different  cell  types  are  shifting.  The  differences  in 
nomenclature of the cell are generally semantic, with a variety of titles that have 
changed over time.  However, the MSC is still generally characterised according to 
Friedenstein’s in vitro observations of the phenotype in the 1970’s (Friedenstein et 
al.  1970).  After isolation from  the  bone  marrow,  MSCs  selectively  adhered  to 
tissue  culture plastic.  This distinguished them  from haematopoetic  stromal  cells 
(HSCs) of the marrow stroma which remained in suspension under tissue culture 
conditions  (Hughes  and  Aubin  1998).  Functionally,  haematopoeitic  cells  are  a 
population of stromal cells of the bone marrow distinct from MSCs that develop 
into  mature  blood  cells  (Young  and  Heath  2000).  The  adherent  population  of 
stromal  cells  were  termed  colony-forming  unit  fibroblasts  (CFU-f)  because  in 
primary  cultures  they  proliferate  into  colonies  which  are  clones  derived  from  a 
single cell (Friedenstein  1994).  The term  ‘fibroblast’ was allocated to these cells 
because  their  in  vitro  morphology  exhibits  a  spindle  shaped,  fibroblastic 
appearance (Rickard et al.  1996; Friedenstein 1994; Owen and Friedenstein 1988). 
MSCs  have  a  capacity  for  self-renewal,  achieving  more  than  20  population 
doublings in vitro (Friedenstein 1994).  In vivo, stem cells are thought to reside in 
specific niches that allow self renewal with descendants that can differentiate along 
a number of pathways (Watt and Hogan 2000).  This results in a MSC repository 
that is most commonly associated with the marrow stroma.  The advantage of this 
ability to replicate and maintain osteogenic capacity means that autologous MSCs 
can be sourced conveniently as a bone marrow aspirate, multiplied in culture and 
reintroduced at a defect site.
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marrow  of the  iliac  crest  will  be  termed  mesenchymal  stromal  cells  (MSCs). 
Where  authors  have  used  the  acronym  ‘MSCs’  to  define  ‘Mesenchymal  Stem 
Cells’,  it  will  be  used  with  the  knowledge  that  some  authors  may  use  the  term 
interchangeably  to  represent  ‘Mesenchymal  Stem  Cells’  and  ‘Mesenchymal 
Stromal  Cells’.  This  is because the  acronym  ‘MSC’,  as defined above,  is a term 
that encompasses the origin of plastic-adherent cells derived from the bone marrow 
stroma  without  implying  the  differentiation  potential  or  homogeneity  of  the 
population,  which  has  not  as  yet  been  sufficiently  characterised  (Horwitz  et  al.
2005).
1.4.3.1  MSCs are multipotent and heterogenous
MSCs have been shown to differentiate into cells of the connective tissue lineage 
such as bone, cartilage, tendon, adipose tissue, fibrous tissue and myelosupportive 
stroma  (Bianco  and  Robey  2000).  The  cells  of these  tissues  are  osteoblasts, 
chondrocytes,  tenocytes,  adipocytes  and  fibroblasts  respectively.  During  MSC 
division,  it  is  possible to  retain the  differentiation  potential  of the  cells  (Caplan 
1991).  In the bone marrow MSCs are only present in a ratio of 1:1,000,000 cells, 
(Hayensworth et al.  1992), but when cultured they continue to be multipotent and 
their  number  can  be  significantly  increased.  However,  when  Freidenstein 
transplanted single cfu-fs under the mouse renal capsule, they were shown to have 
different degrees of differentiation potential.  Fifteen percent of colonies produced 
bone,  adipose,  marrow  reticular  tissue  and  host  induced  haemopoeisis  forming 
heterotopic bone and marrow organ.  Another 15% produced bone with osteocytes, 
but  without  an  osteoblast  layer or bone  marrow cavity  and  the  majority  formed 
connective tissue without osteogenesis (Friedenstein 1980; Owen and Friedenstein 
1988).
Confirmation  of the  plasticity  of MSCs  is  exemplified  in  Freidenstein’s  in  vivo 
assay. Rabbit marrow cells were loaded into diffusion chambers, implanted into the 
peritoneal  cavity  that  excluded  host  cells  but  allowed  nutrient  diffusion. 
Histological  evaluation  confirmed  cartilage  development  in  the  middle  of the 
chamber  and  bone  apposing  the  internal  interface  which  was  encased  by
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highlight  the  different  environmental  cues,  triggering  distinct  phenotypic 
pathways.  Cartilage  formation requires a low nutrient and oxygen concentration 
which occurs in the  absence of blood vessels.  However bone formation requires 
high oxygen concentration, therefore  a blood  supply  is  required for osteogenesis 
(Caplan 1991).
1.4.3.2  MSCs are heterogenous
The  reasons  underlying  heterogenity  in MSC  populations  is  a contentious  issue. 
Caplan’s  experiment  (Caplan  1991),  described  above,  implies  that  the  cells  are 
multipotent  because  they  are  heterogenous.  Heterogenity  can  be  explained 
according to a number of theories.  One theory is that asymmetric division can lead 
to a number of cell populations in different stages of the cell lineage, as supported 
by the work of Conget and Colter. Although MSCs often appear morphologically 
homogenous,  they  in  fact  display  a  heterogenity  in  their  cell  cycle  in  vitro. 
Analysis of DNA and RNA content by FACS (fluorescence activated cell sorting) 
after  staining  with  acridine  orange  showed  that  20%  of MSCs  at  passage  three 
were quiescent in the Go phase of the cell cycle and 70% were in the Gap  1   (Gi) 
phase  (Conget  and  Minguell  1999).  In  the  Go  state,  a  cell  exits  the  cell  cycle 
reversibly or irreversibly and differentiates.  The Gi phase leads the cell into DNA 
synthesis  and  another  cell  cycle  (Freshney  2000).  According  to  Conget  et  al., 
FACS analysis identified 3 populations of MSC that interact with each other.  The 
small,  a-granular,  quiescent  cells  were  termed  recycling  stem  cells  1   (RSI)  and 
were identified by staining with the Ki-67, an antibody directed against proteins in 
the cell cycle.  RS-1  gave rise to RS-2 cells during the lag phase of growth, which 
in turn generate mature MSCs during the log phase. During the log phase, mature 
MSCs rapidly expanded.  RS-2 cells declined with a concurrent increase in RS-1 
cells during the late log phase (Colter et al.  2000).  Essentially this means that the 
self-renewal of mature MSCs depends on the presence of RS-1  cells  (Minguell et 
al. 2001).
A population of cells may  show heterogenity due to the  existence  of committed 
progenitors already within the population. It is possible to derive multipotent cells 
from  isolated  individual  colonies  of  human  MSCs  grown  from  a  single  cell.
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lineages  commonly  used  to  test  multipotency:  osteogenic,  adipogenic  and 
chondrogenic  (Pittenger et al.  1999; Muraglia et al.  2000).  Some clones showed 
restricted  potential,  which  is  partial  evidence  for  the  presence  of  committed 
progenitors with a more limited potential.  In vivo these cells could be subject to 
sequential  activation and  some might just be  genetically predisposed to  be more 
self-renewing  than  others.  Park’s  study  shows  a  close  association  between  the 
adipogenic and osteogeneic  lineage with clones of adipocytes transdifferentiating 
with osteogenic  lineage (Park et al.  1999).  This reflects the inter-relationship of 
the cells with the in vivo marrow environment.  For instance marrow is replaced by 
adipose tissue with aging (Prockop  1997).  Heterogenity in vivo will certainly be 
influenced by so called  ‘niche’  environmental cues such as diffusible factors (i.e. 
cytokines to be  discussed later),  extracellular matrix  (ECM)-cell  interactions and 
cell-cell interactions (Hall and Watt 1989).  Some of these environmental cues are 
employed  in  vitro  using  physiologic  concentrations  of synthetic  glucocorticoids 
such as dexamethasone  and other supplements  in order to  indirectly characterise 
MSCs by differentiation (Jaiswal et al.  1997).
Another  explanation  for  restricted  potential  of  some  clones  is  that  culture 
conditions  caused  a loss  in multipotentiality  (Pittenger et al.  1999;  Bonab  et al.
2006).  Characterising these cells would allow less potent cfu-f s in a heterogenic 
population to  be  discarded  or  set  aside  and  it  would  be  possible  to  pre-select  a 
subset of cells that may already be  slightly more committed to the bone  lineage. 
The osteogenic potential of marrow varies from patient to patient (Phinney et al. 
1999), and decreases with age in women (Muschler et al.  2001)  so expansion of 
MSCs  in  vitro  would  allow bone  remodelling  in  patients  with  a  low  MSC  cell 
count,  i.e.  patients  with age  related disorders  like  osteoporosis  (Bruder  and  Fox 
1999).  Osteogenic  commitment  and  differentiation  in  vitro  prior to  implantation 
may provide more rapid and consistent bone  formation (Caplan A.I.,  2000).  On 
the other hand, it may be beneficial to transplant a heterogenous population of cells 
that  would  already  be  interacting  via  cell-cell  communication  in  order  to  adapt 
better to the in vivo environment.  This is why, in my thesis, I will be using both 
pre-differentiated osteoblasts from MSCs and non differentiated MSCs.
481.4.4  Tissue source of MSCs
MSCs have been found to maintain a reservoir in many adult tissues of the body. 
MSCs have been isolated from several human, skeletally derived tissues including: 
marrow (Rickard et al.  1996), periosteum (Caplan  1991; Hutmacher and Sittinger 
2003),  muscle  (Caplan  1991)  and  fat  (Gronthos  et  al.  2001;  Park  et  al.  1999). 
Isolation of these  cells has also been  successful  from  a variety of animal tissues 
including  fetal  calvaria,  chick  limb  buds  (Caplan  1991)  and  rat  heart  muscle 
(Warejcka et al.  1996). The marrow stroma is thought to be the primary reservoir 
for these  self replicating  cells  (Beresford  1989;  Owen  1985).  The  word  stroma 
literally  means  ‘matress:  anything  spread  or laid  out  for  lying  upon’  and this  is 
exactly  what  the  stroma  of  the  bone  constitutes  (Owen  1985).  Stroma  is 
connective tissue within the marrow that provides structural and functional support 
for haematopoesis (Beresford 1989).  By definition this suggests that stromal cells 
are interconnected and unmoving, supporting the mobile cells of the haematopoetic 
system, which is the other main cell compartment of the bone marrow (Kuznetsov 
et al. 2001).
However,  there  is  some  evidence  of MSCs  circulating  in  the  peripheral  blood 
(Kuznetsov  et  al.  2001)  and  umbilical  cord  blood  (Erices  et  al.  2000),  which 
challenges  previously  held  opinions  that  such  cells  are  quiescent  and  non­
circulating (Bianco and Robey 2000; Kuznetsov et al. 2001).  The rationale behind 
this is that HSCs are required to replicate  continually to maintain the number of 
cells at a constant level (Hall and Watt  1989) whereas MSCs embed in the tissue, 
respond  to  injury  or remodelling,  which  leads  to  their  differentiation  and  limits 
their  self renewing  potential  (Hall  and  Watt  1989;  Bianco  and  Robey  2000). 
Evidence for this is that self-renewal is lost as commitment to a lineage increases 
(Colter et al.  2000).  However MSCs are still purported to be found in the blood 
system,  suggesting that they can be mobilised in response to  injury and have  an 
inherent  homing  capability  (Minguell  et  al.  2001;  Devine  et  al.  2003).  The 
homing  capacity  of  MSCs  and  subsequent  regeneration  of  damaged  tissue  is 
supported by research on skeletal muscle and the heart.  In one paper lacZ marked 
mouse  MSCs  were  injected  into  irradiated  mice  that  had  chemically  induced 
muscle regeneration by injection of cardiotoxin in the tibialis anterior (TA).  MSC
49derived myogenic progenitors were detected in both immature and mature muscle 
fibres in the TA by p-galactosidase staining (Ferrari et al.  1998).  Barbash, I.M. et 
al.  demonstrated  that  intravenous  infusion  of  MSCs  in  rats  with  myocardial 
infarction led to MSC engraftment in the damaged tissue of the heart in preference 
to intact or remote myocardium, although direct left ventricular cavity infusion led 
to  significantly  greater engraftment  in the  ischemic  heart  (Barbash  et al.  2003). 
Furthermore,  when  allogenic  MSCs  were  injected  into  the  jugular  vein  of MI 
(myocardial infarction) induced pigs and analysed for parameters of heart function 
after  3  months,  they  were  found  to  have  less  hypertrophy  and  left  ventricular 
ejection fraction than control animals.  In addition small numbers of MSCs were 
found  in  injured  portions  of the  heart  (Price  et  al  2005).  These  discoveries 
increase  the  possibilities  for  therapeutic  intervention  using  stem  cells.  If  a 
systemic  injection  of  cells  could  be  used  it  may  be  an  expedient  form  of 
transfusion similar to the principles of leukophoresis.
1.4.5  Isolation and characterisation of MSCs
Characterisation  methods  in  vitro  have  primarily  relied  on  differentiation  of an 
adherent  population  of cfu-fs  into  the  three  different  lineages  of skeletal  tissue 
cells:  osteoblasts,  chondrocytes  and  adipocytes  (Pittenger  et  al.  1999).  It  is 
possible to identify these cells by morphology; cell surface characteristics, such as 
antigens  for  immunophenotyping;  and  synthesis  of  extracellular  matrix  and 
biochemical molecules. Markers for adipocytes include intracellular lipid vacuoles, 
the  presence  of  peroxisome  proliferator-activated  receptor  y2  (PPARy2)  and 
lipoprotein  lipase  (LPL).  Chondrocytes will  present collagen X  and  collagen  II 
(Pittenger et al.  1999).  The production of osteoblasts and bone is associated with a 
number of organic components of bone synthesised by the cells at different stages 
of the lineage progression.  Some examples of the extracellular matrix proteins and 
enzymes produced by osteoprogenitors and the  mature  osteoblast phenotype that 
are used commonly for identification in vitro include:  collagen I  (Gronthos et al. 
2001), OC (Muraglia et al. 2000), alkaline phosphatase (ALP) (Jaiswal et al.  1997) 
and  OP  (Gronthos  et  al.  1994).  Collagen  has  previously  been  discussed  as  the 
most abundant protein in the organic matrix of bone.  It is secreted by osteoblasts 
into  the  extracellular  matrix  and  is  composed  of a  triple  helix  of tropocollagen 
molecules.  The tropocollagen aggregates  into  fibrils which are  congregated into
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and  is  secreted  throughout  osteoblast  differentiation  (Hughes  and  Aubin  1998). 
However, collagen I is produced by a number of other cell types and is not specific 
to osteoblasts.  ALP is an enzyme that has been described as prompting phosphate 
ions to accumulate on collagen fibrils.  Osteoblasts express the tissue non-specific 
form of the enzyme which is highly expressed in bone,  liver and kidney (Young 
and Heath 2000).  It is  expressed in differentiating osteoblasts  in vitro.  It makes 
sense  that  ALP  peaks  in  expression  at  day  12  and  then  declines  (Bruder  et  al 
1997)  because  the  function  of ALP  is  to  encourage  mineral  deposition  which 
requires  collagen to  be  present  first.  OC  is  the  most  abundant non-collagenous 
protein in bone and may have a role in bone remodelling (Beresford et al.  1984). 
OC production is almost exclusive to osteoblasts (Hughes and Aubin  1998).  OP 
may  have  a  role  in  attachment  of  cells  to  bone  matrix  via  the  Arg-Gly-Asp 
sequence  of amino  acids  (RGD).  Less  commonly used as markers  are  ON,  and 
proteoglycans,  such as decorin and biglycan, because they are either expressed at 
low levels or are expressed by other cell types within the bone matrix (Hughes and 
Aubin 1998).  As the expression of proteins within each cell type can overlap (i.e. 
ALP  is  expressed  in  many  cell  types  and  OP  is  expressed  in  osteogenic  and 
chondrogenic pathways) (Pittenger et al  1999), the most reliable identification of 
osteogenic  differentiation is a gamut of protein assays  or a mineralisation assay. 
The transcription factor cbfa-l/Runx2 was found to induce and regulate expression 
of multiple genes in osteoblasts and chondrocytes (Karsenty et al  1999; Ducy et 
al  1997)  and  may  be  used  as  a  specific  marker  to  identify  the  preosteoblast 
phenotype  (Nakashima et al  2002).  In addition, the transcription factor Osterix 
acts  downstream  of Cbfal/Runx2  to  induce  differentiation  of preosteoblasts  to 
osteoblasts (Nakashima et al 2002).
Each protein can be described within the context of its physiological role in bone 
formation  and  remodelling,  or  the  temporal  role  it  plays  in  osteoblast 
differentiation  in  vitro  where  investigators  have  often  seen  different  patterns  of 
expression with respective proteins.  There is a changing pattern of expression of 
each  marker  during  osteoblastic  differentiation.  Investigators  have  observed 
different patterns of expression between species and different cell lines.  Variation
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investigation (Hughes and Aubin 1998).
Human  MSCs  have  been  investigated  more  thoroughly  than  any  other  species. 
There  has  still  not  been  a  single  specific  marker  that  completely  identifies  the 
multipotent MSC (Baksh et al. 2004).  It is a common consensus that mesenchymal 
stromal  cells  do  not  express  heamatopoeitic  antigens  CD 14,  CD34  and  CD45 
(Pittenger et al.  1999; Conget and Minguell  1999).  The immunophenotype of the 
MSC  is  defined by the  antigens  it  lacks  when compared to haematopoetic  cells, 
rather than specific antigens on its surface.  This may be a problem as antigens on 
MSCs tend to be present on cells of other tissue types.  The antibodies SH2, SH3 
and SH4 were found to react with MSCs and not haematopoietic cells, osteoblasts 
or osteocytes.  However, they do cross react with fibroblastic cells (Hayensworth 
et al.  1992).  The STRO-1  antibody is similar in that it identifies early osteoblast 
progenitors,  but is not expressed exclusively by the MSC  (Simmons  and Torok- 
Strob  1991).  The  expression  of the  antigen  detected  by  STRO-1  diminishes  as 
cells begin to express the mature osteoblast phenotype (Gronthos et al.  1994).  So 
STRO-1 is another marker that is dependent on the lineage progression of the MSC 
(Wiilling  et  al.  2003).  Figure  1.4  shows  the  antibodies  that  can  be  used  to 
characterise each cell of the osteoblastic development lineage in humans (Wiilling 
et al.  2003).  The  cell  surface markers  for human MSCs  are  shown  in the table 
below (Table 1).
CD105  CD73  CD166  CD166  Stro-1  Stro-1  ALP  ALP
MSC
SH2, SH3, SH4
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osteoblast
osteoblast Osteopro
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  ►
Stro-1
  +
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  ►
Figure 1.4 Osteoblastic differentiation and marker expression (Wiilling etal. 2003).
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Marker  expression
Human MSCs Human MSCs
(Kuznetsov et al., 2001) (Deans and Moseley, 2000)
Fibroblastic
Col I ++
Col  III ++
CD44 ++
Bl  subunit ++
Osteogenic
ON ++
OPN -+
BSP -+
OC -+
Adipogenic
CEBPal -+
PPARy2 -
Endothelial
CD34 - Neg
Muc-18 CD146 + Pos
FactorVIlI -
Endoglin +
Marrow stromal cells
Stro-1 -+
CD106 (VCAM-1) Adhesion molecule + Pos
Smooth muscle
a-smooth muscle actin -+++
Skeletal muscle
MyoD -
Monocyte/Macrophage
CD 14 Dako  LPS receptor - Neg
Leukocyte
CD45 (Dako) leukocyte common antigen -
Nerve
Neurofilament (Dako) -
Histochemical
ALP -+++
Acid Phosphatase +
A-Napthyl acetate esterase +
Oil red 0
20% FBS -+
20% rabbit serum ++
Adhesion molecules
ALCAM CD 166 Pos
1CAM-1  CD54 Pos
ICAM-2 CD102 Pos
E-selectin CD62E Neg
L-Selectin CD62L Pos
P-selectin CD62P Neg
LFA-3 CD58 Pos
Cadherin 5 CD 144 Neg
PEC  A M -1  CD31 Neg
NCAM CD56 Pos
HCAM CD44 ++ Pos
Hyaluronate receptor Pos
Growth factors & cytokine receptors
IL-R (a OR 3) CD121a,b Pos
IL-2r CD25 Neg
IL-3R CD123 Pos
1L-4R CD124 Pos
1L-6R CD126 Pos
IL-7R CD127 Pos
Interferon y R CDwl 19 Pos
TNF- a-IR CD120a Pos
Table 1.1 Cell surface markers for human MSC
531.4.6  Application of MSCs with 3D scaffolds in vitro and in 
vivo
There are two approaches to tissue engineering.  One is to attempt to grow tissues 
in  vitro  with  a  view  to  implanting  the  entire  regenerated  organ  in  place  of the 
damaged one.  The other option is to partially grow the tissue in vitro in order to 
allow for regeneration of the organ in vivo.  Most attempts at regeneration of bone 
tend towards the latter.  The combination of HA, or constructs incorporating HA, 
with  MSCs  or  MSC  derived  osteogenic  cells,  has  proved  feasable  as  a  tissue 
engineered  scaffold  for ectopic  bone  formation  in  small  animal  models  such  as 
mice (Gundle et al.  1995; Harris and Cooper 2004;  Gundle et al.  1997) and rats 
(Okumura et al.  1996).  The  diffusion chamber is a system that can be  used to 
isolate  either autogenic or allogenic MSCs which allows the effects of stem  cell 
origin to be measured.  In these studies the nature of the enclosed system means 
that bone that is produced is derived soley from cells within the diffusion chamber 
(Gundle et al.  1995; Gundle et al.  1997), as diffusion chamber membranes are not 
permeable to cells. When MSCs were loaded onto various HA containing matrices, 
cells induced bone on 2 out of 4 constructs after implantation into the dorsum of 
severe  combined  immunodeficient  (SCID)  mice  compared  to  controls.  This 
showed that MSCs were required for osteogenesis.  However some matrices were 
not inducible, despite the introduction of cells (Harris and Cooper 2004).
Ectopic  models  have  also  been  applied  in  large  animal  models  to  elucidate  the 
osseoinductivity of MSCs.  All the tissue engineered constructs containing HA and 
MSCs formed bone when implanted into the paraspinal muscles of goats (Kruyt et 
al.  2004b).  Orthotopic,  segmental defect models  are  more  representative  of the 
surrounding bone tissue and loading regimens.  MSC loaded HA constructs were 
implanted into segmental defects in rat femora.  They achieved superior union of 
the  host-implant  interface  compared  to  marrow  loaded  or  cell  free  implants. 
However, the diffusion chamber test and ectopic models do not accurately reflect 
the  loading  demands  on  orthopaedic  implants  (Lane  and  Sandhu  1987). 
Additionally,  the  results  on bone  regeneration from  segmental  defects  in  animal 
models  cannot  necessarily  be  translated  into  the  use  of  tissue  engineering
54constructs  for impaction grafting.  A  large animal  study in goats  showed that  all 
constructs  required  the  addition  of  MSCs  to  induce  bone  formation  as,  after 
implantation in the paraspinalis muscles, there was no  sign of bone formation in 
control  constructs  alone  (Kruyt  et  al  2003).  Conversely,  another  study  by  the 
same  group  comparing  the  results  of MSCs  on  HA  at  ectopic  and  orthotopic 
locations  suggests  that  cells  make  a  limited  contribution  to  constructs  in  an 
orthotopic  location.  It  was  observed  that  there  was  significantly  more  bone 
apposition  at  the  shortest  timepoint  compared  with  larger  bone  contributions  at 
early and late timepoints in the ectopic model  (Kruyt et al.  2004c).  Successful 
tissue engineering to repair segmental defects in large animals include:  the use of 
allogenic (Arinzeh et al 2003) and autologous (Bruder et al  1998b) MSCs seeded 
onto HA cylinders to regenerate femoral, canine segmental defects; MSCs seeded 
onto  HA  cylinders  implanted  into  sheep  tibial  segmental  defects,  where  bone 
formed more extensively and indentation testing revealed greater stiffness  in cell 
loaded constructs (Kon et al 2000), and similar results were found in the work of 
Chistolini et al  (Chistolini et al  1999).  The clinical union of critical size defects 
in sheep metatarsals on  tissue engineered coral cylinders with MSCs was defined 
by continuity of both cortices on radiographic analysis (Petite et al  2000).  Since 
metatarsal  diaphyses  contain  no  trabecular  bone  and  have  different  loading 
regimens, it is difficult to compare with femoral or tibial defect models.  However, 
there  was  an  increase  in  clinical  union  in  MSC  treated  samples  compared  to 
marrow or coral alone and some evidence of osteogenesis in the medullary areas in 
MSC  loaded  samples.  Blokhuis’s  group  used  HA  particles  as  a  carrier  for 
autologous marrow in an ovine segmental defect model.  The results show that the 
addition of bone marrow did not lead to acceleration of bone healing compared to 
autologous bone grafting (Blokhuis et al  1999).  However this may be a factor that 
is associated with the use of dense HA granules rather than MSCs.
1.4.7  Clinical application of tissue engineering using MSCs
The mobilisation and transplantation of HSCs has been an accepted form of cancer 
treatment in patients undergoing chemotherapy  since the  1990’s.  Leukaphoresis 
can  be  applied  as  an  autogenic  or  allogenic  treatment  whereby  mobilisation  or 
transplantation  reconstitutes  hematopoeisis  repectively.  The  application  of the
55growth factors  Granulocyte  colony  stimulating  factor (G-CSF)  and Granulocyte- 
macrophage  colony  stimulating  factor (GM-CSF)  reconstitutes  white  blood cells 
and  also  boosts  hematopoeisis,  making the process  more  efficient  (Jansen et al. 
2005).  While  use  of haematopoetic  cells  is  commonly  accepted,  the  clinical 
transplantation of MSCs has just begun and is in the early stages of investigation. 
A  clinical  study  of  three  patients  with  osteogenesis  imperfecta  indicates  that 
allogenic  bone  marrow-derived  MSCs  transplanted  by  intravenous  infusion  can 
migrate  to  bone,  improving  bone  structure  and  function  (Horwitz  et  al.  1999). 
Autologous transplantation of bone marrow has been attempted in tibial shaft non­
unions.  Although there was no negative control,  increased callus formation was 
associated with the number and concentration of cfu-fs in the marrow (Hemigou et 
al  2005).  However there  have been no  investigations  into the  use  of MSCs to 
regenerate new bone in a revision total hip replacement.
Aim
To  enhance  new  bone  formation  around  revision  THRs  by  incorporating 
mesenchymal stromal cells (MSCs) with allograft used for impaction grafting.
Hypothesis
Incorporating MSCs into allograft or HA granules which are then impacted, 
will increase the rate and extent of bone formation.
56CHAPTER 2: In vitro Impaction of Mesenchymal 
Stromal Cells on an Allograft Scaffold
572.1  INTRODUCTION
One  o f the  effective  methods  currently used to  regenerate  bone  stock  at revision 
surgery is  impaction o f cancellous  bone  graft with or without bone  cement.  This 
technique has been shown to provide structural and functional support encouraging 
ingrowth o f host bone  (Tagil 2000;  Soballe et al.  1992).  Impaction occurred with 
cement was first used in combination with implants to treat acetabular protrusion 
(Sloof et al.  1984).  This  technique  was  then  developed by the  Exeter  Group  for 
fixation  o f the  revison  femoral  component  (Gie  et  al.  1992;  Gie  et  al.  1993). 
Impaction  occurred with  cement  does  have  considerable  advantages  and  to  date, 
results  from  various  centres  with  follow-ups  ranging  from  2-10  years  have  re- 
revison  rates  for  aseptic  loosening  o f between  4  and  8  %  (Meding  et  al.  1997; 
Leopold  et  al.  1999;  Mikhail  et  al.  1999).  Histology  from  biopsy  samples  has 
shown viable tissue growth into the graft (Ling et al.  1993). However, regeneration 
o f new bone within defects surrounding revision implants has shown rather lim ited 
and inconsistent results (Ullmark and Obrant 2002; M ikhail et al.  1999).
A number o f animal studies have demonstrated that tissue engineering techniques 
using  autologous  mesenchymal  stromal  cells  (MSCs)  combined  with  a  suitable 
carrier,  can  create  new bone  in the  defect  site  (Bruder  et al.  1998b;  Kruyt  et al. 
2003;  Kon  et  al.  2000).  A  combination  o f tissue  engineering  techniques  using 
autologous  MSCs  with clinical  impaction o f allograft  in revision  surgery may be 
able to  regenerate  bone  stock and  improve  long-term  implant  fixation.  However, 
one question that has to be answered is:  Can MSCs  seeded onto  allograft  survive 
after undergoing normal impaction forces used for revision THRs?
Aim
To answer this question, a study was carried out in vitro to test the viability of 
the MSCs which were seeded  onto the allograft and impacted  at a  range of 
forces obtained during revision THRs.
Hypothesis
MSCs seeded onto allograft scaffolds will survive normal impaction forces.
582.2  MATERIALS AND METHODS
2.2.1  Harvesting MSCs
2.2.1.1 Obtaining bone marrow
Bone  marrow from  the  iliac  crest was  aspirated  from  nine  sheep.  A ll  procedures 
were carried out in accordance with the Animals (Scientific Procedures) Act  1986 
at the Royal Vetinary College, North Mymms. Home Office Licences were held by 
all those taking part in any surgical procedure.
Sheep  were  premedicated  with  intramuscular  Xylazine  at  0.1 mg/kg  10  minutes 
pre-operatively.  Induction  o f  anaesthesia  was by intravenous  injection 
o f Ketamine 2mg/kg and Midazolam 2.5mg.  The  animal was then intubated and 
maintained  on  2% Halothane  and  oxygen  for  the  duration  o f  the  aspiration. 
Intraoperative monitoring consisted o f pulse oximetry,  ECG and end tidal  carbon 
dioxide.
The  sheep  were  placed  in the  left  lateral  position  and the  fleece  above  the  right 
iliac crest was shaved to the skin.  Pevidine surgical scrub was used to wet the area 
at  1  part pevidine to 9 parts water.  Neat pevidine surgical scrub was then applied 
and  worked  into  a  lather.  This  was  left  for two  minutes.  The  area was  further 
sterilised  with  pevidine  antiseptic  solution  by  swabbing  the  area  with  a  spiral 
motion from the  □ steoc o f the aspirate area outwards.  A swab was used to wipe 
down the entire area with Hydrex solution-chlorohexidine and the whole area was 
covered with a drape.
A  stab  incision was  made  down to the  iliac  crest  under  sterile  conditions.  The 
bone  marrow  gauge  needle  was  twisted  into  the  intramedullary  cavity.  A  10ml 
syringe  pre-loaded  with  1ml  heparin  at  1000  iu/ml  was  attached  to  the  marrow 
gauge  needle  and  used  to  aspirate  3ml  o f bone  marrow  from  the  intramedullary 
cavity o f the iliac crest.  The marrow was then transferred into a sterile universal 
tube,  swirled  slightly  to  mix  the  heparin  with  marrow  to  prevent  clotting  and 
placed on ice  for transfer to tissue  culture  facilities.  A  subsequent two  aspirates 
were taken from different positions, working from anterior to posterior, on the iliac
59crest in the same manner as described above.  After the procedure was completed 
the incision was sutured using a resorbable zero vicryl™  suture.
2.2.1.2 MSC Isolation
The bone marrow and heparin mixture,  containing a heterogeneous population o f 
cells,  was  centrifuged  down  a  Ficoll®  (Amersham  Pharmsia  Biotech,  UK, 
17144002) sugar-sucrose  gradient in order to isolate a homogenous population o f 
mononuclear cells consisting o f MSCs.  MSCs were further selected by attachment 
to tissue culture plastic in vitro.  Firstly, 3ml o f Ficoll® was added to a universal. 
The aspirate was gently dispensed down the side o f a universal onto the Ficoll®  to 
give  a bottom layer o f Ficoll® and an upper layer o f bone marrow.  The  sample 
was centrifuged at 1510 rpm (400g) for 30 minutes, leaving a straw coloured buffy 
layer  at  the  interface  between  a  ficoll®   erythrocyte  residue  at  the  bottom  and  a 
plasma  layer  above.  A  transfer  pipette  was  used  to  remove  the  buffy  layer, 
containing mononuclear cells, to a separate universal.
The  buffy  layer  was  resuspended  in  10ml  Dulbecco’s  modified  eagles  medium 
(DMEM,  Sigma  D6429),  spun  at  1500rpm  for  10  minutes  to  pellet  the 
mononuclear  cells,  leaving  the  Ficoll®  and  heparin  in  suspension  which  was 
subsequently  discarded.  The  cell  pellet  was  resuspended  through  a  23  gauge 
needle  using  2ml  o f DMEM  to  give  a  single  cell  suspension.  The  pellet  was 
resuspended in 10ml DMEM, centrifuged at 1500 rpm for 5 minutes.  The pellet o f 
mononuclear  cells  was  further  washed  by  resuspending  and  centrifuging  before
'y
being finally resuspended in DMEM and plated into two 25cm  flasks.  Cells were 
maintained  in  incubators  at  37°C  with  5%  CO2  in  growth  media  consisting  o f 
Dulbecco’s modified eagles medium (DMEM) supplemented with  10% FCS (First 
Link,  West  Midlands,  UK),  penicillin  /  streptomycin  (lOOOiu/ml;  100pg/ml) 
(GIBCO  Paisley,  UK).  These  conditions  remained the  same  for all  in  vitro  cell 
culture procedures unless stated otherwise.
2.2.1.3 Cell culture
A  defining  characteristic  o f MSCs  that  enables  their  selection  in  vitro  is  their 
adherence  to  tissue  culture  plastic  (Colter  et al.  2000;  Friedenstein  et  al.  1976;
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adhere  to  tissue  culture  plastic  for  two  days  before  the  DMEM  was  replaced, 
thereby  diluting  and  eventually  removing  any  haematopoietic  cells  from  the 
suspension.  DMEM was replaced every two to three days and cells were grown to 
subconfluence before harvesting.  Subconfluence is a state o f growth where not all 
the available flask surface is covered.  The lim it o f subconfluence was defined by 
eye at 60-90% coverage.  Confluence is where total growth area is used and MSCs 
make  close  contact  with  one  another.  It  was  important  that  cells  did  not  reach 
confluence  at  any  point  during  culture.  This  is  because  MSCs  w ill  maintain  a 
consistent  phenotype  if  the  cell  density  is  kept  low  and  be  less  susceptible  to 
spontaneous  transformations  (Freshney  2000).  Transformation  is  a  result  o f 
genetic  instability  where  spontaneous  or  induced  permenant  phenotypic  change 
results  from  a  heritable  change  in  DNA  and  gene  expression:  immortalisation, 
aberrant growth control and malignancy (Freshney 2000).
Expansion o f the  cells  was continued by trypsinisation,  to  remove  the  cells  from 
the  flask  surface,  washing  and re-plating  into  new flasks.  DMEM  was  removed 
from the flasks.  The flask was rinsed by the addition o f 5ml PBS. Trypsin (Sigma 
T8003) was then added at a volume o f 2.5ml and a concentration o f 10% with  1% 
HEPES buffer.  The flasks were then placed in an incubator for 5 minutes to allow 
the enzyme to release cells from the tissue culture plastic.  The flasks were agitated 
to  further release  cells.  Enzyme  activity was  quenched with the  addition o f 5ml 
DMEM.  A ll  cells  were  removed  to  a  universal  and  centrifuged  at  1500rpm  to 
pellet the cells and remove trypsin into suspension.  Trypsin was removed and cells 
were  resuspended  in  10ml  DMEM  to  further  wash  the  cells.  After  the  final 
centrifugation  at  1500rpm,  cells  were  resuspended  in  DMEM  and  replated  at 
passage  1   (PI) into three T75  flasks.  Cells were trypsinised into larger flasks on 
subsequent  passages.  Cells  in  this  study  were  used  between  passages  3  and  6. 
This  cell  culture  technique  was  used  for  all  in  vitro  cell  culture  unless  stated 
otherwise.  Cells  were  counted  after  resuspension  in  1ml  o f DMEM.  An  equal 
volume o f this suspension and trypan blue were mixed together and the cells were 
introduced  into  a  coverslipped  haemocytometer.  Cells  stained  blue  were 
considered dead whereas viable, bright and rounded cells were counted where they
61fell within the bounds o f haemocytometer divisions.  This procedure was used for 
all subsequent cell counting.
2.2.1.4  Growth curve for sheep MSCs in monolayer
In  order to  ensure  that  cells  were  impacted  at  the  most proliferative  and  durable 
stage  o f development,  a growth curve  was  constructed.  A  series  o f cultures were 
set up at  a cell  density o f 3  x  104  cells/ml  and the  cells were  counted daily until 
they  reached the  plateau phase.  Three  cell  lines  (n=3  animals)  were  cultured to 
passage  4  using  standard  tissue  culture  techniques  previously  described.  The 
MSCs were trypsinised into suspension with 3 x  104 cells/ml in 25 ml o f medium. 
The cells were seeded onto 24 well plates with 1ml o f cell suspension in each well. 
The cultures were maintained at 37°C with 5%  CO2  in the original growth media 
and cells were counted from three wells o f each plate every 24 hours for five days.
2.2.2  Processing long bones for allograft
2.2.2.1  Harvesting ovine long bones
Allograft was made following North London Tissue Bank Protocols.  Fresh ovine 
femoral bones were harvested from the Royal Veterinary College, North Mymms. 
Femoral  bones  were  frozen  immediately  at  -20°C  until  retrieval  for  processing. 
Bones were thawed for 30 minutes and any attached soft tissue and cartilage were 
removed.  Cortical  bone  was  removed by trimming  on the  Draper bandsaw until 
only trabecular bone remained, which was further cut into manageable pieces.
2.2.2.2. Morsellising, defatting and irradiation of  graft
Sections o f bone were passed through the Lere Bone M ill to morsellise the  graft. 
Further  processing  by  washing  the  morsellised  graft  removed  protein,  cells  and 
tissue,  reducing  the  possibility  o f an  immune  response  o f the  recipient  to  donor 
antigens,  disease  transmission  or  extraneous  contamination.  The  water  in  all  the 
washing  steps  was  maintained  at  55°C.  The  morsellised  graft  was  washed  by 
placing in an ultrasound bath filled with water and sonic washed for  15 minutes to 
remove  cells  and blood.  The  following  series o f washes were:  three  consecutive 
water washes o f 15  minutes, a water wash for 60 minutes, a  10 minute wash with
6270% alcohol to denature cellular proteins and k ill viruses and bacteria, followed by 
two  final  water  washes.  The  allograft  was  patted  dry  ready  for  sieving.  A ll  the 
graft was placed at the top o f the pile o f sieves and shaken for half an hour until all 
the  graft  had  fallen  into  its  relevant  sized  sieve,  so  that  graft  was  sieved  to  a 
uniform  size.  For  this  study,  the  graft  size  was  in  a range  o f 2.4-4.76mm.  The 
allograft  was  sent  to  Isotron  on  dry  ice  to  be  gamma  irradiated  at  25Kgrays 
(Isotron, Reading, UK).  Allograft was maintained in storage at -20°C.
2.2.3  Determining impaction forces
2.2.3.1  Modified impactor
The impaction data used in this project was based on the Exeter X Change system 
and  was  previously  collated  by  Kirsty  Phipps  at  the  Centre  o f  Biomedical 
Engineering  (Phipps  et al.  2002).  In  order to  establish  impaction  forces  used  in 
revision  THR,  the  Exeter  Slap  Hammer  was  modified  to  accommodate  a  piezo 
electric load washer (figure 2.1).  Force readings were emitted by the load washer 
at each impaction which were converted into voltage and recorded on a specialized 
computer  program  (Skylark  Ltd,  London,  UK).  By  impacting  graft  enclosed 
within a  sawbone,  using  a proximal  impactor fitted with a load  washer using the 
instrumented hammer also containing a load washer, it was possible to measure the 
forces  imparted  to  the  graft  material  and  relate  these  to  the  measured  hammer 
forces.
Figure  2.1a  The  Exeter  slap  hammer;  b  Hammer forces  measured  in  the  graft  (G) 
impacted  in  a  sawbone  using  load  washers  (denoted  by  black  squares)  in  hammer 
(H), and in proximal impactor (I) (Phipps 2004)
2.2.3  2 Drop heights to replicate forces used in a normal surgery
The normal  range  o f impaction forces measured by the modified Exeter impactor
was  reproduced  in  an  in  vitro  impactor.  The  piezo  electric  load  washer  was
63attached  to  the  impactor  to  record  forces  in  different  height  o f drops.  3.5g  o f 
allograft  was  added to  a Delrin tube  which  was  15mm  in diameter and 40mm  in 
height.  The  1kg  weight  on  the  impactor  was  dropped  onto  allograft  contained 
within the tube (figure 2.2).  Impactions were performed at a range o f heights from 
2.5  to  20cm  with  increments  o f 2.5cm.  Readings  were  taken  10  times  at  each 
height.  Graft was changed after each height and force readings were recorded.  A 
calibration graph o f force versus drop height was constructed.
Figure  2.2a  Impactor;  b  Detail  of impactor with  Weight  (W),  Weight  stop  (WS)  and 
Delrin tube (D)
2.2.3  3 Optimum number of impact cycles to achieve maximum compaction
The graft material was contained within a Delrin tube. A punch directly attached to 
the impaction hammer, fitting inside the tube and in contact with the graft, delivered 
the  force  o f  each  impact  to  the  graft  at  3kN.  At  the  same  time  a  micrometer 
measured  the  displacement  (compaction)  o f the  graft  for  every  impaction.  The 
number o f impactions used throughout this thesis was  set at the  lim it o f maximum 
compaction,  which  was  the  number  o f  cycles  after  which  there  is  little  or  no 
deformation in the graft.  Different  sizes o f graft were used to represent the choices 
made  in surgery.  Small graft was between 2.0-3.2mm and the  large graft consisted 
o f granules in the size range 4.76-6.68mm.  The graded graft was a mixture o f graft 
sizes (Phipps 2004).
642.2.3.4 The collapse of graft under different loads
Samples  o f  3.5g  o f  allograft  were  placed  into  3  Delrin  tubes.  Each  tube  was 
impacted  at  3,  6 or 9kN.  Readings were taken  100 times at each force to measure 
the  degree  o f collapse  o f the  graft.  A  graph  was  plotted  to  determine  whether  a 
larger  number  o f impactions  at  a  lower  force  could  achieve  the  same  degree  o f 
compression o f the graft as a smaller number o f impactions at a higher force.  Using 
less force to achieve the same degree o f impaction may maintain the viability o f the 
cells seeded onto the graft.
2.2.4 Determining seeding technique: suspension or density 
seeding
Sheep  MSCs  were  trypsinised  from  tissue  culture  flasks,  all  cells  were 
subconfluent at passage 3.  Sheep MSCs were seeded at 2 x  106 cells/g onto 3.5g o f 
allograft  in  a  universal  tube  with  7ml  DMEM  10%  FCS  and  penicillin  / 
streptomycin  (1000  iu/m l;  lOOpg/ml).  Another  sample  o f 3.5g  o f allograft  was 
placed  in  a petri  dish  and  seeded  with  2 xl0 6 cells/g  by  density  seeding.  Density 
seeding was achieved by dispensing the  cells  suspended in 500pl  o f DMEM onto 
each  individual  piece  o f allograft  using  a  Gilsons  pipette.  The  cells  were  left  to 
adhere to  the  graft  for 30  minutes  in the  37°C  incubator,  at  which point the  graft 
was  flooded  with  7ml  DMEM.  There  was  one  allograft  sample  w ith  no  MSCs 
which  was  the  control.  After  72  hours  under  tissue  culture  conditions,  two 
granules  from  each  sample  were  processed  for  SEM  analysis.  The  seeding 
technique was chosen based on even coverage o f the graft by the MSCs.
2.2.5 In vitro impaction of MSCs on allograft
2.2.5.1  Suspension seeding of MSCs onto allograft for impaction
The  decision to  suspension  seed MSCs  onto  allograft  in  a rotator was  due  to  the 
findings from  SEM analysis.  MSCs were trypsinised from culture flasks, counted 
and  seeded  at  2  x  106 cells/g  onto  3.5g  o f allograft  in  a  universal  tube  w ith  7ml 
DMEM,  10% FCS and penicillin / streptomycin (1000 iu/m l;  lOOpg/ml).  A ll cells 
were sub-confluent at passage 3.  Control universal tubes (n=9) contained allograft 
only  with  7ml  o f DMEM.  Cells  were  attached  to  the  allograft  by  rotation  on  a 
TAAB rotator (TAAB, UK) spinning at 4rpm for 2.5 hours at 37°C w ith 5% CO2.
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72 hours pre-impaction, as determined by the growth curve. There were 9  samples 
for each  force  group,  including  the  OkN  control  where  MSCs  were  added but  no 
impaction force was used.  In addition, two granules  o f graft were removed from 
each sample for SEM analysis after 2.5 hours and 72 hours in culture.
2.2.5.2 Impacting constructs in Delrin tubes
Allograft  at  3.5g  was  added  to  a  Delrin  tube  which  was  15mm  in  diameter  and 
40mm  in  height.  Impaction  forces  o f 3kN,  6kN  and  9kN  were  selected  because 
they  represented  low,  medium  and  high  impaction  forces  measured  by  the 
instrumented slap hammer during surgery.  The forces were regulated by the drop 
height o f the  1kg weight attached to the impactor which was specially designed for 
this study (Figure 2.2a &  2.2b). 20 impactions were applied at each selected force. 
OkN was used for the control group.
2.2.5.3 Alamar Blue ™ Assay
The  graft  conduits  were  analysed  using  a  1   in  10  dilution  o f  Alamar  Blue™ 
(Alamar Biosciences,  UK)  with phenol  red free DMEM,  after washing in PBS.  A 
solution  o f Alamar  Blue™  is  a  biochemical  indicator  o f cells  metabolism  that 
changes from blue to pink in response to redox reactions in the cytochrome oxidase 
chain.  Samples  were  incubated  in  Alamar  Blue™  for 4  hours  at  37°C,  5%  CO2. 
The Alamar Blue™ solution was then removed and absorbance was read at 570nm 
w ith  a  reference  wavelength  o f  630nm  on  a  Fluoroscan  Ascent  plate  reader 
(Labsystems  Inc,  USA).  The  grafts  were  then assayed w ith a  1   in  10  dilution o f 
Alamar  Blue™  after  samples  were  impacted.  For  continued  culture,  allograft 
conduits were washed twice with PBS  and fresh DMEM was added to  each well. 
The  samples  were  then  assayed  in  the  same  manner  daily  for  six  days  and 
maintained in culture at 37°C with 5% CO2 with a change o f culture medium every 
day.  One granule o f graft was taken from each impaction group after six days for 
SEM  analysis.  One  sample  from  each  group  was  fixed  for resin  sectioning  after 
six days.
662.2.5.4 Resin embedding of samples
To  demonstrate the presence  and distribution o f MSCs on allograft  samples,  after 
impaction and  incubation for 6  days,  one  sample  from  each impaction group was 
processed in LR White hard grade resin for analysis (as above).  Initially samples 
were rinsed for five minutes in PBS.  This was repeated 3 times then samples were 
fixed w ith neutral buffered formalin for one day.  Samples were placed back into 
cylindrical Delrin tubes.  These were then placed into containers and covered w ith 
50%  industrial  methylated  spirits  (IM S)  in  distilled  water  for  one  day.  The 
solution was discarded and  100% IMS was added and left for one day.  Following 
this, 50% LR White hard grade resin (Agar) in IMS was added to the sample which 
was  placed  under vacuum  to  ensure  complete  penetration o f the  graft w ith resin. 
The  vacuum  was  replenished  every  day  for  two  days.  Finally  this  solution  was 
discarded  and  100%  resin  was  added  to  the  samples  and  subjected  to  a  vacuum 
every  day  for  three  days.  The  samples  were  cast  in  resin.  A ll  solutions  were 
discarded,  and one  drop  o f catalyst was  added  for every  10ml  o f resin and mixed 
using a magnetic stirrer.  This was poured onto the sample.  The sample was placed 
in the fridge so that the resin would set slowly at 4°C.  The samples were sectioned 
in the transverse  plain  using the  Exakt  saw and ground to  a thickness  o f 100  pm 
using  the  Exakt  micro-grinding  system  and  polished  on  the  Monopoly  2000 
(Bueler,  Coventry,  UK).  Prior to  histomorphometric  analysis  o f the  sections  they 
were stained w ith Toludine Blue for 10 minutes, which stains fibrous tissue blue.
2.2.5.5 SEM analysis
A ll DMEM was removed from the samples by washing three times w ith PBS.  The 
samples  were  fixed  w ith  2.5%  glutaraldehyde  (Agar  Scientific  R1011)  in  0.1M 
sodium cacodylate (BDH Chemicals 30118) buffer for 2 hours.  The samples were 
rinsed twice  for 5  minutes  in 0.1 M   sodium  cacodylate buffer in distilled water to 
remove  any  gluteraldehyde.  Dehydration  o f the  samples  involved  a  number  o f 
processing  steps.  Samples  were  covered  w ith  1%  osmium  tetroxide  (Agar 
Scientific R1022) in 0.1M sodium cacodylate buffer for 60 minutes.  The Osmium 
was  then  discarded.  The  samples  were  rinsed three  times  for  5  minutes  in  0.1M 
sodium  cacodylate.  This  was  followed  with  incubation  o f the  samples  in  1% 
tannic acid (Sigma TO 125) in 0.05%  sodium cacodylate buffer for one hour.  The 
tannic  acid  was  discarded  and  samples  were  rinsed  for  10  minutes,  four times  in
670.1M  sodium  cacodylate.  Samples  were  further  dehydrated  in  increasing 
concentrations  o f ethyl  alcohol  for  5  minutes.  Each  step was  repeated  once  with 
concentrations  at:  20%,  30%,  40%,  50%,  60%  and  70%.  Absolute  alcohol  was 
added to the samples twice for ten minutes at each o f the following concentrations 
90%,  96%  and  100%.  Finally  samples  were  placed  into  a  consecutive  series  o f 
fresh  vials  containing  hexamethyldisiazane  (HDMS)  (Agar  Scientific)  for  2 
minutes at a time.  Samples were air dried and mounted on aluminium  stubs.  A ll 
samples  were  fixed  and  gold  sputter  coated  using  an  EMITECH  K550  machine. 
Pictures o f these samples were taken using a JEOL JSM-5500LV.
2.2.6  Statistical analysis
Cell  metabolism  measured  by  Alamar  Blue™  values  for the  force  groups  (OkN, 
3kN,  6kN  and 9kN) at day  5  (the  1st day after impaction) and day  10  (the  6th day 
after  impaction)  were  analysed  by  use  o f  univariate  analysis  o f  variance 
(ANOVA).  The  statistical  software  SPSS  (SPSS vlO .l,  SPSS  Inc,  Chicago,  USA) 
was  used  for  the  analysis.  The  absorbance  values  were  used  as  the  “ dependent 
variable”  and the  impaction  forces  were  used  as  “ group” variables.  If the  global 
analysis  o f  variance  was  significant  at  the  5%  level,  a  post  hoc  pairwise 
comparison Dunnetf s  Test was carried out to examine any differences among the 
impaction forces.
682.3 RESULTS
2.3.1  Harvesting MSCs
2.3.1.1 Observations of MSCs in vitro
After isolation o f the  mononuclear fraction o f cells  from  the  Ficoll® buffy  layer, 
primary  cell  populations  appeared to  be  densely  populated  with cells  o f different 
sizes that remained rounded in suspension.  Adherent cells could be observed after 
one day or two days.  Initially isolated and adherent cells displayed a fibroblastic 
morphology o f one nuclei and elongated spindle-like processes (figure 2.3a).  More 
cells  became  adherent  at  different timepoints  over a period o f four days.  W ithin 
four  days,  most  o f the  cells  in  suspension  were  cleared  from  the  flasks  during 
medium  changes  (figure  2.3b).  During  this  time,  and  usually  after  7  days,  it  was 
observed that the cells had started to form colonies o f varying cell numbers (figure 
2.3c).  The numbers o f cells in each colony continued to grow until subconfluence 
at  days  10-14  (figure  2.3d).  At  this  point  the  cells  were  passaged  to  prevent 
overgrowth o f the cells.  The morphology o f the cells remained consistent up to at 
least  12 passages.
Figure 2.3 Cells in culture at passage P0. a Image of Ficoll® isolated cells after 2 days in 
culture.  The label AC indicates an adherent cell with spindle-like processes,  RC (rounded 
cell)  indicates a cell in suspension;  b Day 4.  There are no cells in suspension,  all cells in 
the field are adherent to tissue culture plastic.
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Figure  2.3c  Day  10. There was an  increase in the number of adherent cells.  D After 
14 days at P0 cells were clustered in round colonies.
2.3.1.2  Growth curve for cells in monolayer
Figure  2.4  shows  the  growth  rate  o f the  MSCs.  A  peak  in  the  growth  rate  was 
observed on day 4 after seeding. Consequently impaction was carried out on day 4 
because the cells were still in the growth phase.
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Figure 2.4 Graph to show the number of live cells in monolayer at daily intervals
702.3.2 Determining impaction forces
2.3.2.1  Normal forces used in surgery
Figure 2.5 shows distal impaction forces measured during a single surgery from the 
load  washer  mounted  onto  the  Exeter  slap  hammer.  In  this  graph  each  bar 
represents  a  single  impaction  and  shows  the  force  detected  by  the  load  washer 
positioned within the hammer.  Averaged  measurements o f intra-operative  forces 
used by 9 surgeons during impaction occurred are in the range o f 1.8 to 8.6kN after 
calibration is taken  into consideration.  These  forces were  calibrated to the forces 
impacted  onto  the  allograft.  The  average  forces  that  allograft  received  during 
revision  THR  were  in  a  range  between  3kN  and  6kN  with  the  highest  forces 
reaching  9kN.  Relating the hammer forces  measured during  surgery to the  forces 
on the  graft  showed that one third of the  impaction force detected at the  hammer
was transmitted to the graft (figure 2.1b and 2.5) (Phipps 2004).
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Figure  2.5a  Impaction  forces  measured  in  the  hammer  during  a  revision  total  hip 
replacement are three  times greater than  those  received  by the graft b  Relationship 
between force in  hammer and force in  impactor,  measured  in an experimental set-up 
with two load washers (Phipps 2004).
712.3.2.2  Impactor drop heights to replicate forces used in a normal surgery
Figure  2.6  shows  the  correlation  between  a  range  o f impaction  forces  and  drop 
heights o f the impactor.  These are:  2.5cm  for a force o f 3kN, 5.2cm for a force o f 
6kN and 10cm for a force o f 9kN.
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Figure 2.6 Correlation between range of graft forces and drop height of the impactor
2.3.2  3 Optimum number of impact cycles to achieve maximum compaction
Most o f the compaction o f allograft occurs with the  first 20 cycles o f impaction as 
shown by the majority o f the reduction in height o f the graft observed in the first 20 
cycles  o f impaction  (figure  2.7).  The  compaction  o f the  allograft  occurs  through 
packing and plastic deformation o f the particles as they are squeezed together.
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Figure  2.7  Average  reduction  in  height  of  morsellised  allograft  in  Delrin  cylinders 
during 100 impactions at 3kN (Phipps 2004)
722.3  2.4 Results showing the collapse of graft under different loads
Impaction o f the graft results in a more compact graft as the force increases.  After 
20 impactions the graft is  11.6mm,  11.2mm and 8.7mm  in height at 3, 6 and 9kN 
respectively.  The degree o f compression o f the  graft is  always  different after the 
same number o f impactions at 3, 6 and 9kN.  However it is possible to achieve the 
same degree o f compression at 3kN force after 30 impactions as at 6kN force after 
20 impactions (see dashed line figure 2.8).  This means it may be possible to hit the 
graft less hard but more times to give the equivalent degree o f compaction at 6kN 
as at 3kN.  However impacting the graft at 3kN or 6kN  100 times did not achieve 
the  equivalent  amount  o f compression  as  impacting  the  graft  20  times  at  9kN 
(figure 2.8).
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Figure 2.8 Compression of allograft at 3kN (blue line), 6kN (pink line) and 9kN (green 
line)  with  logarithmic  scale  on  the  x  axis.  Dashed  line  represents  the  number  of 
impactions at 3kN required to achieve the same graft height at 6kN.
732.3.3 Determination of seeding technique
2.3.3.1  Cell seeding results: SEM and resin images
Figure  2.9a  demonstrates  a  granule  o f  graft  in  a  control  where  no  cells  were 
seeded.  Figure 2.9b shows density and suspension seeded cells on graft.  Density 
seeding resulted in large clumps o f cells overlapping with one another on the graft 
(figure  2.9c).  There  were  also  areas  o f density  seeded  graft  that  were  entirely 
devoid  o f cells  (figure  2.9d).  On  suspension  seeded  graft  areas  o f un-colonised 
bone  could be  identified,  adherent cells were  sub-confluent,  in close  contact with 
the  surface  o f the  allograft  and  more  evenly  distributed  (figure  2.9d).  Although 
these  results  are  qualitative  they  do  demonstrate  that  suspension  seeding 
culminates in a more evenly covered graft surface with MSCs.  It is difficult to tell 
the extent to which cells have penetrated into graft pores from SEM images due to 
the angle at which the images were captured, however it is evident that cells have 
migrated into the pores.
Figure 2.9a Control sample of an allograft granule showing a micropore and a surface 
of varying roughness.
74Figure  2.9b  Density  seeded  samples.  Spread  cells  (SC)  have  adhered  to  one 
another in  layers over the surface of the allograft granule.  RC are rounded cells that 
were beginning to adhere to the surface of spread cells just prior to fixation.
Figure 2.9c  Density seeded sample.  No cells were observed  in this area of allograft 
granule.
75Figure  2.9d  Granule  of allograft from  suspension  seeded  samples.  Adherent  cells 
(AC)  are  subconfluent and  in  close  contact on  the surface  of the allograft.  There  is 
some allograft (AG) that is not covered by cells.
762.3.4  The  effect  of  different  impaction  forces  on  MSCs  in 
allograft conduits
2.3.4.1  Alamar Blue™ results
Figure 2.10 shows that the MSC growth curve for OkN has a lag period and growth 
phase.  Compared with the control (OkN) at day 2  (the  1st day after impaction), the 
impaction at 3kN force showed no significant difference (p=0.06), while both 6kN 
and  9kN  showed  a  significant  difference  respectively  (p<0.001).  However,  the 
MSCs recovered to different levels o f metabolism after impaction. A t day 7 (the 6th 
day  after  impaction),  both  3kN  and  6kN  showed  no  significant  differences 
compared  with  OkN  (p=0.904  for  3kN  and  p=0.095  for  6kN),  but  for  the  9kN 
group, the difference was still highly significant (p<0.001).  The images in figures 
2.11  and 2.12  show samples that are representative  o f cells attached to  graft after 
impaction at different impaction forces.
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Figure 2.10 Percentage absorbance  of Alamar Blue™ on  cells  in  impacted  and  non 
impacted graft.
772.3.4.2  SEM  results  to  show  effect  of impaction  on  suspension  seeded 
MSCs
Figures  2.10a-d  show  MSCs  suspension  seeded  on  allograft  at  2.5  and  72  hours 
before  impaction and demonstrate  spreading o f the MSCs on the allograft surface 
over  time.  Figure  2.11a  and  2.11b  show  that  even  after  2.5  hours  cells  have 
already spread out on the allograft surface.  Rounded cells can also be seen (figure 
2.11a).  After  72  hours  MSCs  are  also  spread  on  the  allograft  surface  (figure
2.1  lc), however, there are still rounded cells present (figure 2.1 Id).  Rounded cells 
at either time-point may suggest cells have already begun dividing or that the cells 
are adhering from the original suspension.  Figures 2.1 le-g show MSCs suspension 
seeded onto allograft on day 6 in the impacted and unimpacted control groups.  In 
the  OkN  control  (figure  2.1 le)  cells  have  continued  dividing  after  6  days  as 
evidenced  by  numerous  rounded  cells  on the  surface  o f the  graft.  A t  3kN  force 
cells  are  spread  on  the  surface  o f the  graft  after  6  days  (figure  2.1 If);  however 
some o f the cells at the surface are fractured across the body o f the cell or at focal 
points.  This  may  be  as  a result  o f impaction  or  abrasion  o f the  granules  against 
each other during tissue culture processing. A t 6kN cells appear stretched between 
depressions  in  the  graft  (figure  2.1 lg )  and  at  9kN  only  cell  processes  can  be 
observed  suggesting cell damage.  These  observations are qualitative but  indicate 
an increasing level o f detriment to the cells w ith force o f impaction, which concurs 
w ith the Alamar Blue™ assay for viability (figure 2.10).
78Figure  2.11a  Cells  on  allograft after 2.5  hours.  There  are  some  rounded  cells  (RC) 
that appear to  be  the  latest cells to  adhere to  the surface of the allograft  (AG),  and 
spread  cells  (SC).  These  could  also  be  cells  dividing  from  nearby  cells  or  those 
underneath.
Figure  2.11b  Cells  on  allograft  after  2.5  hours.  Most  of  the  allograft  surface  is 
covered with spread cells.
79Figure 2.11c Cells on allograft after 72 hours.  Cells cover the surface of the graft and 
are spread cells.
Figure  2.11d  Cells  on  allograft after 72  hours.  Cells cover the  surface of the  graft. 
There are spread cells (SC) and rounded cells (RC).
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Figure  2.11e  Cells  at  OkN  impaction  after 6  days covering  a  large  proportion  of the 
allograft granule surface.
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Figure  2.11f Cells  at 3kN  after 6  days.  Cells  appear light grey,  covering  the  entire 
surface of the graft within  view.  Cells that have adhered  on  top of these  lighter cells 
appear dark grey.  There are also some rounded cells (RC) which are either arrested 
in growth or more likely to be in the process of dividing and growing on the surface of 
other  cells.  One  of the  processes  extending  from  the  cell  appears  to  have  broken 
away from the main body of the cell (BC).
81Figure 2.11g Shows a 6kN  sample after 6 days.  Cells are present on the surface of 
the graft and are stretched between depressions in the graft surface.
Figure  2.11 h  Sample from 9kN group after 6 days.  Cell processes can  be observed. 
There are no cells flattened against the surface of the graft.
822.3.4.3  Histology to show effect of impaction on cells.
Figure 2.12a-d shows MSCs adherent to the surface o f the allograft on day 6 in the 
impacted and unimpacted control groups.
Figure 2.12a-d Histology images of allograft groups stained with toluidine blue. A OkN 
impacted  group  shows  layers  of cells on  the surface of the graft  indicated  by  darkly 
stained nuclei and fibrous tissue stained lighter blue, b 3kN, c  6kN, d  9kN
832.4 DISCUSSION
In revision total hip replacements, impaction occurred has been widely used to fill 
bone  defects  and to  provide  sufficient bone  stock for implant fixation.  Impaction 
forces are variable between surgeons, and cases, and have been recorded in a range 
o f 3-6kN, with some reaching 9kN in a study performed in this laboratory (Phipps 
et al.  2002).  Clinical  studies  have  shown that  a  good  impaction  technique  is  the 
key  factor to  achieving  initial  implant  stability which  is  critical  for the  long-term 
success  o f the  implant (Tagil 2000;  Gie  et al.  1992;  Wang et al.  1999).  Femoral 
bone fractures as well as excessive  stem migration have been noted in some cases 
o f impaction occurred  (Leopold  et al.  1999;  Cabanela et al.  2003).  Therefore  the 
force  o f impaction  allograft  should  not  be  compromised  while  introducing  MSC 
treatment.  This  is  one  o f the reasons that the  viability o f these  cells  at clinically 
relevant forces be determined.
The  adapted  slap  hammer  is  easy  to  use  and  sterile,  and  is  capable  o f instantly 
measuring  and  recording  impaction  force  during  revision  THR.  The  huge 
variations o f impaction forces measured from different surgeons suggested that the 
impaction  forces  should  be  monitored  and  regulated.  Allograft  can  then  be 
consistently impacted to avoid unnecessary bone  fracture and excess migration o f 
the  stems.  G riffon D.J.  et al.  developed  an ovine  model  to  evaluate  the  effect  o f 
impacted  biomaterials  in  unicortical  defects  (G riffon  et  al.  2001).  Differences 
were  found between sites o f implantation using a subjective grading system, w ith 
greater  bone  healing  in  distal  femoral  sites  compared  to  proximal  tibial  sites. 
Proximal femoral defects extended to the far cortex, which may have affected the 
degree o f compaction.  Therefore the distal femoral site was confirmed as a better 
model.  However, the impactor used to impart the forces to the graft was based on 
a design by Brewster et al.  (Brewster et al.  1999).  The  energy o f impaction was 
determined by using a slap hammer to impact graft into a plastic femur on a force 
plate.  A  plastic  femur  is  not  representative  o f the  force  distribution  in  a  human 
femur during  surgery.  The direction o f the hits are different, w ith forces  directed 
downwards  onto the  force  plate  and  sideways  in  surgery,  due to the  shape  o f the 
impactor,  which w ill  affect the  force  going through the  graft.  The  measurements
84made  by  Kirsty  Phipps  used  a  load  cell  within  the  hammer  and  in  the  proximal 
impactor embedded in the graft (Phipps 2004), which is more accurate than forces 
measured  directly  from  the  impactor  on  a  force  plate.  The  forces  used  in  this 
Chapter are also more accurate than Griffon et al. because they were replicated at a 
range  o f forces  from  several  surgeons  and  G riffon  et  al.  uses  only  one  plastic 
femur.  A  greater amount  o f impaction w ill  decrease  the  surface  area o f graft  as 
graft  pores  fracture  and  collapse,  allowing  for  greater  osteoconduction  because 
particles  are  touching  each  other.  However  if  the  graft  is  too  compressed  as  a 
result  o f impaction,  this  may  also  affect  the  vascularisation  o f the  graft  which  is 
essential  for  bone  formation  and  remodelling,  as  a  more  compressed  graft  may 
resist penetration o f blood vessels.  A study by Tagil showed the latter.  Graft was 
compressed to different volumes in a bone conduction chamber and implanted into 
the tibial metaphyses o f 17 rats.  Unimpacted allograft was implanted as a control 
on the contralateral side o f each rat.  Impaction led to a decreased ingrowth o f bone 
(Tagil and Aspenberg  1998).  This may have been because the compression o f the 
graft was not related to clinical impaction forces applied under surgical conditions. 
The  stability  o f an  implant  may  also  be  compromised  depending  on the  level  o f 
impaction o f the graft.  Initial stability o f the implant can be attained by impacting 
graft around the implant to the extent that it can withstand the  load on the  femur. 
I f   impaction  is  inadequate  it  can  result  in  lack  o f  initial  stability,  resulting  in 
migration o f the prosthesis and subsidence  (Tagil  and Aspenberg  1998;  Gie et al 
1992).
Many  studies  showed that  MSCs  can be  differentiated  into  several  cell  lineages, 
which  include  osteoblasts  (Jessop  et  al.  1994;  Muraglia  et  al.  2000).  Several 
animal  studies  demonstrated  that  MSCs  seeded  onto  adequate  scaffold  materials 
can  repair  segmental  defects  and  regenerate  new  bone  in  a  fracture  model 
(Blokhuis et al.  1999;  Arinzeh et al.  2003;  Kadiyala and Jaiswal  1997;  Bruder et 
al.  1998b;  Chistolini  et al.  1999).  However,  most  o f the  scaffolds  used  in these 
studies were solid blocks with a porous structure (Ripamonti  1991; van Eeden and 
Ripamonti  1993;  Harris  and  Cooper  2004).  In  a  study  by  Mushipe  et  al.  the 
suvivourship o f MG63 cells on allograft after impaction was tested in vitro using a 
replica  o f an  acetabular  cup.  DNA  content  o f cells  removed  from  the  graft  was 
measured  after each impact from  the modified  impactor.  After 5  impacts  21%  o f
85the  cells  were  viable  relative  to  the  control.  This  study  shows  that  some  cells 
survived impaction (Mushipe et al.  2006). However the cell line was a transformed 
osteoblastic cell line, which could not be translated to a clinical situation, and may 
behave  differently  to  MSCs.  The  impaction  forces  were  determined  using  a 
wooden acetabulum cup model and were tested using only one surgeon.  M y study 
established that the force o f impaction varies widely between surgeons and I used a 
range o f forces to test MSC viability.
This study is the first in vitro attempt to examine the effect o f impaction forces on 
MSC  viability.  Proliferation  was  measured  using  the  Alamar  Blue™ assay.  This 
assay incorporates an oxidation-reduction (REDOX) indicator that both fluoresces 
and changes  color in response to chemical  reduction o f growth medium resulting 
from cell proliferation.  This assay  is a reliable  method to assess cell viability and 
proliferation, and has a very high agreement with flow  cytometry in indicating the 
number o f living and dead cells in cultures (Reis et al.  2004).  The results from the 
study  showed  that  the  viability  o f the  MSCs  is  associated  with  the  amount  o f 
impaction  force  used  during  surgery.  A  minimal  effect  on  MSC  viability  was 
observed up to 6kN impaction forces, but when using 9kN, the viability o f the cells 
was  significantly  reduced.  The  study  suggests  that  it  is  feasible  to  use  MSCs 
addition to  the  allograft  under normal  impaction  forces  during  revision  THR  and 
excessively high impaction forces such as 9kN should be avoided.  It is possible to 
achieve the same degree o f compression at 3kN force after 30 impactions as at 6kN 
force after 20 impactions.  The viability o f the cells may possibly be maintained if  
they are hit less hard but a greater number o f times.  Increasing the number o f hits 
at  a  lower force  is  not applicable  in this  instance  because  the  cells  recover at the 
6kN impaction.  However, the  same degree o f compression o f the  graft could not 
be achieved in the 3kN group or the 6kN group as in the 9kN group, even after 100 
impactions.  So it appears that survival o f cells after impaction is a consequence o f 
the  forces  used.  It  is  important  to  remember  that  the  force  used  must  achieve 
stability  o f the  graft.  However  it  appears  that  different  surgeons  use  variable 
amounts o f force.  It may be that by using a larger number o f impactions at a lower 
load,  the  graft  is  as  stable  as  that  achieved  using  fewer  impactions  w ith  greater 
force.  If MSCs are used for impaction grafting surgeons should be encouraged to 
use a higher number o f impactions with reduced force.
862.5 CONCLUSION
The results demonstrated that MSCs survived normal impaction forces, but w ill be 
affected if  the  force on the  graft is above  6kN.  The hypothesis that MSCs  seeded 
onto allograft scaffolds w ill survive normal impaction forces that was presented in 
the introduction o f this chapter has been proved.  In conclusion addition o f MSCs 
to the allograft scaffold followed by impaction grafting w ill not destroy the MSCs 
and therefore this technique has potential in regenerating new bone to repair bone 
defects in rTHRs.
87CHAPTER 3: In vitro Impaction of MSC derived 
Osteoblasts on an Allograft Scaffold
883.1  INTRODUCTION
The in vitro study in Chapter 2 showed that MSCs could survive normal impaction 
forces used in revision total hip replacements ranging from 3kN to 6kN (Korda et 
al. 2006; Phipps et al. 2002).  MSC metabolism decreased w ith increased force one 
day immediately after impaction at 3,  6  and 9kN.  By day 7 MSCs impacted at 3 
and  6kN  had  recovered  to  levels  o f metabolic  activity  not  significantly  different 
from the  OkN control,  although the  6kN group was  less metabolically active than 
the 3kN group.  However the 9kN group remained significantly less metabolically 
active after day 7 compared to the OkN group.
The general introduction to this thesis discussed the possibility o f using osteoblasts 
or osteoblasts  derived  from  MSCs  in combination with  impaction occurred  as  an 
alternative to MSCs.  Osteoblasts may be an improvement on using MSCs as they 
are  a  more  mature  phenotype  and  therefore  committed to the  osteogenic  lineage, 
potentially  reducing  the  time  between  lineage  progression  and  therefore  bone 
formation  in  vivo  (Bruder  et al.  1994;  Kadiyala  and  Jaiswal  1997;  Bruder  et al. 
1998a).  The  source  o f more  rapid  bone  formation  from  these  cells  could  come 
from  a  combination  o f  effects.  Growth  factors  such  as  OSF-1  (osteoblast- 
stimulating  factor)  are  produced  by  osteoblasts,  suggesting  that  it  influences  the 
behaviour  o f  the  same  osteoblasts  that  produce  it  locally.  OSF-1  may  also 
influence  osteoblastic  activity by  recruiting  osteoprogenitor cells  or MSCs  from 
the  indigenous  population  to  induce  osteoinduction.  Evidence  to  support  these 
contentions  comes  from  a  study  by  Yang,  X  et al.  where  human  cells  combined 
w ith OSF-1  on a PLGA scaffold implanted subcutaneously in diffusion chambers 
in  athymic  mice  demonstrated  new  bone  formation,  whereas  control  chambers 
without OSF-1  did not.  OSF-1  was also chemotactic and stimulated differentiation 
and mineralisation o f human MSCs on PLGA scaffolds in vitro (Yang et al.  2003). 
Bruder  et  al.  states  that  chondrocytes  are  not  required  for  osteogenesis,  which 
suggests  that  cells  are  recruited  from  the  native  population  by  osteoinductive 
factors  (Bruder  and  Caplan  1990a).  TGF-P  is  produced  predominantly  by 
osteoblasts which have the largest number o f TGF-p receptors.  TGF-P  stimulates 
proliferation  o f MSCs  in  the  periosteum  during  fracture  healing.  Other  factors
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are also produced by osteoblasts as well as other cell types (Solheim  1998).
In  vivo  evidence  to  support  the  use  o f osteoblasts  in  accelerating  and  increasing 
osteogenesis compared to MSCs was found by Yoshikawa et al (Yoshikawa et al 
1996).  Syngenic  rat  MSCs  seeded  onto  HA  blocks  and  subcultured  for  14  days 
either  in  osteogenically  supplemented  or  standard  control  media  were  implanted 
subcutaneously.  After 8  weeks the osteogenically treated samples produced bone 
and control  samples with undifferentiated MSCs did not (Yoshikawa et al.  1996). 
Breibart  et  al.  derived  osteoblasts  by  differentiating  periosteal  cells  and  seeded 
them  onto  polyglycolic  acid  scaffolds  (Breibart  et al.  1998).  Bone  formation  in 
this group was compared to that in polyglycolic acid scaffolds without osteoblasts 
implanted  in  rabbit  calvarial  defects.  New  bone  was  found  in  osteoblast  loaded 
sites whereas only fibrous tissue was found in the group with MSCs (Breibart et al. 
1998).  Additional examples o f the relative benefit o f using osteoblasts compared 
to other cell sources include studies comparing osteoblasts with fresh bone marrow 
(Kadiyala and Jaiswal  1997;  Bruder et al.  1998a;  Bruder and Fox  1999;  Kruyt et 
al.  2003).  These studies suggest that osteoblasts may expedite the process o f bone 
healing relative to other cell sources.
Mature osteoblasts would be inefficient in bone tissue engineering as they are more 
difficu lt to obtain and undergo lim ited expansion in vitro  (Bruder and Fox  1999). 
This  also  applies  to  osteoblastic  cells  derived  from  the  marrow  element  without 
expansion.  Although the experiments cited above suggest the feasability o f using 
fresh  bone  marrow,  the  presence  o f  osteogenic  precursors  w ill  vary  widely 
between patients  and may  be  depleted  in the  elderly  as  a result o f aging  (Bruder 
and  Fox  1999;  Caplan  1994).  Introducing  committed  osteoblasts  may  directly 
induce bone, but these osteoblasts would only be  able to recruit a lim ited number 
o f osteoprogenitors  in a patient whose host tissue bed has been compromised due 
to smoking, diabetes, irradiation, aging or osteoporosis (Bruder and Fox 1999).
MSC derived osteoblasts allow a degree o f control whereby the desired quantity o f 
MSCs  can be  m ultiplied prior to  differentiation into  osteoblasts.  In  addition, the 
stage o f differentiation can be controlled.  Monoclonal antibodies have been used
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osteogenic lineage in embryonic chick periosteum (Bruder and Caplan  1990a) and 
tibia (Bruder and  Caplan  1989).  Osteoprogenitors  proceeded through  a  series  o f 
lineage  steps marked by different antibodies until they stop dividing and begin to 
deposit  osteoid,  at  which  point  they  are  termed  ‘secretory  osteoblasts’.  The 
subsequent, more mature cell types in the osteogenic lineage do not secrete osteoid 
matrix  (Bruder  and  Caplan  1990a;  Bruder  and  Caplan  1989;  Bruder  and  Caplan 
1990b).  ‘Secretory  osteoblasts’  can  be  selected  for  their  osteoid  producing 
properties during differentiation in vitro as they stain positive for ALP  (Bruder et 
al.  1998a; Bruder and Caplan  1990a; Bruder and Caplan  1989; Bruder and Caplan 
1990b).  The osteoblasts in this chapter were selected for impaction at the peak o f 
ALP expression to ensure they had not surpassed the secretory osteoblastic stage o f 
differentiation.  A ll  cells  differentiated  from  MSCs  are  termed  ‘osteoblasts’ 
throughout the rest o f this thesis.
Although  osteoblasts  can  shorten  the  time  between  cell  implantation  and  bone 
formation, their response to different impaction forces was unknown.  This chapter 
w ill  investigate  whether  MSC  derived  osteoblasts  can  survive  normal,  clinical 
impaction forces.  Comparisons w ill be made  between the viability o f osteoblasts 
and the effect o f the same impaction forces on MSCs investigated in the previous 
chapter.
Aim
To  test  the  viability  in  vitro  of osteoblasts  derived  from  MSCs  which  were 
seeded  onto  the  allograft and  impacted  at  a  range  of forces  obtained  during 
rTHRs.
Hypothesis
Osteoblasts  derived  from  MSCs  seeded  onto  allograft  scaffolds  will  survive 
normal impaction forces used during rTHRs.
913.2  MATERIALS AND METHODS
3.2.1  Differentiation of MSCs into osteoblasts
3.2.1.1 MSC culture
MSCs  were  isolated  from  bone  marrow  aspirates  o f 6  sheep  designated  for  the 
study.  The  cells  used  in  the  study  were  spindle  shaped  in  appearance  once 
adherent to tissue culture plastic and displayed this morphology throughout culture. 
The  MSCs  were  expanded  in  culture  until  they  were  at  passage  2  to  achieve 
adequate  numbers  for  cell  seeding  onto  allograft.  After  trypsinisation  lx l0 6 
cells/ml  were  resuspended  in  1ml  o f  10%  Dimethylsulfoxide  (DMSO,  D5879, 
Sigma-Aldrich  Ltd,  Fancy  Road,  Poole,  Dorset,  UK)  in  FCS  (First  Link,  West 
Midlands,  UK).  The  cell  suspensions  were  then transferred to  cryovials  in a  ‘M r 
Frosty’  5100  Cryo  1°C  freezing  container  (Fisher  Scientific,  Bishop  Meadow 
Road,  Loughborough,  Leicestershire,  UK)  containing  isopropan-2-ol  which  was 
placed  in a -70°C  freezer for 24 hours.  The vials were then transferred to  liquid 
nitrogen until resuscitation.
3.2.1.2 Resuscitation of cryopreserved cells
Cryovials o f MSCs and primary sheep dermal fibroblasts (SDFs), made from skin 
explants, were incubated in a waterbath at 37°C until the ice had thawed.  Thawed 
cells were resuspended in  1ml o f growth media which was warmed to 37°C in the 
waterbath  before  being  added.  The  cells  were  allowed  to  come  to  room 
temperature  for  5  minutes  before  addition o f more  growth media.  The  cells  were 
then  added  to  a  universal  tube  and  doubling  volumes  o f warmed  medium  were 
added to the cells until  16ml total volume was reached with 5 minute equilibration 
periods between each addition.  The cell suspensions were centrifuged at 2000rpm 
for  5  minutes.  The  cell  pellets  were  resuspended  in  2ml  o f  growth  media, 
transferred to culture flasks, designated passage 3  and cultured in accordance with 
the protocols described in chapter 2 after resuscitation o f the cells from frozen.
3.2.1.3 Osteogenic differentiation of MSCs
Cells were trypsinised from flasks and resuspended in flasks at 7xl0 4 cells/ml into 
T225  flasks.  After 7  days  MSCs  and  SDFs  had reached  optimal  cell  density  for
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supplemented with osteogenic supplements to make osteogenic media (OM).  The 
OM was made up o f DMEM (DMEM, Sigma D-6429), w ith 10% FCS (First Link, 
West  Midlands,  UK),  penicillin  /  streptomycin  (lOOOiu/ml;  lOOpg/ml)  (GIBCO 
Paisley,  UK)  supplemented  with  lOmM  (3-glycerophosphate  (Sigma  D1756), 
50pg/ml  Ascorbic Acid (Sigma A4544), and  1  x  10'8 M  Dexamethasone (Sigma, 
D-2915),  (Goldstein  2001).  A ll  media  was  changed  every  two  days  to  prevent 
acidification (Collignon et al.  1997; Torricelli et al.  2000).
3.2.1.4 Growth curve for osteoblasts
The  growth  curve  was  constructed  in  order  that  the  production  o f  ALP  and 
osteocalcin could be normalised to cell number, thereby reducing density-variation 
errors  caused by different cell  growth rates.  Three  cell  lines  (n=3  animals)  were 
cultured to passage 3 using standard tissue culture techniques previously described. 
The  MSCs were trypsinised  into  suspension and,  as  described above,  seeded into 
individual T225 flasks for analysis on days  1,7,  14, 21  and 28.  The cultures were 
maintained at 37°C with 5% CO2 in the original growth media.  An equal number 
o f  flasks  were  treated  with  OM.  Cells  were  trypsinised  from  the  flasks  and 
counted  on  respective  days  using  standard  tissue  culture  techniques  described  in 
Chapter 2.2.1.3.  The growth curve on osteogenically-induced MSCs also allowed 
observations  o f  cell  differentiation  stages  to  be  made  -   indicating  when  cells 
reached a secretory osteoblastic phenotype.  In so doing, it indicated at what stage 
the  impaction  forces  need  to  be  applied  to  test  the  hypothesis.  Sheep  dermal 
fibroblasts (SDFs) were also treated with OM and photographed at days  7,  14,  21 
and 28 as a negative control.
3.2.2  Characterisation of osteoblasts
3.2.2.1  ALP assay
To confirm osteoblast differentiation, markers to identify cells as osteoblasts are a 
prerequisite.  The  basic  osteoblastic  phenotype  is  characterized  by  Alkaline 
Phosphatase activity, osteocalcin production and mineralization o f the extracellular 
matrix analysed by Von Kossa staining. Assays for the proteins and mineralisation 
were  carried  out  on  3  different  cell  lines  at  defined  time-points  during  the
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carried  out  on  non-osteogenically  induced  MSCs  (n=3  sheep)  which  acted  as 
negative  controls.  Negative  controls  for  the  Von  Kossa  stain  were  SDF  cells 
treated with osteogenic media.
A t the end o f days  1,7,  14, 21  and 28 the following procedure was carried out for 
the  biochemical  assay.  The  media in the  flasks was  discarded and replaced with 
4ml o f distilled water.  The flask was placed in the -70°C  freezer to lyse the cells 
and  then  thawed  in  a  37°C  incubator  twice.  The  samples  were  thawed  at  4°C 
overnight to allow regeneration o f enzyme activity.  ALP activity was measured in 
3 x 50pl samples o f each cell lysate from each cell line.  Samples were assayed by 
an  automated  process  in  the  COBAS  BIO  centrifugal  analyzer  (Roche,UK).  The 
reagent  p-nitrophenol  phosphate  (RANDOX  Laboratories  Ltd,  UK)  was  added to 
the  samples,  whereby  ALP  cleaved  the  phosphate  group  to  give  p-nitrophenol 
which is yellow at alkaline pH and is monitored in the COBAS BIO (Roche, UK) 
at 405nm.  This gave a measurement o f the activity o f the enzyme.
3.2.2.2 Osteocalcin assay
The osteocalcin assay was performed on the cell  lysate extracted according to the 
protocol described in section 3.2.2.1  above.  Osteocalcin was measured in 2 x 25pl 
samples o f each cell  lysate from each cell line using an Osteocalcin kit according 
to  the  protocol  provided  by  the  manufacturer  (Metra-Biosystems  OC  Enzyme 
immunoassay). The optical densities o f samples were measured at a wavelength o f 
405nm using a Dynatech MR700 plate-reader (Dynatech Laboratories, UK).
3.2.2.3 Histochemistry of mineralized matrix formation
Von  Kossa  staining  was  used  to  detect  phosphate  deposition,  which  is 
representative o f the formation o f bone nodules; allowing an assessment o f matrix 
mineralization to be made -  another indicator o f osteoblastic differentiation (Holy 
et al.  2000;  Erices et al.  2000).  The  stain was performed on the  same  days as the 
assays.  Fresh  stocks  o f 2%  Silver nitrate  solution  (Sigma  S2252),  2.5%  Sodium 
thiosulphate  (BDH  Chemicals  10268)  and  1%  Neutral  red  (Sigma  N6634)  were
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medium  was  discarded and  cells  were  fixed  in ice-cold  80%  methanol.  Sections 
were taken to water, then placed under a bright light in the presence o f a 2% Silver 
nitrate  solution  for  1  hour.  They  were  then  rinsed  3  times  w ith  distilled  water, 
treated with 2.5% Sodium Thiosulphate for 2 minutes and then rinsed in tap water. 
The Neutral red solution was filtered prior to use, and then used to counterstain the 
section for  10 minutes.  Sections were rinsed several times to remove residual dye 
and left to dry.  Sections were examined using a light microscope.  D igital Photos 
were taken using a x40 objective.
3.2.3 Preparation of allograft
Ovine  long  bones  were  harvested,  morsellised  and  sieved to  2-5mm  in diameter. 
The  allograft was  double  bagged with an airtight heat  seal  into  3.5g  aliquots  and 
irradiated and stored as described in the Materials and Methods section o f Chapter 
2, section 2.2.2.
3.2.4 Determining impaction forces
Impaction  forces  were  established  in  Chapter 2  section  2.2.3.2  and  based  on the 
work o f Dr Kirsty Phipps (Phipps et al.  2002).  The average  forces that allograft 
received  during  revision  THR  were  in  a  range  between  3kN  and  6kN  w ith  the 
highest forces reaching  9kN  (Phipps et al  2002).  These  forces were replicated in 
this study using the specially designed impactor shown in figure 2.2.
3.2.5 In vitro impaction of osteoblasts on allograft
3.2.5.1  Suspension seeding of osteoblasts onto allograft
Sheep MSCs treated with osteogenic media for 11  days, to allow for differentiation 
down the osteogenic pathway, were trypsinised from tissue culture flasks.  A ll cells 
were subconfluent at passage 4.  After this point the seeding technique was similar 
to that used in Chapter 2, section 2.2.4.  Osteoblasts were counted and seeded at 2 
x  106 cells/g onto 3.5g o f allograft in a universal tube with 7ml DMEM,  10% FCS 
and  penicillin  /  streptomycin  (lOOOiu/ml;  lOOpg/ml).  A  control  universal  tube 
contained allograft only with 7ml o f DMEM.  Cells were suspension seeded on the
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5%  CO2.  The  constructs  were  then  transferred  to  a  6  well  plate  and  were 
maintained  in culture  for  72  hours pre-impaction,  to  allow attachment  o f cells  to 
the  graft.  There  were  6  samples  in  each  force  group,  including  the  OkN  control 
group where osteoblasts were added but no impaction force was used.  In addition, 
a  small  portion  o f the  sample  was  removed  for  SEM  analysis  after  72  hours  in 
culture to ensure attachment o f cells to the graft.
3.2.5.2 Impacting constructs in delrin tubes
The  impaction  procedure  was  a  replica  o f the  protocol  in  section  2.2.5.2  using 
osteoblasts derived from MSCs.
3.2.5.3 Alamar Blue™ Assay
The Alamar Blue™ assay followed the same procedure as in section 2.2.5.3.
3.2.5A SEM Analysis
SEM analysis followed the same procedure as in section 2.2.5.4.
3.2.6 Statistical analysis
Statistical  analysis  for cell  metaboliosm  in Alamar Blue™ was  carried out  in the 
same way as in section 2.2.6.
963.3 RESULTS
3.3.1. Characterisation of osteoblasts
3.3.1.1  Observations of MSC differentiation in vitro
The  images  in  figure  3.1  demonstrate  the  morphological  changes  occurring  in 
adherent  MSCs  at  specified  time  intervals  during  28  days  o f  differentiation 
compared to  the  SDF  control.  At day  7  MSCs  had a fibroblastic  spindle-shaped 
morphology  to  SDFs.  By  day  14,  the  MSCs  had  become  progressively  more 
cuboidal  and  polygonal.  However,  control  cultures  maintained  a  bipolar  shape 
throughout  the  assay  period  becoming  progressively  more  confluent. 
Osteogenically  induced  cells  then  became  increasingly  round  in  appearance  and 
despite initial proliferation osteoblasts were more sparsely distributed by day 21.
Day 14
Figure  3.1  Phase  contrast  photographs  of  cells  during  assay  period.  Top  row: 
SDF (Control).  Bottom row:  osteogenically induced MSCs.
973.3.1.2 Growth curve for osteoblasts
Figure  3.2  shows the growth rate o f the MSCs and MSCs treated w ith osteogenic 
media over a culture  period o f 28  days.  A plateau in growth was  observed after 
day  21  for  control  cells  in  regular  media.  MSCs  treated  w ith  osteogenic  media 
plateau in growth earlier and at a lower number o f cells.  Cells were  seeded onto 
the  allograft  at  day  11  because  they  were  still  in the  growth  phase,  allowing  72 
hours  for  attachment,  continued  maturity  and  differentiation  o f the  cells  on  the 
allograft before impaction.  It was also the same amount o f time given to the MSCs 
to attach to the allograft before impaction in Chapter 2 section 2.3.1.2
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Figure  3.2  Graph  to  show the  number  of  live  MSCs  in  monolayer,  treated  with 
(MSC+OG) and without osteogenic media (MSC+no OG).  Each MSC point (mean 
± Standard Error) was derived from triplicate cultures.
983.3.1.3 ALP assay
Figure  3.3  shows  the  results  for the  ALP  assay.  At  1,  7  and  14  days  the  enzyme 
activity  was  always  greater  in the  MSCs  treated  with  osteogenic  media  than  the 
control treated with standard media. The pattern o f production o f ALP in the MSCs 
treated with osteogenic media showed a significant increase between day 1   and day 
7 (p=0.05) followed by a decrease at day 21  and at subsequent time-points during 
the  assay.  By  day  7  ALP  activity  was  significantly  greater  in the  MSCs  treated 
with  osteogenic  media  compared  to  the  control  samples  (p=0.05).  The  control 
MSCs  that  had  not  been  treated  with  osteogenic  media  produced  relatively  low 
levels o f ALP that did not vary significantly between time-points.
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Figure  3.3  The  relative  induction  of  ALP  activity  in  cells  treated  with  and  without 
osteogenic media at 7 day intervals for 28 days.  Each point (mean ± Standard error) 
was  derived  from  triplicate  cultures.  The  Mann-Whitney  U  Test  is  represented 
by  A p=0.05, and  Ap=0.05.
993.3.1.4 Osteocalcin assay
Figure 3.4 shows the results for the osteocalcin assay.  Osteocalcin levels increased 
over a 28 day assay period in osteogenically treated MSC samples.  A t days  1  and 
7  no  osteocalcin  was  observed.  However,  the  reading  on  day  7  shows  negative 
osteocalcin  production.  This  may  be  due  to  variations  in  the  sensitivity  o f the 
Dynatech  MR700  plate-reader  (Dynatech  Laboratories,  UK).  Osteocalcin  levels 
significantly increased in the osteogenically induced MSCs (p=0.05) between days 
7  and  14.  A  smaller  increase  in  osteocalcin  was  observed  in  control  MSCs 
between  days  7  and  14,  but  this  was  not  significant  (p=0.127).  Osteocalcin 
production in control MSCs  increased slightly between days  14 and 21  (p=0.275) 
and plateaued between days 21  and 28 (p=0.827), although there was significantly 
more  osteocalcin on day  28  than on day  14  (p=0.05).  Osteocalcin production in 
osteogenically induced MSCs continued to increase from days  14 to 21  (p=0.127) 
and  days  21  to  28  (p=0.05).  At  days  14,  21  and  28  there  was  a  significantly 
greater  increase  in  OC  production  in  osteogenically  induced  cultures  relative  to 
control cultures at p=0.05 at each time point.
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Figure  3.4 The  relative  production  of osteocalcin  by  cells treated  with  and  without 
osteogenic media over 28 days (mean ± Standard Error) (MSC CTRL= mesenchymal 
stromal cells control; OG = Osteogenic Media).
1003.3.1.5 Histochemistry of mineralised matrix formation
Figure 3.5 Von Kossa stain for mineralisation;  Top row a-e) SDF negative controls at days:  a) 1, b) 7, c) 14, d) 21, e) 28; Bottom row f-j) 
MSCs treated with osteogenic media on days: f) 1, g) 7, h) 14, i) 21, j) 28.
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treated  MSCs.  The  osteogenically  treated  MSCs  show  increasing  mineral 
deposition between  14 and 28 days.  The SDF controls show no mineral deposition 
at any timepoint.
3.3.2  In vitro impaction of osteoblasts on allograft
3.3.2.1  SEM for suspension seeding of osteoblasts on allograft
Figure  3.6 below shows  SEM  images o f a network o f rounded osteoblasts  on the 
surface o f the allograft on the day just before impaction.
Figure 3.6 SEM showing rounded cells attached to the allograft surface on the day of 
impaction 3 days post-seeding.
1023.3.2.2  Alamar Blue™ results
Figure 3.7 below shows the effect o f impaction on osteoblasts at a range o f normal 
forces used during THR surgery, where metabolism o f the cells was assayed using 
Alamar Blue™.  The red line on the graph depicts the original, pre-impaction level 
o f metabolism o f the osteoblasts at  100% and is a marker for recovery o f the cells. 
The  metabolism  o f  the  osteoblasts  drops  below  this  level  in  all  groups  after 
impaction.  Compared with the OkN control on day 2 (the first day post-impaction), 
the  impaction  at  3kN  slightly  decreased  metabolism  but  showed  no  significant 
difference  (p=0.110).  However, the metabolism o f osteoblasts  impacted at 6 and 
9kN was significantly less than the control at day 2 (p<0.001  in both cases).
By day 5  and day 8 after impaction, osteoblasts in the 3kN group recovered above 
levels  o f original  pre-impaction metabolism,  indicating recovery.  Although there 
was  an  increase  in  metabolism  over  the  8  day  period  post-impaction,  the 
differences  in  metabolism  o f the  3kN  group  relative  to  the  OkN  control  gained 
significance  from  day  5  at p=0.025  to  day  8  at  p=0.020.  However,  there  was  a 
decrease  in  metabolism  by  day  1   in  the  6kN  and  9kN  groups  with  a  further 
decrease  by  day  9.  The  difference  in  metabolic  activity  remained  highly 
significant relative to the OkN control for both the 6 and 9kN groups (p<0.001).
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Figure  3.7  Percentage  absorbance of Alamar Blue™  on  cells  in  impacted  and  non­
impacted graft.  A red line marks 100% metabolism of the OB cells and represents the 
original metabolism of the OB cells before impaction.
The  graphs  in  figure  3.8  directly  compare  the  effects  of  impaction  on  MSC 
metabolism, analysed in Chapter 2,  and osteoblast metabolism.  At 3kN both cell 
types  show  a  similar  trend  in  cell  metabolism.  Post-impaction,  on  day  1,  both 
MSCs  and osteoblasts  incur a drop in metabolism  followed by recovery to  levels 
above the pre-impaction value (figure 3.8a).  However, in the 6kN group, although 
MSC metabolism recovers by day 4 and continues above pre-impaction levels until 
day  6,  osteoblast metabolism  continues dropping after  impaction.  The trends  in 
metabolism between the  MSC and osteoblast group are similar at 9kN impaction, 
with osteoblasts slightly more affected by impaction.  Osteoblast metabolism does 
not recover after impaction.
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Figure  3.8  Comparison  of  percentage  absorbance  of  MSCs  (MSC:  n=9)  to 
osteoblasts (n=6) at a 3kN, b 6kN and c 9kN impaction.
1053.4 DISCUSSION
3.4.1  Characterisation of osteobiasts
There  is  a  possibility  that  osteoblasts  may  expedite  bone  healing  in  vivo  and 
therefore the viability o f osteoblasts after impaction on allograft was tested in this 
chapter.  Osteoblasts,  unlike  MSCs,  are  committed  cells  that  do  not  go  through 
stages  o f maturation before producing bone.  MSCs harvested from the iliac  crest 
o f sheep  were  differentiated  into  osteoblasts  using  osteogenically  supplemented 
media at concentrations pertaining to the literature (Jaiswal et al.  1997; Kruyt et al. 
2003).  Work  by  Abu,  E.A.  et al  showed that receptors  for  glucocorticoids  were 
expressed  in  osteoblasts  at  bone  forming  and  modelling  sites,  implicating 
dexamethasone  in  bone  remodelling  (Abu  et al.  2000).  Ascorbic  acid  has  been 
shown  to  contribute  to  the  differentiation  o f  the  cells  as  a  co-factor  in  the 
hydroxylation o f proline and lysine residues in collagen and increases synthesis o f 
non-collagenous proteins (Jaiswal et al.  1997).
The  rationale  for  inducing  the  MSCs  in  osteogenic  media  for  14  days  prior  to 
impaction can be explained by changes in the growth curve and the differentiation 
profile o f the cells.  An established standard growth curve was constructed in order 
to allow normailisation o f ALP and osteocalcin to the number o f cells at the chosen 
time point (Bruder et al.  1997).  Figure 3.1  demonstrates that the MSCs expressed 
a progressively more polygonal morphology over the assay period representing the 
osteoblastic phenotype.  The photographic evidence concurs with the growth curve 
in figure 3.2.  A plateau in the growth curve was observed on day 14 after seeding. 
The cells remained in a plateau phase from days  14 to 21  which is indicative o f the 
MSCs  becoming  ‘secretory  osteoblasts’,  where  cell  division  ceases  and  matrix 
production  ensues,  as  defined  by  Bruder  et  al  (Bruder  et  al.  1994;  Bruder  and 
Caplan 1990a; Bruder and Caplan 1990b; Bruder and Caplan 1989).
The ALP assay illustrated in figure 3.3  followed a characteristic trend observed in 
studies  in the  literature  on the  lineage progression o f osteoprogenitors  (Jaiswal  et 
al.  1997).  ALP  activity  peaked  on  day  7,  showing  that  it  is  a  marker  for  early 
osteogenesis, and was followed by an immediate decline in activity.  The reduction 
in  ALP  activity  correlates  with  increased  mineralisation  and  upregulated
106osteocalcin  expression  (figure  3.3).  ALP  is  an  enzyme  that  has  already  been 
described  in  Chapter  1  as  prompting  phosphate  ions  to  accumulate  on  collagen 
fibrils  (Young  and  Heath  2000)  and  is  expressed  in  osteoblasts.  ALP  peaks  in 
expression and then declines (Bruder et al.  1997) because the function o f ALP is to 
encourage  mineral  deposition  which  requires  collagen  to  be  present  first. 
Osteocalcin is the most abundant non-collagenous protein in bone and may have a 
role in bone remodelling (Beresford et al.  1984).  Osteocalcin production is unique 
to bone and almost exclusive to osteoblasts (Hughes and Aubin  1998; Beresford et 
al.  1984).  The  growth  profile,  together  with  the  ALP  and  osteocalcin  data, 
established  that  the  cells  were  sufficiently  differentiated  along  the  osteogenic 
lineage  to  warrant  being  termed  osteoblasts.  The  techniques  established  that  on 
and  after  day  14,  the  cultures  contained  a  population  o f  functionally  active 
secretory osteoblasts.
3.4.2  Effect of impaction forces on osteoblasts
The  hypothesis  was  found  to  be  false  that:  Osteoblasts  derived  from  MSCs 
seeded  onto  allograft  scaffolds  will  survive  normal  impaction  forces  used 
during rTHRs.  The Alamar Blue™ assay demonstrated that cell metabolism was 
significantly reduced after impaction at 6  and 9kN and did not recover above the 
pre-impaction level o f metablolism, which is a marker for cell recovery.  However, 
although there  was  a reduction in cell  metabolism  o f the  osteoblasts  immediately 
post-impaction at 3kN, this was not significant.  The osteoblasts in the 3kN group 
also recovered above original levels o f metabolism after 96 hours post-impaction, 
indicating  that  the  osteoblasts  had  either  proliferated  or  recovered  their 
biosynthetic activity following their initial shock (figure 3.7).
Figure  3.8  compares  the  changes  in  metabolism  o f MSCs  from  chapter  2,  and 
osteoblasts  from  this  chapter after impaction.  Figure  3.8a and  figure  3.8c  shows 
there is not much contrast between the MSCs and osteoblasts in terms o f metabolic 
levels after impaction at 3kN or 9kN.  The  most dramatic  difference between the 
two cell types is at 6kN post-impaction.  Initially both cell types incur a reduction 
in metabolic levels 24 hours post-impaction.  MSC metabolism is reduced by about 
38% and  OB  metabolism  is reduced by approximately  50%.  However the MSCs 
recovered  after  96  hours,  with  metabolism  exceeding  pre-impaction  levels  by
107approximately  30%.  In  contrast,  metabolism  o f  the  osteoblasts  continued  to 
decrease after 24 hours post-impaction and within 96 hours was approximately half 
o f their pre-impaction  levels.  The  contrasting  behaviour  o f these  two  cell  types 
indicates that they have different phenotypic responses to mechanostimultaiton.
The  mechanism  for the  relative  susceptibility o f osteoblasts  to  mechanical  forces 
may be  explained by  studies  in the  literature.  In a study by  Weyts,  F.F.A.  et al, 
immortalised human fetal osteoblasts were subjected to increasing levels o f stretch 
at  varying  stages  o f differentiation.  A  multitude  o f responses  were  observed  at 
different  lineage  points  and  with  the  age  o f  the  cells.  For  instance,  younger 
osteoblastic cultures were induced into apoptosis by stretch, whereas older cultures 
were  unaffected.  An  increase  in  proliferation  was  differentiation  dependent  and 
occurred when ALP levels were high on day  14.  This tight regulation on apoptosis 
by osteoblasts may be particular to ‘secretory osteoblasts’  as non-differentiated  14 
day cultures  did not show the  same proliferative response to  stretch (Weyts et al. 
2003).  This corresponds to the patterns o f differing responses to impaction o f the 
osteoblasts  and  MSCs  in  the  study  in  this  chapter,  the  difference  being  that  the 
level  o f  strain  applied  in  this  chapter  is  not  known  and  is  likely  to  be  m ulti­
directional.  In  addition,  during differentiation the  cells  in the  Weyts,  F.F.A  et al. 
study produced  extracellular matrix  (ECM)  which may have  affected the  cellular 
responses  to  mechanostimultion  (Weyts  et  al.  2003).  In  the  work  by  M ikuni- 
Takagaki,  Y.  et  al,  rat  calvarial  cells  o f  different  osteogenic  lineages  were 
subjected to stretching on Matrigel.  The most responsive cells were populations o f 
intermediaries,  between  mature  osteoblasts  and  osteocyte-like  cells. 
Mineralisation was accelerated by stretching as evidenced by a decline in alkaline 
phosphatase  and  an  increase  in  osteocalcin  production  (Mikuni-Takagaki  et  al. 
1996).  Their  data,  suggesting  that  mechano-responses  are  lineage  dependent, 
corresponds  to  that  o f  Weyts,  F.F.A.  et  al  with  the  additional  suggestion  that 
differentiation o f the cells is further progressed by the application o f strain.
Alamar Blue™ is an assay for the metabolic activity o f cells.  Proliferation, as well 
as  increased  cell  biosynthetic  activity,  can  lead  to  increased  metabolic  activity 
within  a  cell  population.  Conversely,  cell  death  or  a  reduction  in  biosynthetic 
activity  leads  to  a  reduction  in  metabolism.  Therefore,  it  is  not  possible  to
108distinguish  between  the  relative  influence  o f either  proliferation  or  biosynthetic 
activity using Alamar Blue™ alone.  Tritiated thymidine incorporation could have 
been used as an assay for cell proliferation.  Cells that synthesise DNA incorporate 
the isotope and can be quantified using a scintillation counter. Another alternative 
is  Hoescht  33258,  which  is  a  fluorescence  dye  for  DNA  estimation.  The  dye  is 
specific for DNA and binds to adenine-thymine base pairs emitting fluorescence at 
a  wavelength  o f 460nm.  However  this  would  not  have  been  appropriate  for  my 
study  as  allograft  contains  native  osteocytes  and  osteoblasts  which  would  have 
contaminated the  DNA  reading (Freshney 2000).  Both o f the methods  described 
above also require the removal o f the cells from the allograft and the contents to be 
released from  lysed cells.  The  cells  may penetrate  into pores  o f the  graft  so that 
the  release  o f  all  o f  the  cells  from  allograft  by  trypsinisation  could  not  be 
guaranteed.  Neither o f these assays would have allowed continuous assessment o f 
cells seeded on allograft over time, unlike Alamar Blue™.
3.5  CONCLUSION
Clinical  impaction  forces  affect  the  viability  o f MSC  derived  osteoblasts  seeded 
onto  an allograft  scaffold.  However,  osteoblasts  can survive  impaction forces up 
to  3kN,  which  is  in  the  lower  range  o f  normal  impaction  forces  used  during 
revision THRs.  Provided the force o f impaction does not exceed 3kN, cells could 
potentially  recover  and  reach  their  fu ll  osteogenic  potential  to  produce  bone  in 
vivo.  This could be possible through adaptation o f the slap hammer, which would 
allow the  force  to  be  monitored  so  that  it  did  not  exceed  3kN  during  a  revision 
THR (Phipps et al  2002).  The in vivo work that follows in this thesis w ill proceed 
w ith the use o f both osteoblasts and MSCs.  It may be possible to use osteoblasts 
for other clinical applications that do not require impactions such as spinal fusion, 
osteonecrosis o f the femoral head and maxillofacial surgery.
109CHAPTER 4: Bone remodelling of impacted allograft 
and hydroxyapatite with and without autologous
MSCs
1104.1  INTRODUCTION
Chapter two established that cells can survive impaction forces between 3KN and 
6KN in vitro.  It was essential to test the ability o f tissue engineered constructs to 
induce bone formation in an orthotopic site in a large animal model after impaction 
at  a  force  o f 3kN.  A  large  animal  model  is  more  relevant  than  a  small  animal 
model.  The  reasons  are  that  a  larger  volume  o f  graft  material  is  required  to 
represent  the  human  clinical  situation  than  is  possible  to  test  in  a  small  animal 
model.  Also,  blood  supply  is  associated  w ith  bone  remodelling  and  the  graft 
would be  too  close  to  vascularised  surfaces  in  a  small  animal  model.  Therefore 
sheep were chosen for use in this Chapter and throughout this thesis.
A resemblance  between the  iliac  crest o f the  sheep and human has  been reported 
by Pastoureau et al (Pastoureau et al.  1989) in terms o f access for biopsies.  Sheep 
have been used to study musculoskeletal disorders such as:  repair o f fractures and 
articular ligaments,  lim b lengthening, treatment o f osteoarthritis and osteoporosis. 
Other diseases  studied  include:  muscular disorders,  osteomyelitis,  spinal  diseases 
and biomaterial evaluation.
Healing  tends  to  be  faster  in  animals.  The  rate  o f bone  repair  is  known  to  be 
inversely  related  to  the  position  o f the  species  on  a  phylogenetic  scale  (that  is: 
evolutionary hierarchical  scale).  Therefore the  rat has  a higher capacity for bone 
regeneration than humans  (M artini  et al.  2004).  In the  Aerssens  et al.  study, the 
ash  and  IGF-1  content  o f trabecular  bone  in  sheep  was  similar to  humans.  The 
main  differences  between  sheep  and  humans  was  in  the  ash,  hydroxyproline, 
extractable  protein  and  IGF-1  content  o f  cortical  bone  (Aerssens  et  al.  1997). 
Bone mineral composition does not differ between humans, cattle,  sheep and dogs 
except  in  the  early  stages  o f  growth.  Cortical  bone  contains  fewer  Haversian 
canals in sheep than in human cortical, bone but the rate o f bone healing in sheep is 
similar  to  the  human  healing  rate.  The  femoral  condyle  was  chosen  because  it 
contained  the  most  cancellous  bone.  Before  analysing  the  effect  o f impaction 
grafting with stem cells on hip replacements in an ovine model, it was desirable to 
assess  bone  formation  using  a  more  consistent,  simple  and  controlled  site.  This 
model also allowed comparison between different grafts in the same model.
IllThere is also literature pertaining to the efficacy o f sheep as a large animal model 
for  correction  o f osteolytic  defects  in  revision  THRs  using  mesenchymal  stem 
cells.  Tissue  engineered  constructs  have  been  used  successfully  to  heal  critical 
sized defects in small (Kadiyala and Jaiswal  1997) as well as large animal models 
such as dogs and sheep (Kon et al.  2000; Bruder et al.  1998b).  The critical  sized 
defect is:  ‘the smallest size intraosseous wound in a particular bone and species o f 
animal that w ill not heal spontaneously during the lifetime o f that animal’  (M artini 
et al.  2004).  In a study by Griffon et al. unicortical, metaphyseal defects o f 15mm 
were created in ovine long bones and empty defects served as negative controls by 
having the lowest density after 7 weeks (Griffon et al.  2001).  The diameter o f the 
sheep  defects  in  this  Chapter  was  set  at  15mm  to  prevent  spontaneous  healing 
w ithin 6 weeks.
Aim
The  objective  of this  Chapter  is  to  assess  whether  new  bone  formation  of 
impacted  allograft  and  HA  in  a  critical  sized  defect  is  improved  by  using 
autologous  ovine  MSCs  in  vivo.  In  addition  osteoconductivity  of irradiated 
allograft  was  compared  with  60  percent  porous  granular  HA  in  an  animal 
model that simulates bone remodelling within impacted graft in vivo.
Hypotheses
1.  Addition  of MSCs to allograft or HA used  in impaction  grafting will 
increase new bone formation in vivo.
2.  Allograft  will  produce  more  new  bone  than  HA  because  of  its 
osteoinductive nature.
1124.2  MATERIALS AND METHODS
4.2.1  Study design
Twelve  skeletally mature  mule  sheep  were  used to  assess  the  effect  o f MSCs  on 
new bone  growth  and  remodelling  in  impacted  graft.  Six  female  sheep received 
morsellised  allograft  and  six  received  HA  granules.  Defects  o f  15mm  diameter 
were  created  in  the  medial  femoral  condyle  on  both  right  and  left  sides  o f the 
sheep.  The  graft was  inserted at a quantity o f 3.5g to both femoral  condyles.  In 
each  sheep one  condyle  served as  a control,  containing  graft alone,  and the  other 
condyle contained the same graft type with MSCs.
The groups were:
Sheep Graft type
Femoral condyle: 
left or right
Femoral condyle: 
left or right
n=6 sheep Allograft control MSC
n=6 sheep
HA (ApaPore- 
60™)*
control MSC
*Apa Tech Ltd, Hertfordshire, UK
Table 4.1 Study design
The  animals  were  euthanized  at  six weeks.  The  femoral  condyles were  removed 
for hard grade histology processing and histomorphometric analysis.
4.2.2  Preparation of graft
4.2.2.1  Allograft
Allograft was prepared as described in Chapter 2, section 2.2.2.
4.2.2.2HA
The HA was provided in the form o f ApaPore-60™ by Apa Tech (Apa Tech Ltd, 
Hertfordshire,  UK).  ApaPore-60  is  a phase-pure  synthetic  HA with the  chemical 
formula Caio(P0 4 )6(OH)2.  This material  is used in clinical practice for impaction 
grafting.  This  was  supplied  as  irregularly  sized  granules  o f 2-5mm  in  diameter
113with  a  60%  porosity  with  an  average  pore  size  o f  400pm.  This  HA  has  an 
interconnected  structure.  The  HA  was  double  bagged  with  an  airtight  heat  seal 
into 3.5g aliquots and irradiated as described in the Materials and Methods section 
o f Chapter 2.
4.2.3 MSC Culture
MSCs were harvested as bone marrow aspirates from the  12  sheep designated for 
the  study.  The  cells  used  in  the  study  were  fibroblastic  in  appearance  once 
adherent to tissue culture plastic and displayed this morphology throughout culture. 
The  MSCs  were  expanded in culture until they were between passage  3  and 6  to 
achieve  adequate  numbers  for  cell  seeding  onto  graft.  Cell  culture  was  done  in 
accordance with the protocols described in chapter 3.
4.2.4 Suspension seeding MSCs onto allograft and HA
The same method for suspension seeding o f graft was used as in Chapter 2.  MSCs 
were  removed  from  tissue  culture  plastic  by  trypsinisation  and  seeded  at  2 xl0 6 
cells/g  o f allograft  or HA.  Cells  were  attached  to  the  allograft  by  rotation  on  a 
TAAB  rotator (TAAB,  UK)  for 2.5  hours  at  37°C  with  5%  CO2.  The  cells  were 
then transferred to a 6 well plate and were maintained in culture for 72 hours pre­
surgery. The graft was covered by 7ml o f media.
4.2.5 Surgery
A ll  procedures  were  carried  out  in  accordance  with  the  Animals  (Scientific 
Procedures)  Act  1986  at  the  Royal  Vetinary  College  (RVC),  North  Mymms,  as 
described in Chapter 2.  Twelve  skeletally mature  sheep were used for the  study. 
At 48 hours prior to the operation the animals were housed separately and animals 
were starved for 12 hours pre-operatively.
4.2.5.1  Analgesia
A t  induction  each  animal  was  administered  0.6mg  o f  Buprenorphine  (2ml  o f 
0.3mg/ml) intramuscularly for intraoperative analgesia.  The dose was repeated on 
the first post operative day.
1144.2.5.2 Impaction of the graft
Graft  was  placed  into  titanium  tubes,  having  the  same  dimensions  as  the  Delrin 
tubes used in Chapter 3.  Titanium tubes were used for ease o f sterilisation.  Graft 
was  added  and  the  tube  was  then  mounted  into  the  impactor  (figure  4.1a).  In 
Chapter 2 MSCs were  shown to have survived impaction forces o f 3kN and 6kN. 
As  described  in  Chapter  2  MSCs  impacted  at  3kN  recovered  faster  than  those 
impacted at  6kN  and therefore  a  force  o f 3kN  was  chosen  for this  study.  As  in 
Chapter 2,  section  2.3.2.3  twenty  impactions  were  applied  to  the  graft  and MSC 
constructs  as  most  graft  compaction  is  achieved  in  the  first  twenty  impactions 
(figure  4.1b).  After HA  samples  were placed into the titanium tubes  and before 
impaction, they were immediately covered with autologous blood from the jugular 
vein o f the  sheep which was allowed to coagulate before  impaction.  Addition of 
blood  is  normal  clinical  practice  suggested  by  the  manufacturer  (Apa  Tech, 
Hertfordshire, UK).
Figure 4.1a Illustrates the weight stop (WS) at 2.5cm above the weight (W);  b shows 
that dropping the weight from this height delivers a force of 3kN to the graft contained 
in the titanium tube (T).  Impactions were administered 20 times.
1154.2.5.3 Insertion of graft
A ll  surgical  procedures  were  carried  out  under  aseptic  conditions.  Once 
anaesthetised  an  area  over  the  medial  aspect  o f  both  knee  joints,  extending 
proximally over the medial thigh and lower abdomen, was shaved. Betadine (broad 
spectrum topical iodophor microbicide) surgical scrub was applied and the site was 
further  cleaned  with  Hydrex  Surgical  Scrub  (MidMeds  Ltd,  Loughton,  UK), 
containing  chlorohexidine,  an  alkaline  aqueous  antimicrobial  (MidMeds  Ltd, 
Loughton, UK).
Sterile  drapes  were  used  to  expose  the  wound  site  whilst  the  animal  was  in  the 
supine  position for easy access to  both left  and right medial  femoral  condyles.  A 
longitudinal  50 mm  incision was placed over the  medial aspect o f the  femur, just 
proximal to the knee joint and 30 mm posterior to the medial border o f the patella. 
W ith sharp dissection o f the superficial and deep fascia, the vastus medialis muscle 
was exposed.  The muscle was then split along its fibers to expose the periosteum 
on the medial condyle.  The best position was  found for the  femoral plate  (which 
acts  as  a drill  guide)  and a periosteal  elevator was  used to  scrape  the  periosteum 
from  the  surface  o f the  femoral  condyle.  The  femoral  plate  was placed  and two 
2mm diameter holes were drilled into the condyle to accept the  self tapping 2.7 x 
18mm  cortical  screws  (Synthes,  UK)  that  attach  the  femoral  plate  to  the  bone 
(figure 4.2).
Figure  4.2a  The  image  illustrates  the  femoral  plate  (FP)  secured  into  place  with 
cortical  screws (CS) and a  10mm drill centraliser (DC)  used to centralise the drill  bit; 
b illustrates the FP in position in vivo.
116The depth o f the defect was determined by the height o f the  graft after impaction 
(figure 4.3a-b).  The depth o f the defect was drilled to 4mm  deeper (Figure 4.3b) 
than  the  height  o f  the  pellet  created  by  impacting  the  morselised  allograft  or 
granular HA to ensure that all the graft was contained within the defect and did not 
extrude from the top.
Figure 4.3a The graft height was  measured  using  a sterile  ruler.  The  measurement 
obtained was subtracted from the height of the tube (50mm).  To give the final height 
another 4mm was subtracted as this was the depth that the delrin lid projected into the 
tube;  b shows the depth of the defect plus the height of the DC  being  marked  by the 
drill stop (DS).
Plugs were  inserted transversely across the  femoral bone.  The cortex was reamed 
to  produce  a  hole  to  accept  a  cylindrical  shaped  implant.  5,  10  and  15  mm 
pneumatic  and  hand  held  drills  were  used  with  the  aid  o f  drill  centralisers, 
designed  to  enable  accurate  drilling  o f holes,  to  create  the  final  15mm  diameter 
defect in the medial femoral condyle (Figure 4.4).  The defect was washed using a 
syringe with sterile saline to remove bone debris.
117Figure  4.4a  Shows  a  10mm  drill  being  guided  through  the  DC  mounted  onto  the 
femoral plate.  The drill stop (DS) is placed on the drill bit to mark the exact depth for 
the drilling; b  illustrates the drill creating a defect in vivo.
After impaction the delrin lid was removed and the tube  containing the  graft was 
mounted onto the femoral plate. The impacted graft was then gently tapped into the 
defect  site  through  the  femoral  guide  plate  using  a  Delrin  plunger  and  a  mallet 
(figure 4.5).  Once the graft had been driven in the femoral plate was then removed 
before wound closure.
Figure 4.5a  Shows the  delrin  plunger being  used  to tap the  impacted  graft and  cell 
construct  into  the  defect;  b  shows  the  placement  of  the  graft  using  the  same 
procedure in vivo.
118Figure 4.6 Shows the femoral plate surrounding the graft that has just been placed in 
the defect.
Once  the  plug  was  inserted  the  wound  was  closed  in  layers  with  absorbable 
vicryl™   sutures.  The  muscle  apposed with 2  or  3  interrupted  sutures,  continuous 
closure  o f the  deep  fascia and  dermis,  with  interrupted  sutures  to  close  the  skin. 
Post-operatively the animals were recovered in sternal recumbency and housed in 
individual pens for 24 hours.  A sample representing initial impaction for HA and 
allograft was impacted into the femoral condyles o f anewly sacrificed sheep.  The 
procedure  outlined  above  was  performed  on  the  femur  after the  sheep  had  been 
euthanased.  A daily dose o f Ceforex (a cephalosporin antibiotic) was administered 
intramuscularly,  for  5  days  post  operatively.  The  first  dose  was  at  induction  of 
anaesthetic.
4.2.2.4  Histology
After  six  weeks  the  sheep  were  euthanized  with  Phenobarbitone  (50ml  o f 20% 
solution)  intravenously.  Femurs  were  removed  and  debrided o f soft tissue.  The 
femurs  were  cut  down on the  bandsaw until  the  femoral  condyles  containing the 
graft  plug  remained.  The  femoral  condyles  were  fixed  in  10%  buffered  formal 
saline  and  dehydrated  with  solutions  o f ascending  concentrations  o f IMS  (BDH 
laboratory supplies, UK) in a similar manner to the protocol for resin embedding in 
chapter  2,  section  2.2.5.4.  However,  as  the  samples  were  relatively  large,  a 
chloroform  step  was  included  for  defatting  to  allow  adequate  penetration  o f the 
solutions  prior  to  embedding  in  LR  white  resin  (Agar  Scientific  Ltd,  UK).  The 
protocol for fixation is shown in table 4.1.
119Process Number of days
10% buffered formal saline 7
50% IMS 50% distilled water 3
70% IMS 30% distilled water 3
100% IMS (repeat step 3 times) 3
Chloroform (repeat Step twice) 1
100% IMS (change IMS twice per day) 3
50% LR white resin 50% IMS 7
100% LR white resin (under vacuum for 10 seconds) 
Apply vacuum every day
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Cast  in  LR  white  resin  (1  drop  accelerator/10ml 
resin).  Leave in fridge 24 hours
Table 4.2 Histology Processing Protocol
The samples were sectioned in the transverse plain using the Exact saw and ground 
to  a thickness  o f 100pm  using the  Exakt  micro-grinding  system  and polished  on 
the Motopol 2000 (Bueler, Coventry, UK). Prior to histomorphometric analysis o f 
the  sections  they  were  stained  with  Toludine  Blue  for  10  minutes,  which  stains 
fibrous  tissue  blue  and  a  Paragon  stain  for  15  minutes  which  stains  new  bone 
bright pink.
4.2.6  Histomorphometry
4.2.6.1  New bone and remaining allograft
New  bone  and  remaining  allograft  were  quantified  by  area  using  the  KS300 
computer program.  The  samples were  divided  into three  regions  o f interest:  the 
middle,  anterior  host-graft  interface  and  the  posterior  host-graft  interface.  The 
interface regions were selected 3mm away from the host bone and into the graft to
120ensure no overlap with host tissue  (figure 4.7) and to define reproducible regions 
that could be analysed.
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Figure 4.7  Image to  show three  regions  of interest:  Anterior host-graft interface  (A), 
Middle (M) and Posterior host-graft interface (P).
Four pictures were taken at regular intervals along each region to give  12 images in 
total.  Measurements were made o f the field o f view at x 4 magnification, the area 
o f  the  remaining  graft  in  the  field  of  view  and  the  area  o f  new  bone. 
Measurements for anterior and posterior interfaces were averaged to represent the 
host-graft  interface.  The  data was analysed as percentage o f remaining  graft and 
percentage o f new bone formation.
4.2.6.2  Porosity
Time  zero  samples were  analysed to  determine the porosity o f the  graft (the  area 
occupied by the pores) and the graft area (expressed in %).
4.2.7  Statistics
The statistical software SPSS (SPSS vlO .l, SPSS Inc, Chicago, USA) was used for 
the  analysis.  The  Wilcoxon  signed-rank  test  for  non  parametric  data  was  used. 
Significance  was  established  as  p<0.05.  One  sheep  in  the  HA  group  had  to  be 
omitted  from  the  data  analysis  due  to  extrusion  o f the  graft  from  the  control 
femoral condyle.  Therefore 5  animals in the HA group were analysed rather than 
six.  Bars on graphs represent standard error o f the mean (±SE).
1214.3 RESULTS
4.3.1  Allograft Histomorphometry
The  mean for new bone  and remaining  allograft  are  presented  in figures  4.8  and 
4.9.  The  graph  in  figure  4.8  shows  the  differences  in  percentage  new  bone 
formation  between  the  MSCs  and  the  control  within  the  interface  and  middle 
regions  of the  allograft  group.  The  graph  in figure  4.9  shows  the  differences  in 
percentage of remaining graft between the control and MSCs within the  interface 
and middle groups after six weeks in vivo.
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Figure 4.8 The graph  represents  percentage  new  bone formation  at the  middle  and
host-allograft interface (±SE) after six weeks in vivo after impaction at 3kN
Time zero=39%
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Figure 4.9  The  graph  represents  percentage  remaining  allograft  at the  middle  and
interface  (±SE)  after  six  weeks  in  vivo.  The  amount  of  allograft  occupying  the
microscopic field at time zero was 39%.
122There was no significant difference in the mean amount o f new bone formed in the 
MSC  samples compared to the control samples at the interface w ith 23.6% ±  5.4 
SE  and  26.5%  ±2.1  SE  (p=0.753)  respectively,  or the  middle  o f the  graft  with 
9.8% ± 4.2  SE and  11.0% ±2.1  SE  respectively (p=0.600).  The area o f allograft 
remaining was similar at both the interface in the control and MSC group at 8.9% 
±  1.6  SE  and 6.4% ±2.1  (p=0.249) respectively and in the  middle  at  5.7% ± 2.0 
and  9.5%  ±4.1  (p=0.500)  in  the  control  and  MSC  group  respectively.  After 
impaction at time  zero the  allograft had a porosity o f 61%.  The area o f allograft 
occupying  the  microscopic  field  was  39%.  After  6  weeks  the  area  o f allograft 
remaining was 5.6% at the lowest (figure 4.9).
4.3.1.1  Allograft Histology
Histology revealed new bone  formation in  all  regions.  New bone had  formed  in 
both  the  control  and  MSC  treated  samples  and  was  mostly  in  contact  with  the 
remaining  allograft  (figures  4.10a-c).  More  new bone  was  observed  at the  host- 
graft  interface  than  in  the  middle  o f the  graft  in  both  control  and  MSC  groups. 
Blood  vessels  were  observed  in  association  with  new  bone  being  in  close 
proxim ity to  it.  Plump,  basophilic  osteoblasts  were  involved  in  intramembranous 
ossification.  The resorption o f allograft by osteoclasts is evidenced by Howship’s 
Lacunae, depressions in the bone surface seen in figure 4.10b.
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Figure 4.10a Image of the middle region  in the allograft Ctrl group.  The paragon  has 
stained new bone (NB) bright pink.  The allograft (AG) remained light in colour.  Active 
osteoblasts  (OB)  can  be  seen  laying  down  osteoid,  which  stains  lighter in  colour on 
the surface of new bone, b During  intramembranous ossification  (IO) the osteoblasts 
become  enclosed  in  the  mineralising  matrix  becoming  osteocytes.  In  this  image 
osteocytes  are  relatively  flattened,  darkly  stained  specks.  The  Howship’s  Lacunae 
(HL)  are  depressions  in  the  bone  resorbed  by  osteoclasts  that  have  preceded  new 
bone formation.  New  bone  is  associated  with  angiogenesis;  the  marrow cavity  (MC) 
contains blood vessels (BV).FT
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W
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Figure 4.10c Image taken at the middle region of the allograft MSC group.  The MSC 
group shows a similar morphology to the control group with NB forming in contact with 
remaining  AG.  There  is  also fibrous  tissue filling  all  the  gaps  not  occupied  by  new 
bone, allograft or other elements of mesenchymal tissue.
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1254.3.2  HA Histomorphometry
The graph below shows the differences in percentage new bone formation between 
the MSCs and the control within the interface and middle regions o f the HA group 
(figure  4.11).  The  graph  in  figure  4.12  shows  the  differences  in  percentage  of 
remaining  HA  between  the  control  and  MSCs  within  the  interface  and  middle 
groups.
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Figure 4.11  The graph  represents percentage new bone formation at the middle and 
host-graft interface (±SE) after six weeks in vivo after impaction at 3kN
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Figure 4.12 The  graph  represents  percentage  remaining  allograft at the  middle  and 
interface  (±SE)  after six weeks  in  vivo.  The  area  of HA  occupying  the  microscopic 
field at time zero was 49%.
126There was no significant difference in the mean amount o f new bone formed in the 
MSC samples compared to the control samples at the interface, at  16.7% ±5.9 and 
23.1% ± 3.8 (p=0.800) respectively and the middle of the HA at 5.0 ± 2.6 and 7.2 ±
4.1  (p=0.273)  respectively.  The  area  o f HA  remaining  was  similar  at  both  the 
interface  in  the  control  and  MSC  group  at  48.6%  ±  1.7  SE  and  50.4%  ±  2.4 
(p=0.500)  respectively  and  in  the  middle  at  50.1%  ±  2.0  and  51.7%  ±1.9 
(p=0.500) in the control and MSC group respectively. After impaction at time zero 
the  HA had a porosity o f 51%.  The area o f HA occupying the microscopic  field 
was 49%.  After 6 weeks the there was no change in the amount o f HA occupying 
the microscopic field, therefore there was no change in porosity.
4.3.2.1 HA Histology
New bone was observed in both the MSC and control group.  In most samples new 
bone was  associated with the  HA particles.  New bone  formed  in coastal  regions 
around the HA particles and within pores.
Figure 4.13 Image taken at the middle region in the HA control group after 6 weeks in 
vivo.  Remaining HA (HA) appears black and contains pores (P) surrounded with new 
bone (NB) and fibrous tissue (FT).
127Figure 4.14 Image of HA taken at the middle region  in the MSC group after 6 weeks 
in vivo.  Remaining  HA appears black with  new bone  (NB) within  pores and following 
the contours of the HA particles.  Fibrous tissue (FT) is also present.
1284.3.3  Comparison  of  bone  formation  and  graft  remodelling 
in the allograft and HA groups.
4.3.3.1  Control Group
The  quantity  o f new  bone  formation  and  remaining  scaffold  in  the  allograft  and 
HA control groups was compared after six weeks in vivo and is represented in the 
graphs below (figure 4.15 and 4.16).
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Figure 4.15 The graph represents percentage new bone at the interface and middle of 
the graft in Ctrl allograft and HA scaffolds (±SE) after six weeks in vivo
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Figure  4.16  The  graph  represents  percentage  remaining  graft  at the  interface  and 
middle of the graft in Ctrl allograft and HA scaffolds (±SE) after six weeks in vivo
129Analysis  o f the  control  group  reveals  that  at  six  weeks  there  was  no  statistical 
difference  in the  amount o f new bone formation between the  allograft and HA at 
the interface with 26.5% ±2.1  SE and  23.1% ± 3.8 SE respectively (p=0.23) or the 
middle o f the graft with  11.1% ± 2.1  SE and 7.2% ±4.1  SE respectively (p=0.50) 
(figure  4.15).  There  is  a  significant  difference  between the  amount o f remaining 
allograft, at 5.7% ± 2.0  SE compared to remaining HA,  at 50.1% ± 2.0  SE  in the 
control group.  There is significantly more remaining HA than remaining allograft 
at the interface (p<0.001) and in the middle (p<0.001) region o f the sample.
4.3.3.2  MSC Group
The  quantity  of new  bone  formation  and  remaining  scaffold  in  the  MSC  treated 
allograft and HA  groups was compared after six weeks in vivo and is represented 
in the graphs below (figure 4.17 and 4.18).
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Figure 4.17 The graph represents percentage new bone at the interface and middle of 
the graft in MSC allograft and HA scaffolds (±SE) after six weeks in vivo.
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Figure  4.18  The  graph  represents  percentage  remaining  graft  at  the  interface  and
middle of the graft in MSC allograft and HA scaffolds (±SE) after six weeks in vivo
130The MSC treated samples follow  the same trend as the control group.  Analysis o f 
the MSC  group reveals that at six weeks there was no  statistical difference  in the 
amount o f new bone formation between the allograft and HA, with 23.6% ± 5.4 SE 
and  16.7% ±5.9 respectively at the  interface  (p=0.35),  or the middle  o f the  graft 
with 9.8% ± 4.2 SE and 5.0% ± 2.6 SE respectively (p=0.50) (figure 4.17).  There 
is a significant difference between the amount o f remaining allograft compared to 
remaining HA in the MSC groups.  There is significantly more remaining HA than 
remaining  allograft,  with  50.4%  ±2.1  SE  and  6.4% ±2.1  SE  respectively  at the 
interface  (p=0.043)  and  9.5%  ±4.1  SE  respectively  and  51.7%  ±  1.9  SE 
respectively in the middle (p=0.043) region o f the sample.
1314.4 DISCUSSION
4.4.1  The effect of MSCs on new bone formation
The  hypothesis  that:  addition  of MSCs  to  allograft or HA used  in  impaction 
grafting will increase new bone formation in vivo was not proved.  There was no 
significant increase in new bone formation or remodelling with the introduction o f 
MSCs on impacted allograft or HA granules.  In all groups more bone was formed 
at the graft-host interface than the middle o f the  graft, as would be expected from 
the  invasion  o f  osteoblasts  and  progenitor  cells  into  the  scaffold  along  with 
angiogenesis.  The  periphery  o f the  graft  is  nearest to  the  source  o f nutrition  and 
this  is  where  the  vessels  would  form  first  allowing  osteoblastic  activity.  The 
middle o f the graft becomes vascularised later and hence there is less time for bone 
formation  during  the  experiment.  This  is  described  by  early  experiments  where 
rabbit  marrow  cells  were  loaded  into  diffusion  chambers,  implanted  into  the 
peritoneal cavity that excluded host cells, but allowed nutrient diffusion in and out. 
Histological  evaluation  confirmed  cartilage  development  in  the  middle  o f  the 
chamber  and  bone  apposing  the  internal  interface  which  was  encased  by 
vasculature  (Caplan  1991;  Owen  and  Friedenstein  1988).  Kruyt  described  new 
bone  as  forming  from  the  outer  HA  surface  toward  the  centre  o f the  pores  in 
ectopically implanted HA granules seeded with BMSCs in goats.  A fluorochrome 
given  at  five  weeks  was  seen  directly  on the  HA  surface,  whilst the  seven week 
marker  was  advancing  toward  the  middle  o f the  pore  (Kruyt  et  al.  2003).  This 
indicates  that  bone  formation  may  occur  along  a  nutrient  diffusion  gradient. 
However the  granules were only 40mm  , larger constructs may not allow nutrient 
diffusion.  Some  studies  suggest that once  MSCs  were  seeded evenly throughout 
the graft, they would contribute to new bone formation throughout the graft, in the 
middle  as  well  as  the  interface,  even  in  larger  constructs.  Inner  pore  spaces  o f 
MSC-seeded HA constructs, used to assess tibial defect repair in sheep, were filled 
with new bone whereas new bone was limited to the outer surface o f HA controls 
without cells on completion o f the experiment (Kon et al.  2000).  Similarly Bruder 
et al’ s study o f the healing o f critical size defects in the femora o f dogs found that 
the  MSC  treated  porous  ceramic  cylinders  formed  new  bone  throughout  the 
implant, as well as at the cortex (Bruder et al.  1998b).  In MSC seeded granules o f
132HA implanted in the paraspinalis muscles o f goats Kruyt et al.  found that ectopic 
bone was distributed unevenly throughout the granule, with a strong preference for 
the interior (Kruyt et al. 2003).
4.4.2  Comparison of bone remodelling in the allograft and HA groups
The hypothesis that:  Allograft will produce more bone than HA because of its 
osteoinductive nature was unsupported by my work.  Both scaffolds were shown 
to  induce  similar  amounts  o f new  bone  formation.  A t  six  weeks  there  was  no 
significant difference in the amount o f new bone induced in allograft compared to 
HA  in both the  middle region o f the  graft  and the  interface  region.  There  was  a 
significantly  greater  degree  o f resorption  in  the  allograft  group,  allowing  more 
ingrowth o f fibrous tissue.  This makes the  structural  scaffold much more porous 
and therefore more likely to compromise the stability o f the construct. The HA was 
not resorbed after 6 weeks and hence may be more stable.
As  previously  discussed  in  Chapter  1,  autograft  is  the  clinical  ‘gold  standard’  in 
bone  grafting  with  the  capacity  to  be  osteogenic,  osteoconductive  and 
osteoinductive  (Giannoudis  et  al.  2005).  The  most  significant  drawbacks  o f 
autograft  include:  donor  site  morbidity,  extension  o f  the  surgical  procedure, 
unnecessary  invasive  surgery  and  pain  incurred  at  a  healthy  site,  and  limited 
quantity o f graft from the donor site (Niklason 2000; Lane and Sandhu 1987).  The 
most common alternatives to autograft are allografts.  In the decade spanning from 
1989 to  1999 the use o f allograft has increased  15 times and accounts for one third 
o f the bone  grafts performed in the United  States  (Boyce et al.  1999).  However, 
some osteoinductivity o f allograft is limited when the graft is sterilised due to the 
necessity to  remove  cellular  components  that trigger the  acute  allograft  rejection 
response (Giannoudis et al.  2005).  Irradiation at 30 kGy has the least deleterious 
effects  on the  mechanical  properties  o f bone  with 25  kGy,  the  strength  that  was 
used in this Chapter and throughout my thesis, killing most bacteria (Pelker et al. 
1983).  Due to the increasing reliance on allograft instead o f autograft, there is an 
increasingly limited supply available.  Also there are complications associated with 
autograft as mentioned above and in Chapter 1   (Norman-Taylor et al.  1997).
133HA has the advantage over allograft that it is unlimited in availability and there is no 
opportunity for disease transmission.  The results in this chapter show that induction 
o f new bone is comparable in both allograft and HA.  In both cases new bone was 
formed  within  and  in-between  the  graft  particles,  fillin g   and  bridging  the  gaps 
between  them.  This  allows  for  the  formation  o f an  interconnected  and  cohesive 
scaffold.  Substantial  resorption  o f the  allograft  scaffold  in  this  model  initiated 
greater ingrowth o f fibrous tissue. This effect seems to be associated with the rate o f 
bone resorption and although the amount o f new bone formed in the allograft filled 
defect was equal to that seen with the HA filled defect, fibrous tissue formation was 
increased in the former.  The HA graft was not resorbed after 6 weeks.  This makes 
the  allograft/new bone  composite  less  integrated than the  HA/new bone  composite 
and therefore more  likely to compromise the  stability o f the  construct.  If the  graft 
resorbs too soon after impaction grafting then there are implications for the stability 
o f the  hip  replacement  through  subsidence  (Gokhale  et  al.  2005;  Eldridge  et  al. 
1997).  Based on the analysis in this Chapter it would be possible to use HA without 
allograft in an impaction model.
4.4.3  Sources of Error
There  may  be  a variety  o f reasons  why the  MSC  treated  graft  did not  contribute 
significantly to new bone formation and remodelling.  Since new bone was formed 
in  MSC  treated  groups  and  there  was  no  adverse  effect  as  a  result  o f  the 
introduction o f MSCs, they cannot be excluded as inducers o f new bone.  There are 
several  instances  where  the  methodology  may  not  have  been  effective  including 
problems  associated  with  MSC  differentiation,  MSC  seeding,  graft  morphology 
and loading, nutrient diffusion, surgery, length o f study.
4.4.3.1  MSC Differentiation
MSCs  in  this  experiment  were  maintained  in  culture  as  MSCs  and  were  not 
differentiated  into  osteoblasts  prior to  implantation  in the  femoral  defect.  Ovine 
MSCs have been used in other studies and have contributed to new bone formation 
(Petite et al.  2000; Kon et al.  2000).  In one study tibia diaphyseal resections were 
performed  in four sheep.  Two  defects were  filled with HA cylinders  seeded with 
autologous  bone  marrow  stromal  cells  (BMSCs)  and two  sheep  received  control 
samples without BMSCs.  Morphological analysis showed a significant increase in
134new bone formation o f 50% over 7% in controls with no BMSCs (Chistolini et al. 
1999).  However,  other  large  animal  studies  in  goats  have  stimulated  osteogenic 
differentation o f BMSCs by introducing supplemented media prior to implantation 
o f  the  construct.  In  Kruyt  et  al’ s  initial  ectopic  study,  described  above,  HA 
scaffolds  were  seeded  and  maintained  in  static  culture  w ith  osteogenic 
supplemented media for six days prior to implantation.  This resulted in significant 
bone  formation,  whereas  devitalised,  bone  marrow  and  control  samples  did  not 
produce any bone.  This highlighted the importance o f live cells in the contribution 
to new bone  (Kruyt et al.  2003).  A later study by Kruyt et al.  in 2004 compared 
different combinations  o f culture  conditions and grafts  in order to  optimise tissue 
engineering  in  goats.  Treatment  with  osteogenic  supplements  did  not  influence 
bone  formation  (Kruyt  et al.  2004b).  However  future  studies  in  this  thesis  w ill 
include  groups  o f  MSCs  treated  with  osteogenic  supplements  to  promote 
osteogenic differentiation as well as maintained MSCs, as both culture techniques 
have been found to be successful in inducing new bone formation.
4.4.3.2  MSC numbers
In  this  Chapter  MSCs  were  seeded  onto  graft  at  a  concentration  o f  2  x  106 
cells/cm3.  This  concentration o f cells was based on a published study where  cell
seeding density was investigated.  After 3 and 6 weeks in culture, scaffolds seeded
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with  1x10  cells/cm  rat BMSCs showed similar tissue formation as those seeded 
with higher initial cell seeding densities. When initial cell seeding densities o f 1   x
zr  o
10  cells/cm  were  used,  osteocalcin  immunolabelling  indicative  o f  osteoblast 
differentiation  was  seen  throughout  the  scaffolds  after  only  2  weeks  o f in  vitro 
culture  (Holy  et  al.  2000).  The  use  o f cells  at  higher  concentrations  may  be 
necessary  in  large  animal  models  as  metabolism  is  slower.  The  range  o f
ft  'X
concentrations  used  in  large  animal  models  was:  8  x  10  cells/cm  (Kruyt  et al. 
2004a),  10 x 106 cells/cm3 (Kruyt et al. 2003) in goats,  10 x  106 cells/cm3 in a sheep
ft  'X
model  (Petite  et al.  2000),  and  approximately  19  x  10 /cm  were  seeded  in two 
canine models.  However, it was suggested that some cells were not adherent and 
the numbers o f non adherent cells were not detailed in either paper (Arinzeh et al. 
2003;  Bruder  et  al.  1998b).  Due  to  time  and  limitations  in  space,  the  seeding 
density was  restricted  in the  study  in this  Chapter.  However,  in  future  studies  in 
this thesis higher seeding densities w ill be used.
1354.4.3.3 Seeding Technique
The  seeding technique used in this Chapter was optimised to deliver the MSCs to 
the defect site while the cells were  in the most proliferative  and durable phase  o f 
development  after  4  days  in  culture  as  established  in  Chapter  2  (see  Chapter  2, 
section 2.3.1.2).  Choosing preoperative seeding o f 4 days may have been a factor 
in  lim iting the  contribution o f new bone  in the  MSC  seeded  group.  However,  it 
was established in Chapter 2 that the cells remained viable and in a growth phase 
during static culture as shown by Alamar Blue™ analysis. Other authors have pre­
cultured cells on graft (Kruyt et al.  2003).  In addition, when constructs with cells 
incubated for 6 days were compared with samples cultured for 1  day after seeding, 
there was significantly more bone induced in the 6 day cultured constructs (Kruyt 
et  al.  2004b).  Others  prefer  intra-operative  seeding  o f  the  graft  by  vacuum 
(Kadiyala and Jaiswal  1997), vacuum seeding with incubation at 37°C for 3 hours 
(Arinzeh et al.  2003) or by adsorbtion o f cells onto the implant via a polymerising 
substrate  such  as  fibrinogen  (Kon  et al.  2000)  or  fibronectin,  where  the  HA  and 
cell construct was implanted after 3 hours incubation (Bruder et al.  1998b).  Any 
incubation period in these studies was merely to allow cells to adhere to the graft. 
The Kruyt group showed that precultured cells are not essential for bone formation, 
drawing  a  direct  comparison  between  precultured  and  intra-operatively  seeded 
cells.  Amongst  a  range  o f seeding  and  culture  techniques,  cryopreserved  goat 
BMSCs were either seeded onto constructs for  1   week or seeded intra-operatively 
in plasma and implanted ectopically.  No significant difference in percentage bone 
area  or  bone  contact  was  observed  between  these  groups,  but  there  was  a 
significant increase over the control with no cells and bone marrow seeded calcium 
phosphate  scaffolds  (Kruyt  et  al.  2004a).  Therefore  an  intra-operative  seeding 
method is preferable to the complicated logistics o f a preoperative method (Kruyt 
et al. 2004a) and w ill be used in future studies in this thesis.
4.4.3.4 Graft Morphology and loading
Most  o f the  studies  looking  at  TE  constructs,  seed  MSCs  onto  blocks  o f porous 
ceramic  bone  substitutes.  Some  were  much  larger than the  granules  used  in my 
study, being cylinders with a hollow central core (Arinzeh et al.  2003; Bruder et al. 
1998b; Petite et al.  2000) or solid cylinders (Kon et al.  2000).  One study utilised 
individual  disks,  relatively  large  in  size  compared  to  the  granules  used  in  this
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2004c).  There were also ceramic constructs o f similar dimensions to those in this 
Chapter, but these only comprised o f one or two granules (Kruyt et al. 2003; Kruyt 
et al.  2004b; Kruyt et al.  2004a).  The large cylinders may have provided a stable 
scaffold  for  the  cells  compared  to  the  granules  used  in  my  study.  Kruyt  et  al 
(Kruyt et al.  2004c)  showed less  bone  formation at the peripheries  o f ectopically 
placed  TE  constructs  when  compared  to  the  middle.  Micromovement  on  the 
outside o f the implant was cited as a possible reason for the absence o f bone there. 
Intrafragmentary  strain  within  the  impacted  particulate  graft  may  have  played  a 
role  in  the  resorbtion  o f  allograft  and  poor  new  bone  formation  in  both  TE 
constructs.  The  argument  o f increased  interfragmentary  strain  in the  location  o f 
the femoral condyle, where my implants were placed,  is supported in the work o f 
Duda  et al  (Duda  et al.  1998).  This  study  states  that  sheep  bones  are  generally 
under  compression  with  increasing  ventral  and  lateral  shear  forces  towards  their 
ends.  It  is known that  larger shear movement  can lead to  delayed union or non­
union o f fractures, so the femoral condyles may not have been an ideal location for 
a study analysing allograft granules.  In addition, the femoral condyles are located 
adjacent to the joint surface where the bone end forms a saddle shape.  The load is 
therefore more widely distributed over a larger cross sectional area containing solid 
trabecular bone than in the shaft o f the femur, which is a cylinder o f predominantly 
cortical  bone  surrounding  marrow.  Another  consideration  is  that  the  femoral 
condyle  design may not relate to the way a graft responds to  force  around a  s tiff 
metal  implant.  In  a  revision  situation  the  graft  surrounding  the  implant  w ill  be 
subject to stress shielding due to the stiffness o f the implant.
4.4.3.5  Location and vascularisation of the graft
The diameter o f the defects in my study were  15 mm. The cells in the middle o f the 
graft would be  7.5  mm  away  from  the  nutrient  supply  in the  adjacent host bone. 
Small animal models would not achieve this distance therefore the sheep model is 
more realistic to the  clinical  situation.  One  reason why new bone  formation was 
not increased by MSCs could have been that the blood supply from the host in this 
situation  is  relatively  accessible  to  the  graft,  whereas  blood  supply  is  drastically 
compromised in a revision situation.  Therefore new bone formation by the MSCs 
may have been masked by osteoconduction from the host.  However, an alternative
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favourable to fluid diffusion (Deleu and Trueta  1965).  A low oxygen tension and 
poor nutrient supply may cause death o f the newly transplanted MSCs.
Orthotopic  locations  for  tissue  engineering  clinically  sized  constructs  in  large 
animals  are  hard  to  find  in  the  literature  and  reflect  that  cell  survival  may  be 
compromised  by  lower  metabolic  rates  and  slower  vascularisation  (Kruyt  et  al. 
2003;  Kruyt  et  al.  2004b).  In  a  study  on  vascularisation  o f bone  graft  in  the 
anterior chamber o f the eye, penetration o f vessels was faster in rats taking only 4 
days,  whilst  in  rabbits  vessels  penetrated  only  3mm  into  the  graft  after  7  days 
(Deleu  and  Trueta  1965).  However there  are  a  few  studies that  demonstrate  the 
successful  application  o f  tissue  engineering  o f  clinical  sized  constructs 
orthotopically in large animals (Petite et al.  2000; Bruder et al.  1998b; Arinzeh et 
al.  2003).  Orthotopic and ectopic locations are directly compared in one study by 
Kruyt, although the implant dimensions are relatively small.  BMSCs implanted on 
calcium phosphate ceramic scaffolds in the iliac crest o f goats were compared with 
the  same  group  implanted  paraspinally.  There  was  significantly  more  bone 
apposition on the available scaffold surface in the tissue engineered orthotopic site 
compared with control constructs at 9 weeks, but not at  12 weeks. However, there 
was a significant increase above the controls in the  12 week ectopic group (Kruyt 
et al.  2004c).  One explanation they give is that the fracture healing response may 
have  instigated phagocytosis.  Another  explanation they  give  is  that  the  scaffold 
was very osteoinductive,  overriding  any effect o f osteogenesis by donor BMSCs. 
This  is  less  likely to  be  the  case  in my  study  as  large  amounts  o f fibrous  tissue 
were observed in the allograft group.  It is more likely that interfragmentary strain 
was responsible for fibrous tissue rather than new bone formation in my study.
4.4.3.6  Surgery
In  my  model  the  defects  were  only  covered  with  the  vastus  medialis  muscle 
following  the  implantation  o f the  graft.  This  allowed  for the  ingrowth  o f fibrous 
tissue  into the  defects,  which may have  delayed or impeded new bone  formation 
(Gosain et al. 2003b).
1384.4.31 Length of the Study
In  this  study  the  samples  were  harvested  at  6  weeks.  Other  studies  looking  at 
similar constructs  harvested their  samples  at  8  to  9  weeks  (Ohgushi  et al.  1989; 
Kruyt  et al.  2004c).  The  question  remains  whether  more  bone  formation  would 
have  been  seen  at  a  longer  time  point.  Other  studies  have  shown  more  bone 
formation in the TE constructs at 4 weeks (Bruder et al.  1998b).
4.5 CONCLUSION
This study demonstrates that a bone substitute material does not need to be mixed 
with allograft and can be used on its own in an impaction grafting model. HA also 
has the advantage o f being readily available and there are no risks associated with 
disease  transmission.  Additionally  HA  is  more  uniform  in  terms  o f quality  than 
allograft bone and can be engineered to increase the  strength o f the graft particles 
for  different  applications.  In  a  study  by  Van  Gaalen,  S.  et  al,  porous  ceramic 
implants  seeded  with  or  without  autologous  cells  were  placed  either 
intramuscularly  or  paraspinally  in  Dutch  m ilk  goats.  The  implants  with  cells 
formed  more  bone  than  controls,  however  paraspinally  there  was  no  significant 
difference between groups and there was  less new bone than at the intramuscular 
location.  The reason for this was attributed to the slower diffusion o f nutrients due 
to  a less vascularised environment that may lead to  cell  death (Van Gaalen et al. 
2004).  In  order  to  overcome  the  technical  impediments  described  above  and 
encourage  new  bone  formation  by  tissue  engineered  constructs,  the  current 
technique  was  optimised  in the  next  chapter by the  use  o f scaffolds  and  cells  in 
conjunction with plasma in a sheep model.  An ectopic model was used to test the 
osteoinductivity  o f  the  cells,  the  cell  seeding  density  was  increased  and  the 
timescale was increased.
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1405.1  INTRODUCTION
In the  study in Chapter 4 there  was very little  contribution to bone  formation by 
autogenic  MSCs  on allograft  impacted  into  condylar bone  defects  in  sheep.  The 
formation  o f  new  bone  in  the  orthotopic  site  may  have  been  induced  by  a 
combination  o f inductive  factors  in  the  graft,  introduced  autologous  MSCs  and 
osteoconduction  from  surrounding  host  bone.  By  carrying  out  the  study  in  an 
ectopic site the true osseoinductive effect o f the MSCs in regenerating bone can be 
elucidated  without  other  complicating  factors  influencing  bone  formation,  which 
are  inherent  in  the  bone  marrow  and  bone  matrix,  such  as  osteoprogenitor  cells 
from  adjacent  bone  marrow  and  BMPs.  This  study  therefore  investigates  the 
inductive  properties  o f the  cells  by  changing  the  implant  site  to  the  paraspinalis 
muscles,  thus  excluding  the  inductive  influence  o f host  bone.  There  could  have 
been  a  variety  o f factors  leading  to  a  lack  o f increase  in  bone  formation  in  the 
femoral condyl MSC group.  The amount o f bone could have been lim ited by other 
factors such as:  1) the use o f MSCs where differentiated osteoblasts may confer an 
advantage in an impaction scenario, potentially reducing the time between lineage 
progression and therefore  bone  formation  in vivo:  2)  insufficient  cell  numbers  in 
the  in  vivo  model:  3)  inappropriate  preoperative  seeding  regimen:  4)  high  shear 
forces in the distal femur that possibly lead to non union o f graft particles:  5) graft 
morphology: 6) large defect size leading to poor vascularisation o f the graft:7) the 
unsealed defect  allowing  ingrowth o f fibrous  tissue  and the  limited length o f the 
study at 6 weeks.
In  this  Chapter  a  model  where  an  ectopic  site  is  used  which  may  indicate  the 
osteoinductive nature o f the cells and scaffolds.  The cell seeding number and the 
length o f implantation were increased in this study compared to the one reported in 
Chapter 4.  The changes in methodology were primarily based on Kruyt’s ectopic 
study in goats (Kruyt et al.  2004a).  If new bone formation can be increased using 
tissue-engineered  scaffolds  in  an  ectopic  site,  it  indicates  the  potential  for 
regenerating bone in revision hip surgery.
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The  objective  of this  study  is  to  investigate  whether  MSCs  or  osteoblasts 
contribute  to  bone  formation  in  impacted  allograft  or  an  allograft  and  HA 
combination in an ectopic site.
Hypotheses
The sheep ectopic model allows eight sites to be used and therefore a number 
of comparisons  between  different  scaffolds  can  be  made.  This  model  will 
therefore investigate the specific hypotheses that:
1.  Due  to  the  osteoinductive  effects  of MSCs,  impacted  allograft  seeded 
with MSCs will produce:
a.  More new bone than graft only.
b.  More new bone in contact with the graft than graft only.
2.  Due to the fact that MSC derived osteoblasts are more committed to an 
osteogenic  phenotype,  impacted  allograft  seeded  with  these  cells  will 
produce:
a.  More new bone than allograft seeded with MSCs.
b.  More new bone in contact with the graft than graft with MSCs.
3.  Due  to  the  osteoinductive  effects  of  MSCs,  impacted  HA/allograft 
(50:50) seeded with MSCs will produce:
a.  More new bone than impacted HA/allograft only.
b.  More new bone in contact with the graft than with HA/allograft 
only.
4.  Due to the fact that MSC derived osteoblasts are more committed to the 
osteogenic lineage, impacted HA/allograft (50:50) seeded with these cells 
will produce:
a.  More new bone than impacted HA/allograft seeded with MSCs
b.  More  new  bone  in  contact  with  the  graft  than  HA/allograft 
seeded with MSCs.
5.  Due to the osteoinductive effect of MSCs, the unimpacted MSC  seeded 
HA block will produce:
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b.  More new bone in contact with the graft than HA only.
6.  Due to the osteoinductive nature of allograft, the impacted allograft will 
produce:
a.  More new  bone formation  than  impacted HA/allograft (50:50) 
mix
b.  More  new  bone  contact with  the  graft  surface  than  impacted 
HA/allograft (50:50) mix.
7.  Due  to  the  osteoinductive  nature  of  allograft,  the  impacted  allograft 
seeded with MSCs will produce:
a.  More new  bone formation  than  impacted  HA/allograft (50:50) 
seeded with MSCs.
b.  More new bone contact with the scaffold surface than impacted 
HA/allograft (50:50) seeded with MSCs.
8.  Due  to  the  osteoinductive  nature  of  allograft,  the  impacted  allograft 
seeded with MSC derived osteoblasts will produce:
a.  More  new bone formation  than  impacted  HA/allograft (50:50) 
seeded with MSC derived osteoblasts.
b.  More new bone contact with the scaffold surface than impacted 
HA/allograft (50:50) seeded with MSC derived osteoblasts.
1435.2  MATERIALS AND METHODS
5.2.1  Preparation of Graft
5.2.1.1 Allograft Preparation
Allograft was produced according to the protocol outlined in Chapter 2 (Chapter 2 
section 2.2.2.).
5.2.1.2 HA.
The  HA  was  provided  in the  form  o f ApaPore-60™  by ApaTech  (ApaTech Ltd, 
Hertfordshire, UK) as described in Chapter 4, Section 4.2.2.2. HA granules 60/400 
(2-5mm  diameter)  were  used  to  investigate  osteoinductivity  under  impaction. 
Blocks  o f  the  same  material  (5-10mm  diameter)  were  used  to  investigate  the 
effects o f impaction.  They w ill be referred to as HA blocks throughout the rest o f 
my thesis.
5.2.1.3 Packaging of HA and allograft
Individual  samples  were  measured by  weight.  The  graft was  size  sorted using  a 
sieve  shaker.  2-5mm  diameter allograft  was  measured  into  3.5g  aliquots.  In the 
allograft  group,  3.5g  equated  to  5mls.  Eighteen  5ml  aliquots  o f allograft  were 
individually double packaged and heat-sealed.  In the 50:50 allograft / HA group, 
1.75g  o f  allograft  equated  to  2.5ml.  1.75g  HA  equated  to  3.5ml.  The  two
scaffolds  were  mixed  making  a  total  o f  6mls.  Eighteen  samples  were  double 
packaged and heat-sealed.  HA blocks weighing  lg  each and equating to  1ml were 
packaged as above.  A ll  samples were sterilised by gamma radiation at Isotron pic 
as in Chapter 2, Section 2.22.2.
1445.2.2  Cell culture
5.2.2.1 MSCs
Bone  marrow aspirates  were  obtained  from  anaesthetised  sheep  through the  iliac 
crest.  MSCs  were  isolated,  expanded  and  used  in  the  study,  implementing 
techniques described in Chapter 2, section 2.2.1.3.
5.2.2.2 MSC differentiation assay for osteogenesis
In  order  to  investigate  the  effect  o f  incubating  MSCs  in  osteogenic  media  on 
differentiation  into  osteoblast-like  cells  MSCs,  were  trypsinised  from  flasks  and 
resuspended in  18ml o f standard media at a concentration o f 1   x  105 cells/ml.  The 
experiment was performed in triplicate to test for repeatability.  Six wells o f three 
24 well plates were filled with 1ml o f this cell suspension.  Each plate represented 
one timepoint and wells were analysed at  1,  7  and  14 days.  Media was removed 
after 24 hours and 3 wells on each plate were given standard media, the other three 
wells were treated with osteogenic media (OM).  The OM was made up o f regular 
media  o f  DMEM  (DMEM,  Sigma  D-6429),  with  10%  FCS  (First  Link,  West 
Midlands, UK), penicillin / streptomycin (lOOOiu/ml;  lOOpg/ml) (GIBCO Paisley, 
UK)  supplemented  with  lOmM  P-glycerophosphate  (Sigma  D1756),  50pg/ml 
Ascorbic Acid (Sigma A4544), and  1  x  10'8  M Dexamethasone (Sigma, D-2915). 
A t the end o f day 1  and at days 7 and 14, the following procedure was followed for 
the  biochemical  assay.  The  media in the  wells  was  discarded  and replaced  with 
lm l o f distilled water.  The plate was placed in the -70°C freezer to lyse the cells 
and  then  thawed  in  a  37°C  incubator  twice.  The  samples  were  thawed  at  4°C 
overnight to allow regeneration o f enzyme activity.  Samples were assayed by an 
automated  process  in  the  COBAS  BIO  centrifugal  analyser  (Roche,UK).  The 
reagent p-nitrophenol phosphate  (RANDOX Laboratories Ltd,  UK)  was  added to 
the  samples,  whereby  ALP  cleaved  the  phosphate  group  to  give  p-nitrophenol 
which is yellow at alkaline pH and is monitored in the COBAS BIO (Roche, UK) 
at 405nm.  This gave a measurement o f the activity o f the enzyme.
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o f ALP produced in each well to the number o f cells present.  This is because the 
cell number varies due to differences in growth rate, therefore cell numbers would 
be different at each timepoint.  The amount o f DNA is proportional to the number 
o f cells  present.  The  fluorimetric  dye  Hoescht  33342  (Sigma,  B2261,  UK)  is 
DNA-specific  and  binds  to  contiguous  adenine-thymine  base  pairs,  emitting 
fluorescence  at a wavelength o f 460nm.  A standard curve was constructed using 
serial dilutions o f calf thymus DNA (Sigma, D3664, UK).  A lOOpl sample o f each 
lysate described above was added to  lOOpl o f Hoescht dye and the serial dilutions 
for the  standard  curve  and the  cell  lysates  were  measured using the  Ascent plate 
reader (Labsystems, UK).  The amount o f DNA  in the lysate was compared with 
the standard curve to give a value.
5.2.2.3 Analysis
The  test  was  to  determine  if  treatment  o f MSCs  with  osteogenic  media  had  an 
effect on cell differentiation by measurement o f the osteogenic marker ALP.
5.2.2.4 Preparation of osteoblasts for use in vivo
Osteoblasts were differentiated from MSCs.  After passage 2, MSCs were cultured 
in  osteogenic  medium  for  14  days.  The  medium  was  changed  every  3  days. 
Before surgery, cells were trypsinised and resuspended at the time o f operation in 
autologous plasma.
1465.2.3 Suspension seeding
5.2.3.1  Peroperative seeding in plasma
MSC’s and osteoblasts were trypsinised from the culture flasks and placed in 7mls 
o f DMEM or osteogenic media respectively, for transport to the operating theatre. 
On  arrival  in  theatre  the  cells  were  centrifuged  at  2000rpm.  The  media  was 
discarded and the cell pellet resuspended in plasma.
Blood  at  a volume  o f 45ml  was  drawn  from  the jugular vein  of the  sheep  at the 
time  o f intubation and  equally divided between three  pre-chilled T75  flasks.  The 
blood was pre-chilled to delay clotting time by placing the large surface area o f the 
flasks  on  ice  for  5  minutes.  During this  time  the  flasks  were  gently  agitated  by 
hand.  Blood  was  then  transferred  to  pre-chilled  sterile  universal  tubes  and 
centrifuged at 3700rpm for 5 minutes to produce a haematocrit (figure 5.1).  Cells 
were resuspended in the plasma fraction at  lOxlO6 cells/ml o f plasma.  The plasma 
and cell  suspension was seeded onto the scaffold and allowed to form a clot prior 
to implantation.  Plasma alone was seeded on to scaffold in the control group.
Figure  5.1:  Universal  containing  whole  blood  (W)  and  universal  containing  a 
haematocrit (H) of plasma and red blood cells (rbcs).
1475.2.4 Surgery
5.2.4.1  Preparation of the grafts
Six skeletally mature Mule sheep were used for the study. Eight groups were used 
to test three types o f scaffold with six samples in each group.  Each sheep received 
8 scaffolds (8  scaffold groups) in the paraspinal muscles, which were:  1) allograft 
control  (allograft  Ctrl);  2)  allograft  +  MSCs  (allograft  MSCs);  3)  allograft  + 
osteoblasts  (allograft  OB);  4)  50:50  HA/allograft  only  (50:50  Ctrl);  5)  50:50 
HA/allograft  +  MSCs  (50:50  MSC);  6)  50:50  HA/allograft  +  osteoblasts  (50:50 
OB);  7)  HA  block  (block  Ctrl);  8)  HA  block  +  MSCs  (block  MSC).  The  MSC 
(MSC group) or osteoblast (OB group) were resuspended in autologous plasma at a 
concentration  o f  10  x  106  cells  /  ml  plasma.  Plasma  was  used  at  0.9ml/g  o f 
scaffold  to  achieve  full  coverage  o f the  graft  with  plasma.  Three  m illilitres  o f 
plasma were  added to  each  sample  and allowed to  form  a clot.  In the  HA block 
groups,  1   ml  o f plasma was  added to  the  control  groups  and  1  ml  o f autologous 
plasma  with  9  x  106  MSC  to  the  tissue  engineered  group.  Sample  position  was 
varied between 6 sheep (figure 5.2).______________________________________
Scaffold Groups 1-6
Pocket Sheep Sheep Sheep Sheep Sheep Sheep
1 2 3 4 5 6
PI 1 3 5 7 6 4
P2 2 4 6 8 7 5
P3 3 5 7 1 8 6
P4 4 6 8 2 1 7
P5 5 7 1 3 2 8
P6 6 8 2 4 3 1
P7 7 1 3 5 4 2
P8 8 2 4 6 5 3
P 4
P 3
P 2
P 7
P 8
P 5
P 6
Figure  5.2:  Schematic  diagram  of  positions  of  pockets  in  paraspinalis  muscles  of 
sheep.  The  table  on  the  right  describes  assignment  of  scaffold  groups  within 
pockets:1)  allograft control  (allograft Ctrl),  2)  allograft +  MSCs  (allograft MSCs);  3) 
allograft + osteoblasts (allograft OB); 4) 50:50 HA/allograft only (50:50 Ctrl);  5) 50:50 
HA/allograft  +  MSCs  (50:50  MSC);  and  6)  50:50  HA/allograft  +  osteoblasts  (50:50 
OB); 7) HA block (block Ctrl) and 8) HA block + MSCs (block MSC).
1485.2.4.2 Impaction
The  required  volume  of autologous  plasma  with  or  without  MSCs  or  osteoblast 
cells  was  added to  each graft to  form  a clot.  The  clotted sample was transferred 
into a Delrin tube lined with a stainless steel mesh (figure 5.3).
Figure 5.3 Plasma clotted around allograft being loaded into Delrin tube
The  Delrin tube  containing the  sample  was  placed  in the  impactor and  impacted 
twenty times with a force of 3KN (figure 5.4).  The impacted sample was removed 
and the  wire  mesh  was  trimmed to  size  and  sutured  closed  at  both  ends  with an 
absorbable vicryl™  suture.
Figure 5.4a Impactor showing delrin tube and sample, b Allograft after impaction and
suture
1495.2.4.3 Operative procedure
A ll  procedures  were  carried  out  in  accordance  to  the  Animals  (Scientific 
Procedures)  Act  1986.  A ll  procedures  took  place  at  the  Royal  Vetinary  College, 
North Mymms as described in Chapter 4.
Six  adult  sheep  were  used.  Each  animal  received  0.1 mls/kg  2%  xylazine 
intramuscularly  30  minutes  prior  to  anaesthesia.  The  internal  jugular  vein  was 
located  with  2mg/kg  ketamine  and  2.5mg  midazalam  administered  intravenously. 
An  endotracheal  tube  was  placed  under  direct  vision  and  anaesthesia  maintained 
using  halothane  2%.  One  dose  o f  intramuscularly  am oxicillin  (15mg/kg)  was 
given.  End tidal CO2, Pulse oximetry and ECG monitoring took place through out 
the  operation.  A  naso-gastric  tube  was  placed  to  avoid  aspiration.  Each  animal 
was placed prone on the operating table to allow access to both paraspinal muscle 
groups.  Wool  over  both  paraspinal  muscles  was  shaved  and  skin  prepared  with 
betadine  (iodine  based)  antiseptic  solution.  The  area  was  draped  with  sterile 
sheets.  Four skin incisions were  made over the body o f the paraspinalis  muscles. 
Subcutaneous tissue was sharp dissected to the muscle belly.  The epimysium was 
opened  along  the  muscle  fibres  by  sharp  dissection  followed  by  blunt  dissection 
w ithin the muscle belly to prepare a pouch (figure 5.5).
Figure 5.5 Four incisions made to access both paraspinalis muscle groups
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the muscle belly.  The muscle belly was opened along its fibres and a pouch made to 
insert the metal cage.
Each  sample  was  placed  and  fully  covered  within  the  muscle  belly  (figure  4.5). 
The epimysium was closed with 2/0 non-resorbable ethylon suture and the wound 
closed in layers with 3/0 absorbable vicryl™  with interrupted vicryl™  to skin.
Pain  relief  involved  buprenorphine  administered  intramuscularly  (0.6mg  per 
animal)  intraoperatively  and  one-day  post  surgery.  Animals  were  housed  in 
individual pens for one week and then in a group pen thereafter.
5.2.5  Histology
5.2.5.1  Retrieval
A ll animals were sacrificed at twelve weeks.  The animals were euthanized with an 
over  dose  o f  Phenobarbitone  (50ml  o f  20%  solution)  intravenously.  A ll  eight 
samples  were  retrieved,  with  the  attached  muscle  and  placed  in  10%  buffered 
formal  saline.  The  samples  were  then  dehydrated  with  solutions  o f ascending 
concentrations  o f  IMS  (BDH  laboratory  supplies,  UK)  and  then  defatted  with
151chloroform  to  allow  impregnation  o f LR  white  resin  (Agar  Scientific  Ltd,  UK) 
according to and slightly adapted from the protocol outlined in Chapter 4.  Table 
5.1  displays the protocol followed for each sample.
Process Number of days
10% buffered formal saline 7
50% IMS 50% distilled water 1
70% IMS 30% distilled water 1
100% IMS (repeat step 3 times) 1
Chloroform (repeat Step twice) 1
100% IMS (change IMS twice per day) 3
50% LR white resin 50% IMS 2
100% LR white resin (under vacuum for 10 seconds) 
Apply vacuum every day
6
Cast in LR white resin (1  drop accelerator/lOml resin) 
Leave in fridge. 24 hours
Table 5.1 Protocol for processing of sample from retrieval to casting in LR hard resin. 
5.2.5.2  Cutting thin sections
The  samples were cast in resin in the  same manner as those  in Chapter 2,  section 
2.2.5.4.  The  samples  were  a  similar  shape  and  size  to  the  in  vitro  samples  in 
Chapter 2 therefore they were cut on the Exact diamond edged band saw (310 CP) 
in  the  same  manner.  However  the  samples  were  contained  within  the  stainless 
steel mesh within the resin instead o f Delrin tubes, so care had to be taken to grind 
the samples evenly as follows:
152The  samples  were  cut  through  the  longitudinal  axis  o f the  sample  to  expose  the 
area o f interest using the DRAPER Band Saw.  The sample was glued to a perspex 
slide  using  cryanoacrylate  glue  with  the  surface  to  be  thin  sectioned  facing 
upwards.  The  next  procedure  was  followed  to  level  the  sample.  The  exposed 
surface was marked  in all  four comers with permanent marker.  The  sample was 
ground on the  grinding machine  until the marks  were  removed and a flat  surface 
was achieved using medium to coarse grit paper.  Technovit glue was placed on the 
face o f the specimen and a perspex slide was carefully pressed onto the glue until 
there  were no  air bubbles  in the  glue.  The  technovit  samples were placed under 
UV light to cure the glue for 30 minutes.
A slice was cut on the EXAKT saw  1mm away from the technovit glued surface. 
This  new  slide  was  ground  down to  100pm  thickness  using  decreasingly  coarse 
silicon carbide  papers  (from  P240 to P2500).  Sample thickness  o f the  slide  was 
measured  using  the  micrometer.  Sample  thickness  was  evaluated  using  a  light 
microscope.  Once  the  correct  thickness  was  achieved  the  sample  was  polished 
using P4000 paper on the grinder for  10 minutes, followed by 5 minutes polishing 
using aluminium paste.
A ll samples were stained with Toludine Blue for  15 minutes, which stains fibrous 
tissue blue, washed with water and dabbed dry with paper towel.  Slides were then 
stained  further using  Paragon for 20  minutes,  which stains  new bone  bright pink 
and  older bone  lighter pink,  thus  allowing  differentiation between  allograft  bone 
and newly forming bone.
5.2.5.3  Histomorphometry
Slides were examined using a light microscope.  Digital Photos were taken using a 
low power x4 objective through the central area o f the sample. Image analysis was 
performed using Image  Tool  3.0  (UTHSCSA Texas, USA).  Total area o f photos 
were  analysed  and  area  o f  new  bone,  remaining  allograft,  and  remaining 
hydroxyapatite  was  quantified  using  polygons  to  select  regions  o f  interest. 
Percentage  new  bone  formation  was  expressed  as  the  amount  o f new bone  over 
total  area  available  for  new  bone  generation.  New  bone  in  contact  with  the 
scaffold was determined as a percentage by defining whether bone or fibrous tissue
153was  in contact with the  edge o f the  scaffold where it intersected with lines  on an 
overlayed  grid  pattern  o f  500pm.  Histological  analysis  was  carried  out  using 
Image Tool 3.0.
5.2.6  Statistics
For  the  biochemical  expression  o f  ALP,  an  independent  t-test  was  used  to 
determine if  there was a difference in the upregulation o f ALP. Friedman two way 
ANOVA  was  carried  out  on  data  to  examine  any  differences  between  scaffold 
groups.  If a  significant difference  was  found,  a post hoc pair-wise  Wilcoxon test 
was used to examine any differences between two groups. The Wilcoxon test alone 
was  used to  show differences between the  groups.  The  statistical  software  SPSS 
(SPSS vlO .l, SPSS Inc, Chicago, USA) was used for the analysis.
1545.3 RESULTS
5.3.1  Results of MSC differentiation assay for osteogenesis
The results o f the ALP assay at three time-points is plotted below (figure 5.7) (n=3 
animals).  At  every  time-point  the  enzyme  activity  is  always  greater  in  the 
osteogenically treated samples than the control MSCs treated with standard media. 
The  greatest  increase  in  enzyme  activity  is  at  day  14.  The  Independent  t-test 
shows that ALP protein expression is significantly upregulated in sheep cells after 
14 days in osteogenic supplements relative to the control (p=0.026).  Therefore the 
osteoblasts  used  in  vivo  were  defined  as  those  treated  with  osteogenically 
supplemented media for 14 days.
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Figure 5.7 ALP as a proportion of DNA with p values for the Mann Whitmey U test
(p<0.05)
1555.3.2  New Bone Formation
The  graph  below  displays  the  mean  new  bone  formation  in  all  scaffold  groups 
(figure  5.8).  Scaffolds with MSCs incorporated into allograft,  50:50 HA/allograft 
and block groups displayed higher mean values o f new bone area at 4.98% ± 2.28 
SE,  5.15%  ±  1.98  SE  and  7.09%  ±  3.31  SE  respectively,  compared  with  the 
controls at 2.24% ±  1.03  SE,  1.96% ± 0.79 SE and  1.96 ± 0.98 respectively.  The 
osteoblast  groups  produced  less  new  bone  with  2.19%  ±1.17SE  in  the  allograft 
group and 0.82 ±0.26 SE in the 50:50 HA/allograft group.
Friedman  analysis  showed  no  significant  difference  between  treatments  in  the 
allograft group, even though there was a greater amount o f new bone  in the MSC 
treated  samples;  however post hoc tests  revealed  significantly more  new bone  in 
the  50:50  HA/allograft  MSC  sample  when  compared  to  the  50:50  HA/allograft 
control (p=0.046) or 50:50 osteoblast samples (p=0.028).  There was no significant 
difference  between the  impacted  allograft  and  50:50  HA/allograft  without  MSCs 
(p=0.500), with MSCs (p=0.463) or with osteoblasts (p=0.345).  There was also a 
significantly greater amount of new bone in the unimpacted block  MSC  samples, 
which  had  the  highest  mean  new  bone  at  7.09%  ±  3.31  SE  compared  to  the 
unimpacted block control without cells at  1.96 % ± 0.98  SE (p=0.028).  The HA 
block  scaffold  demonstrates that the use  of stem  cells  on an unimpacted  scaffold 
also increases new bone formation.
Allograft  Allograft  Allograft  50:50 Ctrl  50:50  50:50 OB  Block Ctrl  Block
Ctrl  MSC  OB  MSC  MSC
Figure  5.8  Illustrates  New  Bone  Formation  in  all  scaffold  groups  with  p  values  for
*Freidman and  *Wilcoxon-signed rank (p<0.05).
1565.3.3  New Bone in Contact with Remaining Graft
MSCs produce more new bone in contact with the  scaffold compared to the other 
groups  (figure  5.9)  with  means  o f 39.52%  ±  17.77  SE,  8.53%  ±  3.16  SE  and 
14.15%  ±  6.70  SE  in  allograft,  50:50  allograft/HA  and  HA  Block  groups 
respectively compared with the  controls at 29.97% ±  14.80  SE,  2.66% ± 0.81  SE 
and  8.22%  ±  2.43  SE  respectively.  The  osteoblast  groups  produce  the  least 
amount  o f new bone  in  contact with the  scaffold  surface  within each group  with 
21.64% ±  14.78  SE  and  2.57  ±  1.14  SE  in the  allograft  and  50:50  allograft/HA 
group respectively.  However, there is no significant difference between treatments 
in any  scaffold  group  in terms  of new bone  in  contact with the  scaffold  surface. 
There  was  also  no  significant  difference  in  bone  contact  between  the  impacted 
allograft and  50:50 HA/allograft without MSCs  (p=0.116),  with MSCs  (p=0.225) 
or with osteoblasts (p=0.686).
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Figure  5.9  Percentage  new  bone  in  contact with  the  scaffold  surface  in  all  scaffold 
groups with p values for *Freidman analysis (p<0.05).
1575.3.4 Histology Images
5.3.4.1  Allograft images
The  images  reflect  the  data  shown  in  the  graphs.  Bone  forms  directly  without 
endochondral  ossification  (figure  5.10).  New  bone  on  the  allograft  forms  in 
coastal  areas around the  graft pieces  (figure  5.10a).  New Bone was demonstrated 
throughout  the  slides  and  formed  bridges  between  individual  pieces  of allograft 
(figure  5.10a-b).  Osteocytes  and  lacunae  were  clearly  visible.  Surfaces  o f new 
bone  were  covered  in  a  layer  o f osteoblasts,  and  surrounded  by  unmineralised 
osteoid.  Osteoclasts  demonstrated  active  areas  of resorbtion.  In  one  case  there 
was evidence o f new bone forming with no attachment to scaffold (figure 5.10c).
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Figure 5.10a A typical example of allograft control
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Figure 5.10b A typical example of allograft / MSC group; c showing areas of allograft 
(AG)  bridged  by  new  bone  (NB)  and  centres  of ossification  (O)  which  appear to  be 
unrelated to the allograft surface.
1595.3.4.2  50:50 HA/allograft Images
New  bone  predominantly  formed  in  pores  o f the  HA  and  occasionally  bridged 
granules  (figure  5.11).  Remaining  allograft was  often associated with new bone. 
There was very little new bone around the surfaces o f the granules o f HA.
100pm
Figure  5.11  50:50  HA/allograft with  MSCs.  Hydroxyapatite  (HA)  with  evidence  of 
new  bone  (NB) within  pores.  There  are  osteocytes  (OC)  embedded  within  the  new 
bone
1605.3.4.3 HA Block
However in HA, new bone forms in isolated pockets within the HA pores  (figure 
5.12).  Although the HA  may  exist  in large  areas,  new bone  in the  HA  does  not 
tend  to  form  around  the  surface  o f the  HA  granules  as  it  does  with  allograft 
granules.  It is not possible to know from these images whether the MSCs migrated 
within the  pores  o f the  graft  or remained  on  the  outer  surface  immediately  after 
seeding.
Figure 5.12 HA block with MSCs, and osteocytes (OCs) embedded in new bone (NB).
1615.4 DISCUSSION
5.4.1  The effect of cells and graft on new bone formation
In  the  in  vivo  ectopic  study,  all  groups  showed  some  degree  o f bone  formation. 
Control groups composed o f allograft alone, HA/allograft and HA blocks  showed 
little  difference  between  each  other.  This  indicates  that  HA  is  not  only  an 
osteoconductive  material,  it  also  shows  some  osteoinductive  properties;  while 
allograft does not demonstrate greater osteoinductivity than HA.  The study rejects 
the hypothesis (6a) Due to the osteoinductive nature of allograft, the impacted 
allograft will produce more new bone formation  than  impacted HA/allograft 
(50:50) mix.  In addition the hypothesis (7a) Due to the osteoinductive nature of 
allograft,  the  impacted  allograft  seeded  with  MSCs  will  produce:  more  new 
bone  formation  than  impacted  HA/allograft  (50:50)  seeded  with  MSCs  was 
rejected.  In  all  cases  of  MSC  groups  compared  with  their  control  groups, 
there  is  an  increase  in  new  bone  formation,  but  only  the  MSCs  in  the 
unimpacted  block  HA  and  impacted  HA/allograft  induced  significantly  greater 
bone  formation,  so  the  hypotheses  (3a  and  5a)  were  accepted.  However,  the 
hypothesis (la):  impacted allograft seeded with MSCs will produce more new 
bone than  graft only was  not  supported by this  study.  This  may be  because the 
allograft  is  osteoinductive  so  the  osteoinductivity  o f the  MSCs  may  have  been 
masked  by production  o f new bone  derived  from  BMPs.  The  greatest  amount  o f 
new  bone  formation  on  impacted  graft  was  produced  by  the  HA/allograft  MSC 
group with 5.15% new bone. The study showed that the use of osteoblasts did not 
enhance the amount of new bone on any scaffold; therefore the hypostheses (2 
and  4) were  rejected. Again there was no  difference  between different  scaffolds 
seeded with osteoblasts.  Finally, the hypothesis  (8a):  Due to  the osteoinductive 
nature  of  allograft,  the  impacted  allograft  seeded  with  MSC  derived 
osteoblasts  will  produce  more  new  bone  formation  than  impacted 
HA/allograft (50:50) seeded with MSC derived osteoblasts was rejected.
1625.4.2 The effect of cells and graft on new bone contact
For  bone  contact  MSCs  do  not  make  any  significant  difference  for  any  o f the 
scaffolds used, therefore the hypostheses  lb, 2b, 3b, 4b, 5b and also 6b, 7b, 8b are 
rejected. However, allograft scaffold either treated or not treated with MSCs results 
in  more  new  bone  contact  when  compared  to  corresponding  scaffolds.  The 
greatest amount o f bone on impacted graft in contact with the scaffold surface was 
in the  allograft  MSC  group  at  39.52%.  New bone  contact  with the  scaffold  was 
measured because bone formation has a close association with the scaffold surface. 
On  histological  examination  o f human cancellous  grafting  in  a  femur,  new bone 
and  osteoid made  contact with dead  allograft trabeculae  (Ling  et al.  1993).  The 
mechanism o f bone formation on HA was investigated by Chen, Q.Z.  et al where 
strontium  containing  HA  (Sr-HA)  was  placed  in  ilium   defects  in  New  Zealand 
white rabbits and examined using Transition Electron Microscopy (TEM) after 1, 3 
and 6 months (Chen et al.  2004).  New bone formed contact with the HA through 
the  dissolution-precipitation  mechanism.  The  mechanism  is  representative  o f 
calcium  phosphates.  First  crystalline  HA  transforms  into  amorphous  HA, 
producing an over saturated solution.  This causes apatite crystals to precipitate in 
the  presence  o f collagen  fibres  which  become  integrated  with  HA.  Osteoblasts 
were  also  found  near  to  the  Sr-HA  (Chen  et  al  2004).  Many  studies  report 
association o f osteoblasts with HA.  Collagen was reported to have condensed on 
HA,  bone  deposits  in  direct  contact  with  HA  and  layers  o f osteoblasts  line  new 
bone matrix in Ripamonti’s study in Baboons (Ripamonti  1991).  Centripetal bone 
bonding, where bone is initiated at the HA surface and extends towards the centre 
o f the HA pores is also reported in in vivo studies by Kruyt et al., Okumura et al., 
and Goshima et al.  (Kruyt et al. 2003; Okumura et al.  1996; Goshima et al.  1991).
5.4.3 New bone area and new bone contact
M y study shows that allograft/HA (50:50) and HA block produced more new bone 
area than allograft groups,  some o f the new bone forms in central islands without 
contact with the graft. However, there was more new bone contact on the allograft 
scaffold  than  either  the  HA/allograft  or  HA  blocks.  It  is  also  evident  from 
histology that new bone forms mainly in the internal pores o f the HA.  However, in
163allograft, new bone forms predominantly on the external surface.  The precipitation 
o f amorphous  HA  is more  likely in enclosed pores where  it cannot  diffuse  away 
from the surface, encouraging centripetal bone formation, whereas in allograft new 
bone covers a larger surface area.  This may be because the surface o f allograft is 
more  conducive  to  cell  adhesion  due  to  the  presence  o f ECM,  encouraging  new 
bone to deposit on the surface.
This study has shown that MSCs influenced the production o f new bone formation 
on  impacted  allograft  and  in  an  impacted  HA/allograft.  There  was  a  significant 
increase  in  new  bone  in  the  impacted  HA/allograft  and  unimpacted  block  HA 
group  with  MSCs.  However  there  was  no  significant  difference  between  the 
control  and OB  groups.  There are  several  instances where the methodology may 
have  influenced  the  results  o f  the  study,  including  implant  location,  scaffold 
geometry and location,  length o f the  study,  MSC  numbers  and  seeding technique 
and osteoblast cells.
5.4.4  Implant Location
The study in this Chapter was adapted from the orthotopic methodology in Chapter 
4 in order to investigate the hypothesis that sheep MSCs were osteoinductive.  The 
location o f the implants was moved to the paraspinalis muscles, thus removing the 
osteoinductive and osteoconductive influence o f host bone.  Other studies already 
described in this thesis have established that autologous sheep or goat cells seeded 
on bone graft substitutes can be osteoinductive in an ectopic site (Kruyt et al.  2003; 
Van Gaalen et al. 2004; Kruyt et al. 2004b; Kruyt et al.  2004a; Kruyt et al.  2004c). 
These  investigations  have  extended to  inductivity  o f xenogenic  cells  such  as  the 
transplantation  o f  sheep  cells  into  the  subcutis  o f  immunocompromised  mice, 
where  substantial new bone was  formed in contrast with fibrous tissue  in control 
samples (Kon et al.  2000).  However, none have described osteoinductivity o f the 
cells  after  impaction.  The  study  in  this  chapter  has  established  that  HA  and 
allograft  alone  and  in  combination  are  inductive,  but  also  that  the  MSCs 
significantly  increase  the  inductivity  o f the  scaffold  in  the  paraspinalis  muscles, 
both in the impacted  50:50 HA/allograft group and in the unimpacted HA group. 
In  my  study,  the  amount  o f new  bone  ranged  between  4.98%  and  7.09%  in  the 
MSC  group  and  1.96%  and  2.24%  in  the  control  group.  The  results  from  the
164ectopic  implants  in Kruyt’s  studies give values o f between 0.5  and  5.0%  in MSC 
and  osteogenically  treated  groups  (Kruyt  et  al  2004a),  which  are  close  to  the 
quantities  found  in this  chapter.  Table  5.2  summarises  the  amount  o f new bone 
produced in ectopic  studies in the  literature  and my study.  The  studies  listed are 
those that most closely resemble the parameters used in this Chapter.  The studies 
with the black asterix have the most in common with my study methods and also 
produce  new  bone  in  a  similar  range.  From  these  studies  and  my  study,  the 
amount o f bone produced in an ectopic site is low, but these models are still able to 
discern osseoinductive materials for other less effective scaffolds.
165Location Animal
Time
(weeks)
Histomorphometry Scaffold
Seeding
technique
New Bone Publication
Ctrl MSC OB
Bone
marrow
Ectopic
Paraspinal Goat 12
Percentage of 
available space 
occupied by bone
50-60%
Biphasic
calcium
phosphate
Precultured 0.6 ±0.8 N/A 10.2 ±2.9 N/A
(Kruyt et al., 
2004c)
* Ectopic 
Intramuscular 
Lumbar
Goat 12
Percentage of 
available space 
occupied by bone
Granules: 
*HA 60%
* Direct seed 
Precultured
N/A
0
0.5-1.0 
2.0-4.0
N/A
N/A (Kruyt et al.,
HA 70%
Direct seed 
Precultured
N/A
0
3.0-5.0
9.0-13.0
N/A
N/A
2004b)
Ectopic
Intramuscular
Thoracolumbar
Goat 9
Percentage of 
available space 
occupied by bone
50%  porosity 
HA/TCP cube
Peroperative
Precultured
0.2
0.7
14.0
11.2
11.5
11.7
N/A
4.2
(Kruyt et al., 
2004a)
* Ectopic 
Intramuscular Goat 12
Percentage of 
available space 
occupied by bone
Two granules: 
*HA 60%
HA 70%
Precultured
0
0
0
0
3.5 ±4.0 
13.2 ±  15.9
0
0
(Kruyt et al., 
2003)
*Ectopic 
Paraspinalis muscles Sheep 12
Percentage of 
available space
* Allograft 
*Allo/HA 60%
Peroperative 2.24 ±  1.03 
1.96 ±0.79
4.98 ± 2.28 
5.15 ±  1.98
2.19 ± 1.17 
0.82 ± 0.26
N/A
N/A Chapter 5
occupied by bone HA 60% 1.96 ±0.98 7.09 ±3.31 N/A N/A
Table 5.2
*lmpacted scaffold
*Studies that most closely resemble the parameters used in Chapter 5
1665.4.5  Scaffold geometry and location
Most  studies  in  the  literature  have  used  large,  individually  implanted  ceramic 
blocks as scaffolds, rather than granules (Arinzeh et al.  2003; Bruder et al  1998b; 
Petite  et al.  2000;  Kon  et al.  2000).  My  study  used  allograft  and  HA  granules 
ranging from 2-5mm in diameter in an ectopic location.  A reason for changing 
the  location  o f the  graft  to  an  ectopic  site  was  that  intrafragmentary  strain  is 
greatest  in  the  femoral  condyles  (Duda  et  al.  1998).  Work  by  Kenwright  and 
Goodship provides evidence that micromovement that exceeds defined boundaries 
can be deterimental to the bone healing process.  The study investigated the effect 
o f load  or  displacement  on  fracture  healing  in  the  sheep  tibia  by  keeping  one 
parameter  constant  and  manipulating  the  other by  the  use  o f an  external  fixator. 
Although  small  micromovement  o f  0.5mm  assisted  the  healing  process, 
displacement  o f  2mm  was  detrimental  to  mineralisation  and  fracture  healing 
(Kenwright  and  Goodship  1989).  This  is  supported  by  Lacroix  et  al  who 
demonstrated that high shear strain loaded fractures,  simulated in a finite  element 
model,  stimulated  fibrous  tissue,  whereas  lower  strains  were  needed  to  produce 
cartilage and bone (Lacroix and Prendergrast 2002).  There is evidence to  suggest 
that the use o f granules may be just as influential in disrupting optimal new bone 
formation  as  the  implant  location.  The  geometry  o f  the  granules  may  act 
independently  from  the  effect  o f ectopic  location,  as  Ripamonti  found  that  bone 
induction occurred only in rods rather than granules (Ripamonti  1991).  Geometry 
may have an influence in two ways.  Firstly by accumulation o f inductive  factors 
within  porous  ceramics  with  cavities  rather  than  solid  ceramics  (Yamaski  and 
Sakai 1991).  For instance, although my grafts are porous, inductive factors w ill be 
more  likely to  diffuse  away  from the  small  individual  granules  than from  within 
large  blocks,  where  inductive  factors  may  be  contained  during  resorbtion  o f the 
ceramic.  Secondly,  the  granules  may  be  more  susceptible  to  interfragmentary 
movement because  they  are  less  stable  than  a block,  causing  disruption between 
the  granules  which  may  increase  fibrous  tissue  formation  (Ripamonti  1991). 
Therefore the use o f granules as a scaffold in an ectopic  site may also cause high 
levels  o f  inter-granular  strain  and  inhibit  new  bone  formation.  This  may  have 
prevented  further  quantities  o f new  bone  forming  in  the  study  in  this  chapter. 
Similarly,  van  Eeden  found that  bone  differentiation was  indicative  o f blocks  o f
167HA rather than granules, suggesting that micromotion between individual granules, 
and granules and the adjacent bone interface may lead to fibrous union (van Eeden 
and Ripamonti  1993).  However, in this study the use o f granules was consistent as 
granules  are  more  clinically  relevant  in  impaction  surgery  than  strut  grafts  or 
equivalent  HA  blocks.  For  this  reason,  a  mixture  o f  allograft,  promoting 
osteoinduction,  and  hydroxyapatite,  to  provide  a  stable  scaffold  for 
osteoconduction, was used.  Allograft alone was introduced for clinical relevance. 
In  order  to  address  the  issue  o f interfragmentary  strain,  unimpacted  HA  blocks 
were  used  to  compare  my  study  with  others,  as  well  as  to  examine  the 
osteoinductive effects o f MSCs.
5.4.6 Length of Study
Sheep were  sacrificed after  12 weeks to analyse  new bone  formation using tissue 
engineered  bone  graft  in  femoral  condyle  defects  in  chapter  4.  Increasing  the 
duration  o f  the  experiment  was  likely  to  produce  more  bone.  The  in  vivo 
timeframe  o f  12  weeks  was  more  representative  o f the  length  o f studies  in  the 
literature  compared  to  6  weeks.  For  example  experimental  duration  in  large 
animals was 8.5 weeks (Kon et al.  2000), 9 weeks (Kruyt et al  2004a; Kruyt et al. 
2004c),  and  12  weeks  (Van  Gaalen  et al.  2004;  Kruyt  et al.  2003;  Kruyt  et al. 
2004c).  In these  studies  new bone  was  found  in the  tissue  engineered  constructs 
similar to those used in this chapter.  The length o f the study in this chapter o f 12 
weeks  was  sufficient  as  new bone  was  formed  in tissue  engineered  samples  and 
distinguishable from the amount formed in the controls.
5.4.7 MSC numbers and seeding technique
The number o f MSCs used in this chapter was increased from the previous study in 
chapter 4.  W ith reference to chapter 4, previous studies have used similar numbers 
o f cells.  The range o f concentrations used in large  animal  goat and sheep models
f \  ^  ,
includes:  8x10  cells/cm  in an ectopic and orthotopic model respectively (Kruyt 
et al.  2004a;  Kruyt et al.  2004c),  10 x  106 cells/cm3  (Kruyt et al.  2003)  in a goat 
ectopic model,  10x10  cells/cm  in a sheep orthotopic model (Petite et al.  2000). 
In  this  study,  all  groups  were  seeded  with  9xl06  MSCs/g  o f graft.  In  order  to 
compare this to studies in the literature, the number o f cells can be normalised to 
volume  o f  graft,  which  was  about  5cm  in  allograft  and  allograft/HA  granule
168groups.  Therefore the number o f cells were 6x10  cells/cm  .  This concentration 
o f cells  was  taken  into  account  whilst  considering  time  and  space  limitations  in 
culture.
A  peroperative  seeding  method  was  chosen  for  the  study  in  this  chapter,  the 
reasons having been cited in the discussion section o f chapter 4.  To reiterate, in an 
ectopic  study  in  seven  adult  goats,  ceramic  scaffolds  were  seeded  with  BMSCs 
either  7  days  preoperatively  or  during  surgery.  Some  pre-seeded  samples  were 
treated with supplemented media for ostogenic differentiation.  Bone area (11.2 to 
14%)  and  bone  contact  with  the  scaffold  surface  (22.8  to  27.3%),  quantified  by 
image analysis, was found to be  similar in all tissue engineered groups regardless 
o f seeding technique (Kruyt et al.  2004a).  A possible reason why new bone may 
be increased by preculturing cells on graft is the production o f extra cellular matrix 
(ECM).  However,  devitalised  samples,  with  ECM  only,  contained  significantly 
less bone than all the  BMSC  seeded groups,  indicating that viable  cells  are  more 
significant inducers o f new bone than ECM (Kruyt et al.  2004a).  It was therefore 
noted  that  for  this  study,  preculturing  was  unnecessary  and  logistically  more 
complicated  than  direct  seeding  at  the  time  o f surgery.  A  preoperative  seeding 
method,  which would involve  cells cultured on a scaffold  in vitro,  would require 
labour  intensive  cell  culture  techniques.  Maintenance  o f the  cells  would  require 
more expensive cell culture technology,  such as perfusion bioreactors,  in order to 
sustain  cell  growth  within  the  scaffold  pores.  It  is  also  easier  to  standardise 
nutrient diffusion to the cells  if  they are transported to  surgery in suspension and 
then seeded directly onto the scaffold at surgery.
5.4.8  Osteoblast cells
There  was  no  increase  in  new  bone  formation  or  new  bone  in  contact  w ith  the 
scaffold surface with the addition o f osteoblasts on impacted allograft or impacted 
HA/allograft.  In  this  chapter  MSCs  were  differentiated  into  osteoblasts  by 
supplementing  the  growth  media  with  osteogenic  supplements.  The  cells  were 
defined by the presence ALP, a marker for osteogenic differentiation.  Many other 
studies  use  a  variety  o f markers,  including  ALP,  to  characterise  osteoblasts  or 
osteoblast-like  cells,  being  an  early  marker  for  osteoblastic  differentiation. 
Previous  studies have  shown that differentiation o f sheep  cells  in the presence  o f
169such  supplements  results  in a  significant  increase  in ALP  activity  determined by 
biochemical  assay  (Collignon  et  al.  1997;  Torricelli  et  al.  2000).  Osteoblastic 
differentiation was shown with increased alkaline phosphatase activity, production 
o f osteocalcin and the formation o f a mineralised matrix.  In conflict w ith this data 
is  the  literature  pertaining  to  sheep  MSCs  that  have  been  shown  not  to  express 
ALP  in response  to treatment with dexamethasone  (Kon et al.  2000).  In Kon et 
al’ s study this is not necessarily an adverse  indicator o f cell behaviour in vivo  as 
HA  ceramic  cubes  with  MSCs  improved  on  the  amount  o f new  bone  in  control 
mouse and sheep ectopic sites (Kon et al.  2000).  However in the study by Kruyt, 
the  effect  o f adding  osteogenic  media  to  MSCs  cultured  on  scaffolds  does  not 
enhance new bone formation compared to untreated cells on scaffolds (Kruyt et al. 
2004a).  Ideally  all  the  cells  would be  characterised using  an  array  o f markers  to 
follow   expression  o f  osteoblastic  proteins  during  differentiation.  Another 
determinant o f osteoblast expression is cbfa-1  (Runx2),  a transcription factor that 
influences  osteoblast  differentiation  (Ducy  et  al.  1997).  Transcription  o f cbfa-1 
could be measured using rt-PCR.  However, the primers are not available for sheep 
sequences and the study is therefore beyond the remit o f this thesis.  In Chapter 3, 
section  3.2.2,  cells  were  characterised  using  biochemical  markers  for  ALP, 
osteocalcin and the histochemical stain for phosphate deposition, Von Kossa after 
14 days treatment with osteogenic media.  In this Chapter MSCs were treated with 
the  same  regimen as  in  Chapter 3,  therefore  characterisation was  lim ited to  ALP 
staining.  The  reason  why  osteoblastic  cells  derived  from  MSCs  may  not  have 
contributed to new bone formation in this Chapter may be because MSCs cultured 
in osteogenic  media  differentiated  into  osteoblast  cells  that  are  known to  have  a 
higher  metabolic  activity  and  therefore  require  greater  oxygen  supply  (Vacanti 
2004).  This  could  diminish  their ability to  survive  in  a low oxygen  environment 
such as  a large  graft where  nutrient diffusion would be  slow in  some  areas,  thus 
resulting in equivalent amounts o f new bone as the controls seen in this chapter.
Further studies are underway in our Institution using MSCs  in impaction grafting 
and  a  revision  total  hip  replacement  model.  Further  work  is  needed  in 
characterising osteoblasts in sheep.
1705.5 CONCLUSION
A ll groups  showed some degree o f bone formation.  Control groups composed o f 
allograft alone, HA/allograft and HA blocks showed little difference between each 
other.  This indicates that allograft is not particularly osteoinductive.  In all cases 
there  is  an  increase  in  new  bone  formation  when  autologous  MSCs  are  added. 
MSCs in the block HA, as well as in impacted allograft and HA/allograft, induced 
greater bone formation.  The results  suggest that if  there is  a clinical requirement 
for  new  bone  contact  with  the  scaffold  surface,  the  scaffold  choice  should  be 
allograft  with MSCs,  as  this  yielded the  largest  quantity  at  39.5%.  For  example, 
implant  stability  may  be  more  likely  if   bone  is  contiguous  w ith  the  scaffold 
surface, thereby promoting osteoconduction and integrity with the implant surface. 
If the  requirement  is  a  large  amount  o f new  bone,  a  combination  o f  HA  and 
allograft with MSCs should be used.  This study also  showed no added benefit in 
seeding the graft with MSCs cultured in osteogenic  supplements.  The efficacy o f 
using allograft with MSCs in a representative ovine clinical impaction model w ill 
be tested in the next chapter.
Summary:
•  MSCs increase new bone on any scaffold after impaction.
•  There is no advantage of seeding osteoblasts on graft.
•  Use a combination scaffold if areas of new bone are required and  an 
allograft  scaffold  where  contact  of  new  bone  with  the  scaffold  is 
required.
171CHAPTER 6: New Bone Formation in a Revision Hip
Replacement
1726.1  INTRODUCTION
This  chapter  investigates  whether  bone  formation  can  be  enhanced  using  tissue 
engineered  allograft  in  a  model  that  approximates  impaction  allografting  in  a 
human THR situation.  In chapter 5 MSCs were found to increase osteoinductivity 
in an ectopic site after impaction on an allograft as well as allograft / HA scaffold. 
Bone  formation  reported  in  Chapter  5  was  relatively  low.  This  may  have  been 
because the amount o f bone  formed in the  ectopic  site was  directly related to the 
contribution o f MSCs alone.  In this chapter the number o f cells was increased to 
further  enhance  new  bone  formation.  The  amount  o f  bone  produced  in  the 
intramedullary  cavity is  expected to be  greater because  o f bone  formation due to 
osteoconduction  from  the  host  bone  and  osteoinduction  from  native 
osteoprogenitors residing in the host stroma.  In this study the contribution o f new 
bone  w ill  not  only  be  from  osteoconduction,  but  also  from  the  additional 
mechanical  influence  o f the  local  environment  and  the  pressure  o f  impaction. 
Impaction  grafting  in  a  hemiarthroplasty  sheep  model  represents  impaction  in  a 
human situation, imitating the local mechanics occuring around a femoral stem and 
in THRs.  In this way the ovine model reflects how the load is distributed from the 
implant onto the surrounding bone and allograft.  The essential difference between 
this  and  the  ectopic  study  in  Chapter  5  is  that  impacted  allograft  surrounds  an 
implant which is contained within the  femoral cavity, resulting  in residual  stress. 
The  load  is  therefore  imparted  to  the  prosthesis  and  results  in  increased  bone 
stresses that may initiate a continuous repair process (Tagil 2000).
The  main reason  for the  use  o f a  sheep  model  in this  study  is  that the  proximal 
femur is similar to sclerotic bone, being very tubular and therefore akin to bone in 
a revision situation (Goel et al.  1982).  The ovine hemiarthroplasty model was used 
by Blom et al. to investigate the compatibility o f ceramic bone graft substitutes as 
allograft extenders for impaction grafting in the  femur because o f its  sim ilarity to 
the  human clinical  situation (Blom  et al.  2005).  Equally  pertinent  are  hip joint 
forces that have been compared in sheep,  dogs and man by telemetry using strain 
gauges attached to the femoral component in a THR.  The magnitude and direction 
o f hip joint  forces  in  the  sheep  are  comparable  to  those  in  humans  and  this  is
173another reason why sheep are  a good model for femoral implants in the proximal 
femur (Bergmann et al.  1984).
Aim
The  main  objective  of this  part  of my  study was  to  regenerate  new  bone  in 
defect  areas  adjacent  to  a  hemiarthroplasty  using  impaction  grafting  with 
allogenic bone combined with either MSCs or osteoblasts derived from MSCs.
Hypotheses
1.  There  will  be  a  significant  improvement  in  peak  vertical  Ground 
Reaction  Force (pvGRF)  in the MSC  group  compared  to  the  control 
and osteoblast groups.
2.  There will be a significant increase in new bone formation in the MSC 
group compared to the control and osteoblast group.
3.  There will be a significant increase in new bone formation at the host 
allograft interface compared with the host implant interface within the 
control, MSC and osteoblast group.
4.  There will be a significant increase in new bone formation in the MSC 
group  compared  to  the  control  and  osteoblast  groups  within  the 
allograft implant interface or the host allograft interface.
5.  There will  be  a  significant increase  in  contact  of new  bone with  the 
implant  in  the  MSC  group  compared  to  the  control  and  osteoblast 
group.
The hypotheses postulate that MSCs w ill make more o f a contribution to new bone 
formation,  bone  contact  and  function o f the  limb than  osteoblasts  or the  control. 
This is because the results in the ectopic study in Chapter five showed that MSCs 
produced more new bone than the control, whereas osteoblasts did not.  The same 
pattern occurred where contact o f new bone with the graft was tested. Therefore it 
is expected that the trend w ill continue in the orthotopic model.
1746.2  MATERIALS AND METHODS
6.2.1  Preparation of allograft
6.2.1.1 Allograft Production
Allograft was produced according to the protocol outlined in Chapter 2 (Chapter 2 
section 2.2.2.1).
6.2.1.2 Sieving the graft
The allograft used in the proximal region o f the  femoral  component in this  study 
was  sieved  to  within  the  3-5mm  range.  In  this  case  the  granule  size  for  the 
proximal  region was  2.4-4.76mm.  This  was the  size  o f graft used  in  Chapters  2 
and 3 for in vitro analysis.  A ll the graft was placed at the top o f the pile o f sieves 
and  shaken  for  half an  hour  until  all  the  graft  had  fallen  into  its  relevant  sized 
sieve.  A range o f granules o f larger size was used distally to the implant in order 
to fill the cavity.  The graft required for the distal region included larger granules 
o f  >4.67mm  mixed  with  2.4-4.76mm  granules,  these  grafts  were  bagged 
separately.  Fine  granules  o f  1-1.2mm  were  collected  to  fill  the  grooves  o f the 
implant  so  that  contact  o f the  graft  with the  implant  was  as  close  as  possible  to 
allow for bone ingrowth.  This was double bagged separately.  The allograft was 
gamma  irradiated  in  a  frozen  state  at  25KGrays  (Isotron,  Reading,  UK).  The 
allograft was stored at -20°C.
6.2.2 Cell culture
6.2.2.1  Obtaining bone marrow aspirates
A ll  procedures  were  carried  out  in  accordance  with  the  Animals  (Scientific 
Procedures)  Act  1986  at  the  Royal  Veterinary  College  (RVC),  North  Mymms. 
Home Office licenses were held by all those taking part in the surgical procedure. 
Bone  marrow aspirates  were  obtained  from  anaesthetised  sheep through the  iliac 
crest.  MSCs were harvested and isolated in the study, implementing the  standard 
tissue culture techniques described in Chapter 2.
1756.2.2.2 MSCs
Cells in this study were used between passages 3 and 6 according to the techniques 
described in Chapter 2, section 2.2.1.3.
6.2.2.3 Differentiation of MSCs into osteoblasts
MSCs  were  differentiated  using  the  same  methods  described  in  Chapter  3.  The 
techniques  used  in  Chapter  3  established  that  differentiation  o f the  MSCs  into 
osteoblasts had been achieved after  14 days  in culture  with supplemented media. 
Assays  to  determine  a  characteristic  pattern  o f  ALP  regulation,  a  decrease  in 
proliferation  rate,  increased  osteocalcin  and  deposition  o f  mineralised  matrix 
converged  on  day  14  confirming  an  osteogenic  phenotype.  A t  P3  to  P6  regular 
media  was  replaced  with  media  supplements  at  concentrations:  lOmM  p- 
glycerophosphate  (Sigma  D1756),  50mM  Ascorbic  acid  (Sigma  A4544),
o
Dexamethasone  1x10'  M (D-2915  Sigma).  Media was changed every three days 
for  14  days  until  cells  changed  to  a  cuboidal  morphology.  The  cells  were  then 
harvested for transplantation in surgery.
6.2.3 Operative procedure
6.2.3.11ntra-operative seeding of MSCs and MSC derived osteoblasts
Cells were  seeded onto graft during surgery.  A  separate table was  draped for all 
aseptic,  peroperative  seeding  o f graft.  Either  MSCs  or  osteoblasts  derived  from 
MSCs  had been trypsinised  from  flasks,  rinsed  in regular DMEM  and  measured 
into aliquots o f 100 x  106 cells in  10ml DMEM.  Cells were transported in regular 
DMEM  in  universals  to  the  RVC  where  the  operation  was  to  take  place.  Cells 
were seeded at a concentration o f 10 x  10  cells per cm  volume o f graft.  Because 
each femoral cavity varied in size, extra aliquots o f cells were brought and seeded 
at the above concentration in circumstances where more  graft was required to fill 
the femoral cavity.  The volume o f allograft that was used for proximal impaction 
was measured out using a 10ml syringe.
6.2.3.2  Plasma preparation
Plasma was  prepared  in a  similar manner to  the  protocol  described  in  Chapter  5 
section 4.2.3.  Forty five m illilitres o f venous blood was collected from the jugular
176vein o f the anaesthetised animal, pre-cooled in T75 tissue culture flasks containing 
15ml o f blood per flask on a tray o f ice, to prolong clotting time.  Whole blood was 
then centrifuged at 3000 rpm for 5  minutes, creating a haematocrit with a plasma 
and erythrocyte fraction. Either MSCs or osteoblasts were centrifuged at  1500rpm 
and resuspended in  10ml o f plasma aspirated from the hematocrit using a transfer 
pipette.  The plasma with the cells was passed through the transfer pipette twice in 
order to  achieve  a  cell  suspension  in the  universal  and  then  flushed  through  the 
pipette  onto  the  10ml  of  2-5mm  allograft  for  proximal  impaction  (medium 
graft/cell composite).  As the plasma reached room temperature the rate o f clotting 
around  the  graft  increased,  binding  the  cells  and  graft  particles  together  (figure 
6.1).  This made the graft easy to handle during surgery.  The same procedure was 
used  to  seed  2xl06  cells  onto  the  2ml  volume  o f 1-1.2mm  graft  particles  (small 
graft /cell composite).  Plasma alone was added to allograft in the control group.
Figure 6.1a Illustrates the pre-cooled plasma in the liquid phase being dispensed onto 
allograft; b) illustrates the plasma clotted around the graft.
6.2.4  Surgery
A ll  procedures  were  carried  out  in  accordance  with  the  Animals  (Scientific 
Procedures)  Act  1986  by  those  with  valid  Home  Office  project  licenses.  A ll 
procedures took place at the Royal Veterinary College, North Mymms as described 
in Chapter 3.
177There were  15  adult  sheep  in the  study divided into 3  groups with five sheep  in 
each group. The groups were:
1)  A llograft control without cells
2)  Allograft seeded with MSCs
3)  A llograft seeded with osteoblasts differentiated from  MSC origin
A ll animals underwent an uncemented hemiarthroplasty through an anterior-lateral 
approach  using  HA  coated  hip  stems  specially  designed  for  the  sheep.  Once 
anaesthetized, an area over the lateral aspect o f the right leg extending proximally 
over  the  pelvis  to  the  proximal  knee,  was  shaved.  Betadine  (broad  spectrum 
topical  iodophor microbicide)  surgical  scrub and alcoholic  solutions were used to 
clean  and  decontaminate  the  skin.  On  the  operating  table  the  animal  was 
positioned presenting the right lateral  side.  An area around the  intended incision 
was  draped.  A  skin  incision  about  10cm  adjacent  to  the  greater  trochanter  was 
made, where the tip o f the greater trochanter was at the mid region o f the incision. 
The  incision was  2cm  anterior o f the  greater trochanter.  The  septa  between  the 
fascia  lata and  the  glucobiceps  muscle  was  divided,  the  mid  gluteal  muscle  was 
retracted  and  the  deep  gluteal  muscle  was  sectioned  as  close  as  possible  to  its 
insertion point  on  the  neck  of the  femur.  The  synovium  was  divided  using  a  T 
shaped incision.  The head o f the femur was located and the ligamentum teres was 
divided whilst retracting  the  femur (figure  6.2).  If possible,  at this  stage  the  hip 
was dislocated but more often the femoral head was resected and removed from the 
joint after resection.
Figure 6.2a The incision placed adjacent to the greater trochanter; b The ligamentum 
teres was divided whilst retracting the femur.
178The  marrow  cavity  o f the  femoral  canal  was  completely  debrided  o f all  fat  and 
trabecular bone by curretting and  flushing the  cavity with saline, using suction to 
remove  debris  until  the  appropriate  sized  reamer  could  be  passed  down  the 
intramedullary cavity.  This left a radial space o f at least 2-4mm around the stem to 
fill with allograft (figure 6.3).
Figure 6.3a Trabecular bone of the femoral canal being curretted;  b The final size of 
the radial space left after curetting.
On a guide rod a threaded intramedullary cement restrictor was inserted 3cm below 
the final position o f the stem. The distal impactor was threaded over the guide rod 
and  allograft was  impacted onto the  plug  using a hammer on the  distal  impactor. 
Medium  and  large  sized  graft  was  impacted  into  the  distal  region  o f the  femoral 
canal  (figure  6.4).  The volume o f graft used  in the distal region ranged  from  15- 
25ml as measured in a syringe.
Figure  6.4  Allograft  being  added  to  the  femoral  cavity;  b  the  allograft  being 
impacted with a hammer on the distal impactor
1796.2.4.1 Femoral and head components
The  femoral  stem  was  made  by  Stanmore  Implants  Worldwide  Ltd,  Stanmore, 
Middx,  UK, to  fit sheep femoral  geometry.  This  allowed for a  gap  surrounding 
the  implant  for  impaction  allografting.  The  centre  o f  the  femoral  head  was 
matched to the anatomical centre o f the sheep femur.  The stem was titanium alloy 
and was  fitted  with a 25mm  diameter modular cobalt chrome  (CoCr) head.  The 
neck length could be selected by choosing an appropriate femoral head supplied by 
Biomet Merck Ltd.  (Biomet Merck Ltd.,  Swindon,  Wiltshire,  UK).  The  collared 
proximal  stem was grooved to a depth o f 2mm and a width o f 2.5mm.  The  stem 
was  sent  away  for  HA  coating  at  Plasma  Biotal  Ltd  (Plasma  Biotal  Ltd, 
Derbyshire, UK).  The stem was autoclaved prior to surgery.
HA
coating
Figure 6.5 Titanium  alloy femoral  stem with  proximally  located  grooves and  a  CoCr 
modular head.  The stem is coated with HA.
6.2.4.2  Addition of graft/cell composite
The medium graft/cell composite was added proximally around a tube which fitted 
over  the  guide  wire.  After  loose  packing  o f the  graft,  the  tube  was  removed 
leaving a small hole in the centre of the graft.  A small sized femoral impactor was 
fitted  over  the  guide  wire  and  impacted  through  the  small  hole,  forcing  and 
impacting the surrounding graft onto the endosteal surface.
180Figure  6.6a  The  small  graft/cell  composite  set  with  plasma  being  pressed  into  the 
grooves  of the  femoral  implant;  b  the  femoral  implant  with  the  graft/cell  composite 
completely filling the grooves of the implant.
If necessary,  at  this  stage  more  graft  was  introduced  around  this  small  phantom 
which was then removed.  A  larger phantom  was  impacted  before  impacting the 
femoral  stem.  The small graft/cell composite was pressed into the grooves o f the 
HA coated femoral stem before insertion (figure 6.6).  The modular femoral head, 
25mm  in  diameter  with  appropriate  length,  was  placed  onto  the  trunnion  and 
secured by a gentle tap. The hip was reduced; the wound was washed and closed.
6.2.4.3  Closing the wound
The  wound  was  closed  in  layers  with  absorbable  vicryl™   sutures.  The  muscle 
apposed with 2 or 3  interrupted sutures, continuous closure o f the deep fascia and 
dermis,  with  interrupted  sutures  to  close  the  skin.  Post-operatively  the  animals 
were recovered in sternal recumbancy and housed in individual pens for 24 hours.
1816.2.5 Ground Reaction Force (GRF)
Sheep  walking  was  carried  out  in  accordance  with  the  Animals  Scientific 
Procedures  Act  1986 by those with valid Home  Office  project  licences.  Ground 
reaction  forces  (GRFs)  were  measured  in the  sheep  using  a Kistler™   force  plate 
9287  (Kistler Instruments  Ltd.,  Hampshire,  UK).  The  ground reaction force  is  a 
measurement  o f  extent  o f  recovery  o f  the  operated  limb  and  is  therefore  a 
reflection o f the functionality o f the hip joint after insertion o f the implant.  Sheep 
were  guided through a  gated walkway to  achieve  heel  strike  on the  centre  o f the 
force  plate.  The  piezoelectric  transducers  mounted  underneath  the  force  plate 
detected and converted the force exerted into an electrical signal that was amplified 
by  the  Kistler  Charge  Amplifiers  type  5001  (Kistler™ ,  Biomec  Ltd,  Hampshire, 
UK)  and recorded.  The  peak vertical  GRF  (pvGRF)  from  12  heel  strikes  o f the 
right  hindlimbs  was  collected  pre-operatively  and  12  weeks  post-operatively. 
After pvGRF was collected the sheep was weighed on the force plate in Newtons 
and the pvGRF was normalised to body weight.  The mean post-operative GRF o f 
the  right  limb  was  then  expressed  as  a  percentage  o f  the  mean  pre-operative 
pvGRF o f the right limb.
6.2.6  Histology
After twelve weeks the sheep were euthanised with Phenobarbitone (50ml o f 20% 
solution) intravenously.  Femurs were removed and fixed in  10% buffered formal 
saline.  Radiographs  were  then taken o f the  removed  femora.  Incisions,  using  a 
band saw, were made at 2cm intervals on alternate sides o f the femur down to the 
level o f the plug to ensure complete penetration o f fixing and embedding reagents. 
The  samples  were  then  dehydrated with  solutions  o f ascending  concentrations  o f 
industrial  methylated  spirits  (IMS)  (BDH  laboratory  supplies,  UK)  and  then 
defatted  with  chloroform  prior to  embedding  in  LR  white  resin  (Agar  Scientific 
Ltd, UK).  The following protocol was observed:
182Process Number of days
10% buffered formal saline 7
50% IMS 50% distilled water 3
70% IMS 30% distilled water 3
100% IMS (repeat step 3 times) 3
Chloroform (repeat Step twice) 1
100% IMS (change IMS twice per day) 3
50% LR white resin 50% IMS 7
100% LR white resin (under vacuum for 10 seconds) 14
Cast  in  LR  white  resin  (1  drop  accelerator/ 10ml 
resin).  Leave in fridge
24 hours
Table 6.1  Histology protocol for femurs 
6.2.6.2 Cutting sections
After casting the specimens in resin, sections were cut through the transverse plane 
in three regions o f the bone:  ‘proximal’,  ‘mid’  and  ‘distal’  from the  medial  neck 
line.  Radiographs were used to determine the position o f each cut.  The proximal 
section  was  cut  5mm  from  the  medial  neckline,  the  distal  section  was  cut  5mm 
from the tip o f the  implant and the mid section was  established halfway between 
these two points  (figure  6.7).  The  200pm  sections  were  made  on perspex  slides 
after sticking samples down with Technovit glue. The sections were then ground to 
a thickness o f 100  pm using the Exakt micro-grinding system and polished on the 
Motopol 2000 (Bueler, Coventry, UK). Prior to histomorphometric analysis o f the 
sections they were stained with Toludine Blue for 10 minutes (which stains fibrous 
tissue  blue)  and  Paragon  for twenty minutes  (which  stains  new bone  bright pink 
and older bone a lighter pink).
1835 mm from tip midpoint 
between tip and neck
5mm from medial neck line
Figure  6.7  Cutting  regimen  for  harvested  femurs.  T=Tip  section,  M=mid  section, 
P=Proximal section.  Vertical lines represent cutting planes.
6.2.7 Histomorphometry
6.2.7.7 New and remaining bone
New  bone  and  remaining  allograft  were  quantified  by  area  using  the  KS300 
computer  program.  Images  were  taken  in  anterior-posterior  and  medial-lateral 
planes from 4 quadrants in distal, medial and proximal sections.  A ll images were 
taken  using  a  x4  objective  lens.  New  bone  was  scored  in  transects  within  each 
quadrant that  extended  from  the  inner  surface,  defined  as  the  closest  field to  the 
implant, to the outer surface,  defined as the  closest field to the cortex (see figure 
6.8).  Percentage new bone  formation was  expressed  as the  amount  o f new bone 
over total area available for new bone generation.
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Figure  6.8  Schematic  diagram  to  represent  method  of  analysis  on  a  transverse 
section of the femur.
6.27.2  Contact of new bone with implant interface
Contact o f viable bone  with the  implant interface  was  quantified by counting the 
number  of times  lines  on  a  500  micron  grid  intersected  with  new  bone  and  the 
implant.  A grid o f parallel lines was superimposed on the computer screen image 
o f the implant-bone interface.  Bone contact along the entire contour o f the implant 
surface was determined.
6.2.8  Statistics
6.2.8.1  GRF
The  peak  vertical  component  o f the  GRF  (pvGRF),  measured  in  Newtons,  was 
normalised  by  body  weight  (Fmax/weight)  and  the  right post-operative  GRF  for 
the  hindlimb  was  expressed  as  a  percentage  o f the  right  preoperative  hindlimb. 
The Kruskal-Wallis Test for non-parametric  data was  carried out to  examine any 
differences between treatment groups. Significance was established as p<0.05.  If a 
significant difference was found, a post-hoc, pair-wise Mann-Whitney U Test was 
used  to  examine  any  differences  between  two  treatment  groups.  The  statistical 
software SPSS (SPSS vlO .l, SPSS Inc, Chicago, USA) was used for the analysis.
1856.2.8.2  New bone area and contact with the implant
The Kruskal-Wallis Test for non-parametric  data was  carried out to  examine  any 
differences between treatment groups. Significance was established as p<0.05.  If a 
significant  difference  was  found,  a  post-hoc,  pair-wise  Mann-Whitney  Test  was 
used  to  examine  any  differences  between  two  treatment  groups.  The  statistical 
software SPSS (SPSS vlO .l, SPSS Inc, Chicago, USA) was used for the analysis.
1866.3 RESULTS
6.3.1  GRF analysis
The  graph  below  shows  the  mean  percentage  pvGRF  (figure  6.9).  Mean  post­
operative  pvGRF  o f the  right  limb at  12  weeks was expressed  as  a percentage o f 
mean  pre-operative  pvGRF  o f the  right  limb,  (right  post  operative  /  right  pre­
operative  x  100),  and  was  greater  in  the  MSC  group  than  the  control  or  the 
osteoblast group at  108.16% (±10.99  SE),  82.54% (±8.30  SE) and 60.83% (±6.17 
SE)  respectively.  The  Kruskal  Wallis  test  showed  there  was  a  significant 
difference  between  the  groups  at  p=0.036.  The  post-hoc  Mann-Whitney  U  Test 
revealed the difference to be significant between the MSC and osteoblast group at 
p=0.034,  however  there  was  no  significant  difference  between  any  o f the  other 
paired groups.
140 p=0.034
Ctrl MSC OB
Figure  6.9  Mean  percentage  pvGRF  with  post  operative  values  expressed  as  a 
percentage  of pre-operative values  in  the control,  MSC  and  osteoblast group  (±SE). 
*Mann-Whitney U Test (p<0.05).
1876.3.2 New Bone Formation
The  data  for new  bone  formation  was  plotted  as  the  mean  percentage  new bone 
formation  in  the  available  space  for  each  treatment  group  and  is  shown  in  the 
figure  below  (figure  6.10).  The  Kruskal-Wallis  Test  revealed  a  significant 
difference  in  new  bone  formation  between  all  the  groups  (p=0.001).  On  closer 
inspection,  using  the  Mann-Whitney  U  test,  there  was  a  significant  difference 
between the amount o f new bone in the control, at 28.69% ± 3.9SE and the MSC 
group,  with  more  new  bone  in  the  MSC  group  at  46.77  %  ±  3.27SE  (p=0.003). 
Mann-Whitney  U  tests  also  revealed  significantly  more  new  bone  in  the  MSC 
group compared to the osteoblast group which had an average new bone formation 
o f 27.25% ± 2.88SE (p<0.01).  However there was no significant difference in new 
bone formation between the control and the osteoblast group.
Ctrl  MSC  OB
Figure 6.10 Mean percentage new bone formation in the available space (±SE)
1886.3.3 New Bone Formation at Implant and Host Interfaces
The data representing mean percentage new bone formation in the available space 
was  separated  into  the  transect  analysed  at  the  graft/implant  interface  termed 
‘inner’  and the transect at the host/graft interface termed ‘outer’  and plotted in the 
graph below in order to compare the two interfaces (figure 6.11).  There is a trend 
towards  more  new  bone  at  the  endosteal  interface  within  all  the  groups  with 
39.95%,  51.39%  and  37.31%  in  the  endosteal  region  compared  with  25.0%, 
44.43% and 19.8% in the implant interface for control, MSC and osteoblast groups 
respectively.  Scaffolds  with  MSCs  incorporated  into  the  allograft  displayed  a 
higher mean value o f new bone than any other treatment group within implant and 
endosteal  interfaces  and  the  osteoblast  group  produced  less  new  bone  within 
implant and endosteal interfaces than MSC or control groups.
The  Kruskal-Wallis  Test  showed  a  significant  difference  between  all  the  groups 
(p<0.001).  The Mann-Whitney U Test revealed there was significantly more new 
bone at the  endosteal  interface  (39.95%) when compared to the  implant interface 
(25.0%)  within  the  control  samples  (p=0.039)  and  the  osteoblast  group  (37.31% 
and  19.8%  respectively,  p=0.004).  Although there  was  a  greater  degree  o f new 
bone formation at the endosteal interface compared to the implant interface within 
the  MSC  group,  at  51.39%  and  44.43%  respectively,  this  difference  was  not 
significant (p=0.462).
When comparing the treatment groups  at the  implant interface,  Mann-Whitney U 
tests showed that there was significantly more new bone in the MSC treated group 
at 51.49% compared to the control at 39.95% (p=0.015), and in the MSC group at 
51.49% than in the osteoblast group at 37.31% (p<0001).  However, although there 
was more new bone in the control compared to the osteoblast group, this was not 
significant (p=0.743).  When comparing the treatment groups w ithin the endosteal 
interface,  the  MSCs  had  more  new  bone  than  the  control  group  at  44.43%  and 
25.0%  respectively,  however this was  not  significant  (p=0.089).  The  MSCs  also 
had more  new bone  than the  osteoblast  group  (19.8%)  and the  control  had more 
new bone  than  the  osteoblast  group,  neither  o f which  were  significant  (p=0.073 
and p=0.818 respectively).
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Figure  6.11a-c  Percentage  New  Bone  Formation  comparing  the  implant  interface 
(‘inner’) with the host interface (‘outer’): a p values show significantly more bone in the 
outer group within  control and  osteoblast samples;  b there  is a  significant difference 
between  treatments  in  the  inner  groups  between  MSC  and  control  and  MSC  and 
osteoblasts;  c  there  is  no  significant  difference  between  treatments  in  the  outer 
groups.
1906.3.4 Contact of New Bone with the Implant
The  data  for  new  bone  in  contact  with  the  implant  was  plotted  as  a  mean 
percentage o f new bone  in each treatment group  and  is  shown in the  figure  6.12. 
There  is  marginally  more  new bone  contact  with  the  implant  in the  MSC  group 
than  in the  control  group  and the  least  amount  o f new bone  in  contact  with  the 
implant is in the  osteoblast group,  with the mean new bone  contact at  18.71%  (± 
6.31SE)  16.92%  (±  6.15SE)  and 4.12%  (±4.12  SE)  respectively.  The  Kruskal- 
Wallis  Test revealed  a  significant difference  between the  groups  (p=0.015).  The 
Mann-Whitney U Test revealed no significant difference between the  control and 
MSC  group  (p=0.775).  However there  was  a  significant  difference  in new bone 
contact with the  implant between the control  and the osteoblast  groups  (p=0.041) 
and the MSC and osteoblast group (p=0.019).
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Figure 6.12 New bone in contact with the implant (±SE)
6.3.5 Histology Images
6.3.5.1  Time Zero
Impaction grafting at time zero was performed on cadaveric bone under the same 
operative conditions as in a living animal.  Graft was impacted evenly around the 
stem o f the prosthesis so that the stem was never in contact with the host bone. The 
images below show that there was always a layer o f graft between the stem and the
p=0.041
p=0.019
Ctrl MSC OB
191endosteal  cortex  (figure  6.13).  This  shows  that  the  model  was  appropriate  for 
studying bone  induction in impaction grafting.  If contact o f the  implant with the 
endosteal  surface  had  been  allowed,  bone  may have  been recruited  directly  from 
the host and osteoinductivity associated with the  graft or the cells may have been 
less influential. Allograft granules were between 2-5mm in size and were o f similar 
distribution along the stem so that small graft did not sink to the tip.  Distribution 
of graft was  shown to be even in the cadaveric  animal at time  zero  (figure  6.13). 
There is evidence o f the original trabecular bone remaining in the proximal section 
(figure  6.13).  However,  this  is  in the  lesser trochanter and removal  o f this  bone 
would not equate to a real revision situation.
Bars represent 1cm
Figure  6.13  Macroscopic  images  of toluidine  blue  and  Paragon  stained  transverse 
sections through a femur at time zero.  Images represent Proximal (top left),  Mid  (top 
right)  and  Tip  (bottom  left)  levels.  The  black  line  represents  1cm.  The  arrow 
directions represent Posterior (P), Medial (M) Lateral (L) and Anterior (A) aspects. ‘TB’ 
is trabecular bone, ‘AG’ is allograft, T is implant.  The implant detached from the slide 
during processing of the Mid section.
1926.3.5.2 Histology at 12 weeks
The  images  below  are  transverse  sections  through  the  femur  12  weeks  after 
impaction grafting surgery in the control, MSC and OB groups (figure 6.14).  Graft 
can be seen adjacent to the implant interface in both the control and MSC sections 
at the mid level.  A ll other implant surfaces are surrounded by fibrous tissue which 
appears  light  pink  in the  images,  or there  is  a  gap  between the  implant  and  the 
organic tissue which is a processing artefact causing the tissue to separate from the 
implant.
These  images  show  that  tissue  has  filled  the  gap  between  the  cortex  and  the 
implant  and  is  more  densely  distributed  in  most  cases  than  at  time  zero.  More 
bone can be seen in conjunction with the endosteal interface in all instances apart 
from  the  osteoblast  group  at tip  level  (figure  6.14).  This  may  be  because  some 
graft was lost from the section during processing.
193Bars represent 1cm
Figure  6.14  Macroscopic  histological  images of toluidine  blue  and  Paragon  stained 
transverse  sections through  the femur  harvested  after  12  weeks  in  vivo  at  Proximal 
(left column),  Mid  (central column) and Tip  (right column)  levels.  The top  row is the 
control group, the middle row is the MSC group and the bottom  row is the OB group. 
T  is the  implant,  ‘TB’  is trabecular bone,  ‘FT’  is fibrous tissue,  ‘C’  is the cortex,  ‘g’  is 
the  processing  artefact  surrounding  the  implant.  The  black  line  on  each  image 
represents  1cm.  The arrow directions represent Posterior (P),  Medial (M),  Lateral (L) 
and Anterior (A) aspects.
1946.3.5.3 High power images at the implant interface
The  high  power,  time  zero  image  below  (figure  6.15a)  shows  the  sparse 
distribution  o f allograft  across  the  transverse  section  o f the  femur  immediately 
after  impaction  at  the  tip  level.  There  is  little  contact  o f the  allograft  with  the 
implant and there are gaps between adjacent pieces o f allograft.  The rough edges 
of some of the graft pieces show where the force o f impaction has caused the bone 
graft to fracture.  Fibrous tissue can be seen surrounding the implant in the control 
group section shown in figure 6.15b and the osteoblast group section in 6.15d.  In 
between the  fibrous  tissue  and  the  HA  coating  the  implants  is  a  gap,  which  is  a 
processing  artefact,  adjacent to  the  HA.  Figure  6.15c  shows  new  bone  that  has 
integrated with the HA layer coating the implant in the MSC group.  The new bone 
is also contiguous with the surface of the implant forming a virtually uninterrupted 
coating along the boundary o f HA.
Figure  6.15  Transverse  sections  of  the  femur  at  different  levels  in  the  implant 
interface, a Time zero;  b Control group at 12 weeks; c MSC group at 12 weeks; d OB 
group at 12 weeks;  ‘AG’  is allograft, T  is the  implant,  ‘HA’  is  hydroxyapatite,  ‘g’  is an 
artefact induced gap, ‘NB’ is new bone, ‘FT’ is fibrous tissue.
1956.3.5.4 Control Group
The  images below are typical o f samples  from an impaction grafted THR control 
after  12  weeks  in vivo.  Bone  formed  directly,  without  endochondral  ossification, 
on existing areas o f allograft bone (figure 6.16a).  Evidence o f new bone formation 
can be seen in the pink, darkly stained matrix.  New bone formed around the edges 
o f  fragmented  and  intact  allograft  granules  (figure  6.16a).  Fibrous  tissue  has 
formed in some o f the spaces between impacted allograft granules in figure 6.16a. 
Figure  6.16b  shows  new  bone  following  the  contours  o f the  endosteal  surface 
adjacent  to  the  femoral  cortex.  This  is  indicative  o f the  majority  o f new  bone 
arising from osteoinduction derived from host bone and osteoconduction along the 
host  bone.  New  bone  also  follows  the  coastal  regions  o f  individual  allograft 
particles in a thin strip showing that the allograft  is osteoinductive  (figures  6.16b 
and 6.16c).
Figure 6.16a-c Typical examples of control samples showing areas of allograft (AG), 
fibrous tissue (FT) and new bone (NB), b Osteoconduction and osteoinduction of new 
bone along the endosteal surface (E),  showing the cortex (C),  c  New  bone following 
the contours of the allograft granules.
1966.3.5.5  MSC Implant
The  images  below  are  typical  o f samples  from  an  impaction  grafted  THR  using 
allograft seeded with MSCs.  After  12 weeks  in vivo,  surfaces o f new bone were 
covered  in  a  layer  o f  osteoblasts,  and  surrounded  by  unmineralised  osteoid. 
Osteoblasts can be clearly distinguished from the mesenchyme and blood cells by 
their plump,  basophilic  morphology and  are mostly encased by the  osteoid.  The 
osteoblasts are providing new bone in direct intramembranous ossification (figure 
6.17a).
There  is  no  evidence  o f allograft  in figure  6.17a or  6.17b,  however new bone  is 
mostly  seen to  be  associated with remaining  allograft  in this  study.  Although  it 
was  observed  that  a  large  proportion  o f  the  bone  in  this  group  formed  by 
intramembranous  ossification,  figure  6.17c  shows  evidence  o f bone  formed  by 
endochondral ossification.
Large  cartilage  lacunae  can  be  observed  on  the  allograft  surface.  There  is  also 
evidence o f intramembranous ossification where darkly purple  stained osteoid has 
formed without any underlying allograft being present.  However, the  allograft on 
which  the  osteoid  has  formed  could  be  outside  the  plane  o f the  image.  Figure 
6.17d  shows  new  bone  following  the  contours  o f  the  endosteum  by 
osteoconduction.  In this group it is possible that the source o f new bone is derived 
from MSCs  as  well  as  osteoinduction from host  bone,  as  more  new bone  can be 
seen at the endosteal surface in the MSC group compared to the control.
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Figure 6.17a-d  Sections through the middle of an MSC / allograft impacted THR after 
12  weeks  in  vivo:  a  There  is  evidence  of  new  bone  (NB)  and  fibrous  tissue  (FT), 
osteoblasts,  osteoid  (O),  blood  vessels  (BV);  b  New  bone  and  fibrous  tissue;  c 
Endochondral  ossification  (EO)  on  allograft  surface  indicated  by  cartilage  lacunae 
(CL); d New bone at the endosteal surface (E).
1986.3.5.6 Osteoblast Implant
In  the  allograft  seeded  with  osteoblasts  group,  new  bone  is  formed  in  a  similar 
manner to the control and MSC treated groups.  New bone  surrounds granules of 
remaining  allograft  and  it  is  possible  that  new  bone  may  have  formed  without 
association with allograft as  some new bone  appears to be  surrounded by fibrous 
tissue  (figure  6.18).  New  bone  is  not  always  associated  with  allograft  in  the 
osteoblast  group  as  in  the  MSC  group.  Most  o f the  new bone  in  the  osteoblast 
group  is  associated  with  the  endosteum  (figure  6.18b).  Some  o f the  allograft 
granules appeared to have relatively little new bone attached to them compared to 
the control and the MSC group.
100pm
Figure  6.18a-c  Sections  through  the  middle  of  an  osteoblast  treated  allograft 
impacted THR; a There is evidence of allograft granules ‘AG’, fibrous tissue ‘FT’ and 
new bone ‘NB’ which  is associated with  and  independent of existing allograft;  b  New 
bone attached to the endosteum ‘EN’;  c allograft granules and new bone.
1996.4 DISCUSSION
The  aim  o f the  study  in  this  chapter  was  to  improve  new bone  formation  in  an 
allograft impaction THR model in sheep by the addition o f MSCs or MSC derived 
osteoblasts with allograft as a control.  The  study was required because bone was 
impacted  under  realistic  conditions.  New  bone  formation  would  have  been 
associated with the local mechanics o f the intramedullary cavity in THRs; also the 
local  factors  influencing  bone  formation  were  different  to  those  in  the  ectopic 
study in Chapter 5 and included osteoinduction and osteoconduction from the host 
bone.  Various  parameters  were  measured to  assess  the  degree  o f success  o f this 
tissue  engineering technique to reconstitute  bone  stock  in the  sheep  femur.  This 
included measurements  o f GRF,  new bone  formation,  new bone  contact with the 
implant, and new bone at the implant and host interfaces.
6.4.1  Comparison of GRF between control, MSC and osteoblast groups
GRF was an indicator o f functionality o f the operated lim b as it gave an expression 
o f the degree o f the return o f the femur to normal use after the THR.  The degree o f 
GRF relates to the willingness  o f the  animal to  put weight on the  operated  limb. 
This correlates  indirectly with the  quality o f implant fixation as  an animal would 
be less likely to put weight on a loose  implant.  Therefore, higher GRF reflects a 
more adequate fixation o f the implant and suggests that the incorporation o f graft is 
better.  Definitive conclusions cannot be drawn from  GRF data alone as it is also 
related  to  the  degree  o f muscle  manipulation  incurred  as  a  result  o f  operative 
technique (Bassey et al.  1997; Bergmann et al.  2001).  The findings from analysis 
o f GRF in this study do not support the hypothesis that there will be a significant 
improvement in peak vertical Ground  Reaction Force (pvGRF) in the MSC 
group compared to the control and osteoblast groups.  However, the magnitude 
o f GRF was  greatest in the MSC  group,  less  in the control  group and least in the 
osteoblast group.  The  osteoblast group produced  significantly less  GRF  than the 
MSC group.  This is evidence that the use o f osteoblasts may have no effect on the 
function o f the limb.  It does not demonstrate that the application o f osteoblasts is 
necessarily detrimental to limb function as the GRF is not significantly less in the 
osteoblast group than in the control group.  The hierarchy o f MSC superiority over
200the control, which is better than osteoblast cells in terms o f limb function,  is also 
observed in new bone formation.
6.4.2 The effect of cells on new bone formation
The  order o f magnitude  o f new bone  formation was  greatest  in the  MSC  group, 
then the control group and finally the osteoblast group.  This was the same trend as 
that o f the GRF data.  The hypothesis that: there will be a significant increase 
in  new  bone  formation  in  the  MSC  group  compared  to  the  control  and 
osteoblast group can be accepted because there was significantly more new bone 
in the MSC group than in the control.  The MSC group also produced significantly 
more  new  bone  than  the  osteoblast  group.  MSCs  had  been  differentiated  and 
identified  as  osteoblasts  by  their  increased  production  o f ALP  in  chapter  3,  and 
mineralisation.  In this chapter, as in chapter 5, the trend is also for more new bone 
in the MSC treated group than in the control or the osteoblast group.  There is also 
some evidence in the literature that the effect o f adding osteogenic media to MSCs 
cultured on scaffolds does not enhance new bone formation compared to untreated 
cells on scaffolds (Kruyt et al.  2004a).  MSCs were pre-differentiated because,  as 
discussed in chapter  1, it is possible that osteogenic commitment in vitro, prior to 
implantation, may provide more rapid and consistent bone formation (Caplan A.I., 
2000).  However, the data for new bone formation in this chapter suggests that it is 
more  beneficial  to transplant a heterogeneous  population o f prim itive  MSCs  that 
would already be interacting via cell-cell communication in order to adapt better to 
the in vivo environment.
6.4.3 New bone formation at implant and host interfaces
Evaluation o f new bone at the interface o f allograft with the implant and with host 
bone  was  made  by  comparing  both  interfaces  within  each  group.  There  was  a 
trend  o f more  new  bone  produced  at  the  host  interface  in  all  the  groups.  The 
hypothesis that: there will be a significant increase in new bone formation at 
the host allograft interface compared with the host implant interface was not 
accepted.  Both the control group and the osteoblast group produced significantly 
more  new  bone  at  the  host  interface  than  at  the  implant  interface.  However, 
although  more  new  bone  was  found  at  the  host  interface  than  at  the  implant
201interface  in  the  MSC  group,  there  was  no  significant  difference  between  these 
regions.  The source o f new bone could be osteoconduction from inductive factors 
such as BMPs and MSCs or osteoblasts residing in host bone.  One explanation o f 
these  results  is  that  diffusion  o f nutrients,  cells  and  vascularisation  towards  the 
implant  interface  reduces  with  distance  from  the  endosteal  interface,  thereby 
decreasing the contribution o f new bone from the host.  The control reflects this 
principle.  My  study  indicates  that  new  bone  is  derived,  either  directly  or 
indirectly,  from  implanted  MSCs.  These  are  distributed  evenly  throughout  the 
allograft before implantation and in this study application o f these cells resulted in 
a  more  even  distribution  o f  bone  formation,  indicating  that  MSCs  make  a 
contribution to bone formation at the implant interface.  According to data for new 
bone  formation, there is not a large contribution o f new bone from osteoblasts as 
they  produce  the  least  amount  o f new  bone.  The  more  mature  cells  such  as 
osteoblast cells are known to have a higher metabolic activity and therefore require 
greater oxygen supply (Vacanti 2004). This could diminish their ability to survive 
in a low oxygen environment such as a large graft, where nutrient diffusion would 
be slow in some areas especially at the implant interface.
The trend whereby more new bone was produced in the MSC group was observed 
when respective interfaces from each group were compared. The hypothesis that: 
there will be a significant increase in new bone formation in the MSC group 
compared  to  the control  and  osteoblast  groups within  the  allograft implant 
interface or the host allograft interface was not accepted.  The  fact that there 
was significantly more new bone in the MSC group compared to the control group 
at  the  implant  interface,  but  no  significance  in  the  greater  amount  in  the  MSC 
group at the host interface,  shows that the  MSCs made more  o f a contribution to 
new bone formation at the implant interface than at the host interface.  The same is 
true o f the significantly greater proportion o f new bone at the implant interface in 
the MSC group compared to the osteoblast group, whereas at the host interface the 
increase in the MSC group over the osteoblast group is not significant.  There was 
more  bone  in  the  control  group  than  in  the  osteoblast  group  at  both  interfaces. 
However, this was not significant at either interface, indicating that osteoblast cells 
are  not  effective  in  creating  more  new  bone  at  interfaces,  but  neither  are  they
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at implant or host interfaces.
6.4.4 Contact of new bone with the implant
The  order o f magnitude  o f contact  with the  implant  in descending  order was  the 
MSC  group,  then the  control  group  and  finally the  osteoblast  group.  This  trend 
followed that o f new bone  formation and GRF  data.  The hypothesis that: there 
will be a significant increase in contact of new  bone with the implant in the 
MSC  group  compared  to  the  control  and  the  osteoblast  group  was  not 
accepted.  The amount o f new bone contact was only slightly greater in the MSC 
group compared to the control, and was not significant.  However, in this instance 
there was significantly less new bone in the osteoblast group than in the MSC and 
control group.  Contact with the implant implies that the new bone is more likely to 
be attached to the implant and w ill therefore be well integrated for greater stability. 
The fact that there was significantly less contact with the implant in the osteoblast 
group  indicates  that  osteoblast  cells  may  be  detrimental  for  bone  contact  and 
potentially,  stability  o f  the  implant.  The  explanation  for  this  may  be  that 
introduction o f osteoblasts triggers  osteoclastogenesis  via the  RANK pathway  as 
osteoblasts cells have receptors for osteoclast precursors (Khosla 2001).  This may 
have sped up the cycle o f resorbtion o f new bone at the implant surface.
6.4.5 Experimental design
The  ovine  hip  model  was  equivalent  to  a  revision  hip  replacement  and  the 
procedures  followed  were  similar  to  those  used  in  a  clinical  impaction  grafting. 
The sheep were skeletally mature and over 2 years old.  They were all o f a similar 
age as observed by the fact that the sheep were chosen on the basis o f retention o f 
all o f their teeth. The duration o f the study was  12 weeks.  The length o f the study 
was the same as in chapter 4 and has already been discussed in the context o f other 
studies  cited in the  literature  (see  section 4.4.3).  MSC  and osteoblast  cells  were 
seeded in greater numbers than in the ectopic  study in chapter 4.  The numbers o f 
cells  were  increased  from  6  x  106  cells/cm3,  in  the  ectopic  study,  to  10  x  106 
cells/cm  in this chapter and were more representative o f the quantity employed in 
other  studies  in  the  literature  where  the  seeding  o f cells  has  been  effective  in
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confirmed, by analysing the stress/strain behaviour o f morsellised cancellous bone 
graft in a Jenike  shear box, that graded graft improved the mechanical strength o f 
the  morsellised  bone.  The  drawback  o f graded  graft  is  that  close  packing  may 
inhibit the revascularisation and therefore incorporation o f the  graft.  Grading the 
graft to test the theory in vivo is beyond the remit o f this thesis, therefore the graft 
w ill  be  sieved  to  the  size  commonly  used  in  clinical  practice.  Gie,  G.A.  et  al. 
stipulates that morsellised graft used in a revision THR should be large enough to 
allow  the  compressed  chips  to  have  ‘body’.  This  excludes  bone  slurry  as  the 
consistency is too low (Gie et al.  1993).  A case study o f four patients summarised 
the technique  commonly  used in impaction grafting  and morsellised  fresh frozen 
allograft to between 3  and 5mm in diameter (Nelissen et al.  1995).  Allograft was 
used as it is currently more accepted in a clinical setting.  Also, allograft was found 
to encourage more contact o f new bone with the scaffold surface in chapter 5.  This 
may be beneficial for attachment and therefore integration o f the implant with new 
bone,  thereby  increasing  the  stability  o f  the  implant.  Scaglione,  S.  et  al 
investigated  whether  ovine  MSCs  seeded  directly  onto  a  3D  scaffold  produced 
more bone than MSCs cultured in 2D prior to scaffold loading and then implanted 
ectopically into nude mice.  Analysis o f new bone was quantified by the amount o f 
bone in the available  space, which was the  same  method o f analysis employed in 
my thesis.  The amount o f new bone was greater in the 3D seeded constructs than 
the 2D  constructs after 8  weeks.  The  amount o f bone produced after  14  days  o f 
static  loading  in  3D  and  2D  culture  and  8  weeks  in  vivo  was  12  %  and  6% 
respectively  (Scaglione  et  al.  2005).  The  percentage  o f  bone  produced  in 
Scaglione et al’ s study was less in all groups than that produced in all groups in my 
study.  This  may  be  because  the  work  o f  Scaglione  is  in  an  ectopic  site  and 
therefore there is no contribution from osteoconduction.  In a study by Kruyt et al., 
the  amount  o f  new  bone  in  the  available  pore  space  produced  in  iliac  crest 
orthotopic sites, where unimpacted BMSC loaded implants were analysed after  12 
weeks,  was 29.0%  compared to  46.77  %  in the  MSC  group  in this  chapter.  The 
control  group  produced  25.1%  compared  to  the  28.69%  in  my  study.  The 
discrepancies  between these  studies  are that the  defect  is  considerably  smaller in 
Kruyt’s work measuring 017 x 6mm (Kruyt et al.  2004c).  As discussed in Section 
4.4.4, the ectopic study by Kruyt shows that BMSCs treated with supplements for
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(11.2%) as those without supplements (11.7%), which concurs with the findings in 
this chapter as osteoblast cells do not make a contribution to bone formation.  In a 
study by Bruder et al.,  MSCs  loaded onto  ceramic  cylinders  o f 014mm x 21mm 
and  placed  into  canine  segmental  bone  defects  created  new  bone  more  closely 
approaching  the  amounts  achieved  in  this  chapter.  However the  evaluation  was 
carried out after 16 weeks.  The mean values for new bone were 39.9% in the MSC 
treated  group  and 24%  in the  control  group  (Bruder et al  1998b).  In  Arinzeh’s 
study,  where  MSCs  were  also  loaded  onto  a  ceramic  cylinder for reimplantation 
into  a  canine  segmental  defect  and  analysed  after  16  weeks,  there  was  a 
comparable  amount  o f new bone  produced  as  in  other  studies  mentioned  above, 
with new bone at 42.3% in the MSC treated group and 24.6% in the control group 
without MSCs (Arinzeh et al.  2003).  These percentages are closest to those found 
in this chapter.  The largest discrepancy between the cell seeded and control group 
was found in Kon et al’ s study, where MSCs were loaded onto HA cylinders and 
implanted  into  sheep  tibial  defects  for  two  months,  giving  54.2%  new  bone 
compared to controls containing 8.6% new bone.
6.5 CONCLUSION
MSCs  added  to  allograft  produce  more  new  bone  than  either  allograft  alone  or 
allograft supplemented with osteoblasts.  This  indicates that MSCs could be used 
in conjunction with impaction allografting in the clinic.  MSC  derived osteoblasts 
make no contribution to new bone formation.
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2067.1 GENERAL DISCUSSION
Osteolysis around THRs often results in subsidence and failure o f the implant.  The 
loss o f bone stock compromises immediate fixation and long term  stability o f the 
rTHR.  The  overall hypothesis  for this thesis was that incorporating MSCs into 
allograft or hydroxy  apatite granules which  are then  impacted, will increase 
the  rate  and  extent  of  bone  formation.  The  flow   diagram  (figure  7.1) 
summarises the questions and conclusions from each Chapter o f my thesis that led 
to answering this overall hypothesis.
It was essential to ascertain whether MSCs survived normal impaction forces used 
in  clinical  impaction  grafting.  Chapter  two  o f my  thesis  tested  the  viability  o f 
MSCs seeded onto the allograft and impacted at a range o f forces obtained during 
rTHRs.  The forces were replicated in vitro using  an impactor designed by Kirsty 
Phipps  (Phipps  2004).  MSCs  survived  impaction  forces  up  to  6KN.  This  was 
within the range  o f normal  impaction  forces  imparted  during  surgery.  Although 
MSCs do not survive at 9kN it was shown that mean forces above 6kN impaction 
were  at  the  highest end  o f the range  and  only  experienced  in a  small  number o f 
cases  (Phipps  2004).  It  is  therefore  feasible  that  impaction  can be  used  without 
affecting  MSCs.  Although  force  was  measured,  strain  may  have  been  an 
alternative parameter to replicate.  However strain is the deformation o f a physical 
body  under the  action  o f applied  forces.  Strain  differs  depending  on  where  the 
contact is on each individual granule, so impaction o f the granule was measured by 
graft height as a consequence o f the applied force and not stress or resultant strain 
as this would have been very difficult to measure.
MSCs can be expanded prior to differentiation into osteoblasts, possibly expediting 
the rate and extent o f bone formation compared to MSCs.  The question asked was 
would  the  osteoblasts  survive  better  than  MSCs  after  impaction  on  allograft? 
Chapter three o f my thesis tested the viability in vitro o f osteoblasts derived from 
MSCs  which  were  seeded  onto  the  allograft  and  impacted  at  a  range  o f forces 
obtained during rTHRs.  This  study found that osteoblasts  can survive  impaction 
forces  up  to  3kN,  which  is  in the  lower  range  o f normal  impaction  forces  used 
during revision THRs, however these cells did not seem to be as resilient as MSCs.
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by their involvement in mechano-transduction during bone remodelling.  It is not 
known  exactly  how  bone  perceives  mechanical  stimuli.  However  the  literature 
suggests that osteoblasts and osteocytes detect strain which can stimulate apoptosis 
in immature osteoblasts and induce proliferation in older osteoblasts (Weyts et al. 
2003).  In this Chapter osteoblasts were selected after 14 days o f differentiation in 
osteogenic  supplements.  It  is  possible  that  at  other  stages  in  the  osteogenic 
lineage, osteoprogenitor cells may respond differently to impaction forces.  Further 
experiments  could  test  the  effect  o f  impaction  forces  on  cells  at  stages 
phenotypically  defined  by  the  temporal  expression  o f cell  surface  markers  on: 
osteoprogenitor cells, pre-osteoblasts, transitory osteoblasts,  secretory osteoblasts, 
osteocytic osteoblasts and osteocytes (Bruder and Caplan 1989; Bruder and Caplan 
1990a; Bruder and Caplan 1990b).
Another avenue for future work is to consider the possibility that MSCs are not the 
only  source  o f bone  forming  cells.  Mature  cells  o f other tissue  types,  given the 
correct stimuli, could differentiate into bone tissue.  The controversial theory that a 
cell  from  one  tissue  can  transform  into  another  tissue  type  is  termed  stem  cell 
‘plasticity’.  There  are  several  possible  mechanisms  o f  plasticity  such  as:  de- 
differentiation  (also  known  as  retrodifferentiation)  where  a  differentiated  cell; 
converts  to  a  precursor  cell  or  stem  cell;  trans-differentiation,  where  a 
differentiated  cell  converts  to  a  different  type  o f  differentiated  cell  or 
transdiffemtiation  via  de-differentiation  followed  by  re-differentiation 
(Lackshmipathy  and  Verfaillie  2005).  The  controversy  stems  from  the  fact  that 
assessment  of  plasticity  is  not  functional  but  characterised  by  phenotype  and 
therefore  mistakenly  attributed to  transferal  o f mixed populations  o f donor cells. 
Cell  fusion, which is  a combination o f two  or more  individual  cells  forming one 
cell,  can  also  erroneously  be  identified  as  plasticity.  Also,  a  failure  to  replicate 
findings  adds  to  the  scepticism  surrounding  plasticity  (Lackshmipathy  and 
Verfaillie 2005). However, if  plasticity does occur and osteoblasts could be derived 
from any tissue, then non-invasive procedures could be used to harvest cells  such 
as  fibroblasts  for tissue  engineering  o f bone.  One  study  shows  that  when  MSC 
implants become infiltrated with fibroblasts in vivo, bone formation is reduced.  In 
vitro  assays  included ALP,  calcium  and cartilage  cultures with different ratios  o f
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mice for bone formation.  In both the in vitro and the in vivo assays bone formation 
decreases  with  increasing numbers  o f fibroblasts  (Lennon et al.  2000).  Although 
stem cell plasticity is not investigated in this study, it would suggest that plasticity 
is not occurring as fibroblasts do not appear to contribute to new bone.  However, 
in  fibroblast  cultures  treated  with  osteogenic  media  there  was  minimal 
mineralisation and a change in morphology.  It could be argued that implanting the 
cells subcutaneously did not give the fibroblasts the correct environmental cues to 
differentiate  into  osteoblasts.  An  alternative  study  could  involve  probing  the 
fibroblasts  for  osteogenic  cell  surface  markers  and  implanting  fibroblasts  into 
orthotopic sites.
Another approach to tissue engineering would be the co-culture o f cells in order to 
enhance  MSC  numbers,  allowing  scale-up  for  large  defects  requiring  larger 
numbers  o f autologous  cells  or  for  allogenic  widespread  clinical  application.  A 
study  hypothesised  that  replating  non-adherent  MSCs  that  are  usually  discarded 
during  cell  culture  would  result  in  more  osteogenic  MSCs  than  from  primary 
cultures alone (Wan et al. 2006).  The authors confirmed that the number o f MSCs 
increased  by  36.6%  and  after  subcutaneous  implantation  in  SCID  mice  on 
HA/TCP, there was new bone in all implants with MSCs.  However, it should be 
noted that there was no quantative evaluation so it could not be established whether 
replated  cells  enhanced  in  vivo  bone  production  (Wan  et  al.  2006).  In  another 
study  non-adherent  osteoblast  accessory  cells  (OAC),  which  comprise  another 
subset  o f  cells  in  the  heterogenous  stem  cell  compartment,  trigger  MSC 
development  into  the  osteogenic  lineage  stimulating  bone  precursor  cells  to 
express osteonectin and ALP (Eipers et al.  2000).  In addition, the work by Baksh 
et al.  shows increased numbers o f osteoblast colony forming units (cfu-o) and cfu- 
fs from suspension-derived cells o f unsorted compared to sorted HSCs and MSCs. 
Therefore  MSC  growth  is  increased by  coculture  with HSCs  (Baksh et al.  2003; 
Baksh et al.  2005).  A study by Baksh, D. et al has the added advantage o f being in 
serum  free  culture  which  is  required  for  clinical  grade  application  o f stem  cells, 
although it should be noted that the addition o f growth factors not normally used in 
static culture, were required (Baksh et al.  2003).  It may be advantageous to grow
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enhanced osteogenic potential by using a similar bioreactor system.
Chapter  four  o f  my  thesis  assessed  whether  new  bone  formation  o f  impacted 
allograft and hydroxyapatite in a sheep critical sized defect was improved by using 
autologous  sheep  MSCs  in  vivo.  In  addition  osteoconductivity  o f  irradiated 
allograft was  compared with 60 percent porous  granular HA  in an animal  model 
that  simulates  bone  remodelling  within  impacted  graft  in  vivo.  There  was  no 
significant increase in new bone formation or remodelling w ith the introduction o f 
MSCs on impacted allograft or HA granules.  Both scaffolds were shown to induce 
similar amounts o f new bone formation, although there was a significantly greater 
degree o f resorption o f the allograft allowing more ingrowth o f fibrous tissue.  In a 
femoral  defect  model,  ‘controlled  compression  is  applied  over  the  defect  area, 
whereas  grafting  material  impacted  around  a  femoral  stem  is  exposed  to  a 
combination  o f compression  and  shear  forces’  (G riffon  et  al.  2001).  No  other 
study has attempted to implant MSCs at the femoral condyle.  The size o f the graft 
and interffagmentary strain could have prevented penetration o f blood vessels and 
transport  o f nutrients  to  the  cells,  reducing  new  bone  formation.  The  literature 
shows that MSCs contribute to new bone formation in vivo in bony sites (Arinzeh 
et al.  2003; Kadiyala and Jaiswal  1997; Bruder et al.  1998b).  Based on this data it 
is  reasonable  to  postulate  that  the  distribution  o f mechanical  forces  at  the  bone 
ends  may  have  had  a  detrimental  effect  on  new  bone  formation.  In  contrast, 
although MSCs did not increase new bone formation it was possible that the model 
was  very  osteoinductive  due  to  the  large  quantities  o f healthy  trabecular  bone 
surrounding  the  allograft  /  cell  composite.  The  cells  from  the  host  may  have 
masked  the  contribution  o f new  bone  from  implanted  MSCs.  Considering  this 
explanation,  it would  still be  feasible to  use  MSCs  in a revision hip replacement 
where the surrounding tissue has a compromised vasculature or an ectopic situation 
where  the  surrounding  tissue  is  not  osteoinductive,  in  order  to  test  the 
osteoinductive  capability  o f the  cells.  Future  work  could  include  increasing  the 
number o f cells used in this study to test for the osteoinductive capacity o f MSCs 
and restricting the micromovement o f the graft particles by sealing the defect with 
gauze.
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bone  formation  in  impacted  allograft  or  an  allograft  and  HA  combination  in  an 
ectopic  site.  In all cases there  is  an increase in new bone formation when MSCs 
are used.  The use o f osteoblasts did not enhance the amount o f new bone on any 
scaffold.  This  study has  shown that MSCs increased the production o f new bone 
formation  on  impacted  allograft  and  in  an  impacted  HA/allograft.  There  was  a 
significant  increase  in  new  bone  in  the  impacted  HA/allograft  and  unimpacted 
block  HA  group  with  MSCs.  However,  there  was  no  significant  difference 
between the control and OB groups.  Therefore this study showed that in an ectopic 
site MSCs had a significant positive effect.
Chapter 5  also  showed that allograft produces the most new bone in contact with 
its  surface  compared  to  all  the  other  scaffolds,  although  there  is  no  significant 
difference  in  new  bone  contact  between  the  scaffolds.  The  MSCs  also  produce 
more new bone in contact with the scaffold surface than any other treatment group. 
Surgeons should consider using allograft in combination with MSCs, in preference 
to  HA  and  allograft  combined,  as  this  combination  encourages  osteoconduction 
which may lead bone to integrate with the implant surface.  Pull-out tests o f MSC 
treated,  allograft  impacted  hemiarthroplasties  would  confirm  the  stability  o f the 
implants.  Future  work  could  involve  the  addition  o f osteoblasts  on  an  impacted 
HA  scaffold  to  see  if   they  encourage  further  osteogenic  differentiation  and 
therefore more new bone.
Chapter  6  of my thesis  aimed  to  regenerate  new  bone  in  defect  areas  adjacent to 
revision hip  replacements  using  impaction  grafting  with  allogenic  bone  combined 
with  either MSCs  or  osteoblasts  derived  from  MSCs.  MSCs  produce  more  new 
bone  than the  control  group  which produces  more  new bone  than the  osteoblast 
group.  In the case o f new bone, the difference is significant between the MSC and 
control  group.  MSC  derived  osteoblasts  make  no  contribution  to  new  bone 
formation and have  a detrimental  effect on new bone  contact with the  implant in 
this  impaction model.  HA or an HA and allograft mix with MSCs or osteoblasts 
could have been additional groups used in this part o f the  study in Chapter 6.  In 
Chapter  5  HA  combined  with  MSCs  induced  the  most  ectopic  bone.  However 
concern over the stability and strength o f HA in an impaction grafting situation led
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due to the concern that MSCs would have died when subjected to the temperature 
o f cement during polymerisation.  There  is  a possibility that micromotion may be 
increased in uncemented stems.  If cement had been used,  stability o f the  implant 
may have allowed new bone produced by MSCs to attach to the implant.  Further 
studies could include analysis at later time-points, such as 6 months or even longer, 
to  provide  insight  into  the  pattern  o f  bone  turnover  and  whether  new  bone 
formation was maintained long term  in vivo.  In addition osteointegration o f new 
bone with the implant could have been tracked over time.  Tracking the MSCs in 
the in vivo experiments by GFP or Lac Z labelling and subsequently investigating 
organs for these markers may indicate whether MSCs have contributed directly to 
new  bone  formation  at  the  defect  site  or  systemically  migrated  to  other  tissues. 
The next stage o f investigation should also involve validating the function o f new 
bone  by  using  a pull-out  test.  In  addition,  density  scanning  using  DEXA  (Dual 
Energy X-Ray Absorptiometry) could analyse real time quality and remodelling o f 
new bone.
2127.2 CONCLUSIONS
•  MSCs  survive  normal  impaction forces  used  in  clinical  impaction grafting  in 
the range o f 3-6kN.
•  Osteoblasts  derived  from  MSCs  survive  normal  impaction  forces  used  in
clinical  impaction grafting at  3kN only  and  are  therefore  more  susceptible  to
impaction.
•  There was no  significant increase  in new bone  formation or remodelling with 
the introduction o f MSCs on impacted allograft or HA granules in the femoral 
defect model.
•  There was a significantly greater degree o f resorption o f the allograft allowing 
more ingrowth o f fibrous tissue in the femoral defect model.
•  MSCs increase new bone on any scaffold after impaction in an ectopic site with 
a significant increase in the HA/allograft and unimpacted block HA group with 
MSCs.
•  There is no advantage o f seeding osteoblasts on graft as there is no significant
difference between control and osteoblast seeded scaffolds in an ectopic site.
•  MSCs  contribute  to  new  bone  formation  in  the  rTHR  model  and  this  is
especially evident in regions where new bone formation is compromised such 
as regions adjacent to the implant interface.
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